Molecular Biology of Bronchial and Vascular Remodelling by Alagappan, V.K.T. (Vijay Kumar Thyagarajan)
 
 
 
Molecular Biology of Bronchial and 
Vascular Remodelling 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vijay Kumar Thyagarajan Alagappan 
   
 
 
 
Work presented in this thesis was in part financially supported by the Netherlands Asthma 
Foundation (Research Grants # 95.46 and # 97.73) 
 
 
 
Molecular Biology of Bronchial and Vascular Remodelling 
Thesis, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.   
 
 
ISBN-10: 90-9020652-3 
ISBN-13: 978-90-9020652-3 
 
 
Ó Vijay K.T. Alagappan, 2006 
 
All rights reserved.  Save exceptions stated by the law, no part of the publication may be 
reproduced, stored in a retrieval system of any nature, or transmitted in any form or by 
means, electronic, mechanical, photocopying, recording or otherwise, including a complete 
or partial transcription, without prior written permission of the author. 
 
 
Cover design and concept: Vijay Alagappan 
Cells image source: Lentz, Thomas L. "Cell fine structure: An atlas of drawings of whole 
cell structure".  
 
 
 
Printed by Asian Printers, Chennai, India.     
 
 
 
 
 
Printing of this thesis was financially supported by Astellas Pharma Europe R&D 
(Leiderdorp, The Netherlands), Erasmus University (Rotterdam, The Netherlands), Pfizer 
bv (Capelle aan den IJssel, The Netherlands) and Astma Fonds (Leusden, The Netherlands). 
   
 
 
 
 
Molecular Biology of Bronchial and  
Vascular Remodelling 
 
 
 
Moleculaire biologie van bronchiale en vasculaire remodellering 
 
 
 
 
Thesis 
 
 
 
to obtain the degree of Doctor from the 
Erasmus University Rotterdam 
by command of the 
rector magnificus 
Prof. dr. S.W.J. Lamberts 
and in accordance with the decision of the Doctorate Board 
 
 
 
 
The public defence shall be held on 
 
 
 
Wednesday, May 31, 2006 at 15.45 hours 
 
 
 
 
 
 
 
by 
 
 
 
Vijay Kumar Thyagarajan Alagappan 
 
 
born in Madras, India 
  
 
 
 
Doctoral Committee 
 
Promotor: Prof.dr. P.R. Saxena 
 
Other members: Prof.dr. J.M.J. Lamers 
 Prof.dr. B.N.M. Lambrecht 
 Prof.dr. A.J.J.C. Bogers 
 
Copromotor: Dr. H.S. Sharma 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To Nachu, 
 Appa and Amma
  
Molecular Biology of Bronchial and Vascular Remodelling 
 
Chapter 1: General Introduction ........................................................................................... 10 
1.1 Respiratory system ..................................................................................................... 10 
1.2 Chronic airway diseases ............................................................................................. 12 
1.3 Pathophysiology......................................................................................................... 14 
1.4 Airway remodelling ................................................................................................... 15 
1.5 Bronchial vasculature in chronic airway disease ....................................................... 19 
1.6 Bronchial angiogenesis and vascular remodelling..................................................... 20 
1.7 Role of growth factors................................................................................................ 23 
1.8 Airway smooth muscle and beyond ........................................................................... 27 
1.9 In vitro models of bronchial and vascular remodelling ............................................. 31 
1.10 Aims of the thesis..................................................................................................... 33 
1.11 References ................................................................................................................ 34 
Part I. Bronchial Remodelling ...................................................................... 41 
Chapter 2: Role of Insulin-Like Growth Factor-I and IGFR-I in Airway Epithelial Repair 44 
2.1 Introduction ................................................................................................................ 44 
2.2 Materials and methods ............................................................................................... 45 
2.3 Results ........................................................................................................................ 50 
2.4 Discussion .................................................................................................................. 58 
2.5 References .................................................................................................................. 60 
Chapter 3: Role of Fibroblast Growth Factor-Receptor System in Bronchial Epithelial 
Repair .................................................................................................................. 64 
3.1 Introduction ................................................................................................................ 64 
3.2 Materials and methods ............................................................................................... 66 
3.3 Results ........................................................................................................................ 70 
3.4 Discussion .................................................................................................................. 76 
3.5 References .................................................................................................................. 79 
Part II. Vascular Remodelling ...................................................................... 81 
Chapter 4: Bronchial Vascular Remodelling in Chronic Bronchitis/ Emphysema............... 84 
4.1 Introduction ................................................................................................................ 84 
4.2 Airway remodelling ................................................................................................... 86 
4.3 Vascular remodelling in COPD ................................................................................. 87 
4.4 Growth factors involved in vascular remodelling...................................................... 92 
4.5 Vascular remodelling in Emphysema and Chronic Bronchitis .................................. 93 
4.6 Conclusion.................................................................................................................. 97 
4.7 References .................................................................................................................. 98 
Chapter 5: Vascular Endothelial Growth Factor and its Receptors in COPD .................... 104 
5.1 Introduction .............................................................................................................. 104 
5.2 Materials and methods ............................................................................................. 106 
5.3 Results ...................................................................................................................... 108 
5.4 Discussion ................................................................................................................ 117 
5.5 References ................................................................................................................ 120 
  
 
 
 
Chapter 6: Pro-inflammatory Cytokines and Vascular Remodelling..................................124 
6.1 Introduction...............................................................................................................124 
6.2 Materials and methods..............................................................................................125 
6.3 Results.......................................................................................................................128 
6.4 Discussion.................................................................................................................132 
6.5 References.................................................................................................................134 
Chapter 7: Vasoactive Peptides and Bronchial Vascular Remodelling...............................138 
7.1 Introduction...............................................................................................................138 
7.2 Materials and methods ..............................................................................................139 
7.3 Results.......................................................................................................................145 
7.4 Discussion.................................................................................................................150 
7.5 References.................................................................................................................152 
Chapter 8: Regulation of VEGF Expression by Nitric Oxide in ASM Cells ......................156 
8.1 Introduction...............................................................................................................156 
8.2 Materials and methods..............................................................................................157 
8.3 Results.......................................................................................................................161 
8.4 Discussion.................................................................................................................164 
8.5 References.................................................................................................................167 
Chapter 9: Cyclically Stretched Human ASM Cells and Angiogenic Molecules ...............170 
9.1 Introduction...............................................................................................................170 
9.2 Materials and methods ..............................................................................................172 
9.3 Results.......................................................................................................................175 
9.4 Discussion.................................................................................................................182 
9.5 References.................................................................................................................184 
Chapter 10: General Discussion ..........................................................................................188 
10.1 Epithelial injury/repair and bronchial remodelling.................................................188 
10.2 Vascular remodelling and role of airway smooth muscle derived mediators.........190 
10.3 Limitations of in vitro models ................................................................................193 
10.4 Clinical relevance and implications for future research .........................................194 
10.5 Concluding remarks................................................................................................196 
10.6 References...............................................................................................................198 
Summary ............................................................................................................................204 
Summary in English........................................................................................................204 
Samenvatting (Summary in Dutch) ................................................................................209 
Appendix ............................................................................................................................215 
Acknowledgement ..........................................................................................................215 
About the author .............................................................................................................218 
List of Publications .........................................................................................................219 
List of Figures.................................................................................................................221 
List of Tables ..................................................................................................................222 
List of Abbreviations ......................................................................................................223 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General Introduction 
 
General Introduction                                                                                                 Chapter 1 
 10 
Chapter 1:  General Introduction 
 
1.1 Respiratory system  
The respiratory system includes lungs, the diaphragm and muscles of the chest wall, the 
regulatory neural circuits, pleural spaces and the upper respiratory tract (nasopharynx, 
trachea and larynx). The most important function of the respiratory system is gas exchange, 
fulfilling the basic requirement of continuous oxygen supply to the body tissues. Gas 
exchange involves the transfer of oxygen from air to blood, and carbon dioxide from blood 
to air.  Other functions include acid-base balance, sound production (phonation), 
participating in number of biochemical reactions that affect body functions and providing 
defence mechanisms to prevent the deleterious effects of environmental hazards. The 
respiratory system is subdivided in to two main zones based on morphology and functions.  
The conducting zone, which warms, moistens, and filters the incoming air, includes the 
nasal cavities, paranasal air sinuses, pharynx, larynx, trachea, primary bronchi, lobar 
bronchi, segmental bronchi, bronchioles and terminal bronchioles.  The respiratory zone, 
where gas exchange between alveolar air and the blood stream occurs by diffusion includes 
the respiratory bronchioles, alveolar ducts and alveolar sacs.  
 
1.1.1 Structure and function of the normal airways 
The conducting airway is composed of an epithelial layer, basement membrane, lamina 
propria and cartilages (Figure 1.1).  The epithelial lining is predominantly composed of 
pseudo stratified ciliated columnar epithelium interspersed with mucous glands and 
separated from lamina propria by a basement membrane.  The basal cells, closely attached 
to the basement membrane, are considered to be progenitor cells for the airway epithelium.  
The epithelium serves as a barrier between the respiratory system and the external 
environment.  It forms not only a physical barrier but also an immunologic and metabolic 
barrier (1).  Epithelial damage, observed in asthma, may result in increased permeability 
and easier access of allergens, pollutants, and inflammatory and contractile agents to sub 
epithelial layers (2, 3).  The lamina propria contains loose fibrous tissues with tiny blood 
and lymphatic vessels, elastic and smooth muscle fibres (under control of the autonomic 
nervous system, vagus nerve and sympathetic nervous system). The epithelium together 
with the lamina propria and the basement membrane forms the mucosa (4).  The 
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submucosa, beneath the mucosa, contains; smooth muscle, glands and cartilage.  Smooth 
muscle tone is important in determining airway diameter and thus affects airway resistance.  
Moreover, an increase in the permeability of this microvasculature and plasma exudation is 
considered to be important features of asthmatic airways (5-9).  New vessel formation 
(angiogenesis) can contribute to the thickening of the airway wall. Figure 1.1 is a 
representation of a cross-section of normal human airway. 
 
1.1.2 Pulmonary circulatory system  
The pulmonary circulatory system is comprised of a dual blood supply; bronchial and 
pulmonary arteries as well as veins (10).  The pulmonary arteries supply the bulk of blood 
flowing through the lungs.  Pulmonary arteries bring relatively deoxygenated, carbon 
dioxide-rich blood from peripheral tissues to the lungs via the right ventricle of the heart. 
Pulmonary artery branches run parallel to airways to the level of the terminal bronchioles 
where they break off to form the capillaries in the alveolar walls.  The pulmonary arteries 
are relatively thin-walled vessels with elastic fibres and relatively less smooth muscle than 
systemic arteries.  The bronchial artery arises as an outgrowth from the aorta, providing 
oxygenated blood (11).  The vessels extend longitudinally along the airways to the lung 
periphery as far as the terminal bronchioles.   These vessels have relatively smaller lumen 
and thicker walls than the pulmonary arteries associated with the same bronchus.  The 
bronchial and pulmonary circulations anastomose freely with each other throughout the 
tracheobronchial tree (12). 
 
1.1.3 Factors in normal lung development 
Lung development is influenced by different signalling molecules, growth factors and their 
receptors which mediate tissue interactions by paracrine, autocrine and endocrine 
mechanisms (13).  This regulation of a variety of cellular functions is critical for normal 
lung development and homeostasis.  Growth factors such as fibroblast growth factor (FGF), 
epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and platelet-
derived growth factor (PDGF) signalling via tyrosine kinase receptors, promotes cell 
proliferation and differentiation, while transforming growth factor (TGF) β1 and bone 
morphogenetic protein (BMP) signalling by serine-threonine kinase receptors opposes these 
effects (14, 15). Besides their involvement in lung pattern formation, growth and cell 
differentiation during organogenesis, these factors have also been implicated in modulating 
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injury-repair responses in the adult lung (16). Disturbances in respiratory function may be 
due to disturbed ventilatory function, altered pulmonary circulation, or difficulty in gas 
exchange and they may be acute or chronic. 
1.2 Chronic airway diseases 
Respiratory diseases are increasing cause of morbidity and mortality for all age groups and 
races in the changing global environment.  Today, almost one fifth of all deaths are 
attributable to respiratory illnesses.  The International Classifications of Diseases (ICD-10) 
recognizes many chronic respiratory conditions including the upper respiratory tract like 
rhinitis and chronic inflammation as well as lower respiratory tract conditions such as 
bronchitis, interstitial lung diseases, cystic fibrosis, bronchiectasis besides the major chronic 
airway diseases; chronic obstructive pulmonary disease (COPD) and asthma. 
 
1.2.1 Chronic obstructive pulmonary disease (COPD) 
COPD is a disease state characterized by limitations in lung airflow that are not fully 
reversible.  The airflow limitation is usually both progressive and associated with an 
abnormal inflammatory response of the lungs to toxic particles or gases (17, 18).  Based on 
World Health Organization (WHO) data from 2004, COPD ranks as the fourth leading 
cause of death worldwide, trailing only cardiovascular disease, pneumonia, and HIV/AIDS.  
In terms of morbidity (as measured in Disability Adjusted Life Years, DALYs), COPD 
ranks thirteenth.  Annual healthcare costs are greatly affected by COPD, being estimated at 
2.8x108 € in The Netherlands (in 2000) and over 32.1x109 US$ direct costs in the USA 
(NHLBI morbidity and mortality chart book, 2002) (19).  A diagnosis of COPD should be 
considered in any patient who has symptoms of cough, sputum production, or dyspnoea 
(difficult or laboured breathing), and/or a history of exposure to risk factors for the disease.  
Risk factors (Table 1.1) for COPD include both host factors particular to the patient and 
environmental exposures, and the disease usually arises from an interaction between these 
two types of factors (WHO).  Tobacco smoking including passive smoking, is the main risk 
factor associated with about 80% of COPD cases (20).  Airway hyperresponsiveness, 
α1-antitrypsin deficiency and certain occupational exposures are other established risk 
factors for the development of COPD (The Global Initiative for Chronic Obstructive Lung 
Disease; GOLD).  The diagnosis is confirmed by spirometry, which measures lung function 
and capacity.  Chronic cough and sputum production often precede the development of 
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airflow limitation by many years; although not all individuals with cough and sputum 
production go on to develop COPD. 
 
1.2.2 Asthma 
Asthma is a chronic inflammatory disorder characterized by difficulty in breathing due to 
hyperresponsive airways.  The airways react by narrowing or obstructing the air movement 
and this causes a combination of symptoms such as wheezing, coughing, shortness of breath 
and chest tightness.  Asthma attacks people of all ages, but often starts in childhood.  
Asthma varies in severity and frequency from person to person and may occur from hour to 
hour and day to day.  Although largely avoidable, asthma tends to occur in epidemics and 
usually affects young people giving rise to a severe economic burden.  Worldwide, the 
economic costs associated with asthma are estimated to exceed those of TB and HIV/AIDS 
combined (WHO).  According to the “The Global Initiative for Asthma (GINA)”, host 
factors include genetic predisposition to asthma or atopy, airway hyperresponsiveness, 
gender and ethnicity.  Main environmental factors are exposure to allergens and 
occupational sensitizers, infections, diet, tobacco smoke and socioeconomic status.  Table 
1.1 summarizes the potential risk factors involved in the development of asthma and COPD. 
 
Table 1.1: Potential risk factors for the development of COPD and Asthma  
 Risk Factors  COPD Asthma 
Host Factors Genetic predisposition 
• α1-antitrypsin 
deficiency 
• polymorphism 
Airway hyperresponsiveness 
Lung growth 
Genetic predisposition 
Atopy 
Gender 
Airway hyperresponsiveness 
Race/Ethnicity 
Environmental Factors Tobacco smoke 
Indoor and outdoor air 
pollution 
Infections 
Socioeconomic status 
 
Indoor and outdoor allergens 
Indoor and outdoor air 
pollution 
Infections 
Occupational sensitizers 
Tobacco smoke 
Diet and drugs 
Socioeconomic status 
Based on GOLD (21) and GINA (22) 2005 reports. 
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1.3 Pathophysiology 
The functional consequence of asthma and COPD is airflow limitation, which is mostly 
reversible in asthma and not fully reversible in COPD (23).  The airflow limitation is due to 
cellular and structural changes; remodelling of the small airways and the lung parenchyma, 
promoting airway narrowing and obstruction (24).  The airways in the main categories of 
diseases differ in nature and extent of the inflammatory cell infiltrate, degree of gland cell 
enlargement and goblet cell hyperplasia, bronchiolar smooth muscle mass, reticular 
basement membrane thickening, loss of alveolar attachments, and destructive airspace 
enlargement.  Notwithstanding these differences, there is substantial overlap of these 
conditions in pathological appearance as well as in suspected mechanisms of architectural 
transformation (23).  In a similar context, the “Dutch hypothesis", introduced the concept 
that the airways obstruction associated with asthma, chronic bronchitis, and even 
emphysema is related to different expressions of a primary abnormality in the airways, and 
this might result from a variation in the host response to the external stimuli (25).  In 
asthma, CD4+ T lymphocytes, eosinophils, and mast cells are the predominant cells 
involved, whereas in COPD, the pulmonary inflammation consists of neutrophils, 
macrophages, CD8+ T cells (less prominent in severe COPD), mast cells, and eosinophils 
during exacerbations or in COPD patients showing reversible lung function (23, 26-28). 
COPD can be divided based on either clinical manifestations or pathological features into 
three different disorders: chronic bronchitis with airflow limitation, emphysema and chronic 
bronchiolitis.  COPD is characterised by a progressive lung function decline, measured as 
an increased annual decline in forced expiratory volume in one second (FEV1) (17, 18).  In 
emphysema, alveolar septa are deteriorated resulting in reduced gas exchange, and loss of 
elastic recoil of lung tissue (29).  In chronic bronchitis with airflow limitation, bronchial 
gland enlargement and goblet cell hyperplasia leads to overproduction of mucus, resulting 
in mucoid airways obstruction (29).  Often, COPD patients show a combination of these 
disorders.  Pathophysiological features, in addition to decreased lung function, include 
chronic cough and dyspnoea.  In smokers, epithelial cell metaplasia often occurs, whereas in 
chronic bronchitis a goblet cell metaplasia is seen.  Both types of metaplasia result in an 
impaired ciliary function.  In chronic bronchitis, the hypersecreted mucus cannot be cleared 
sufficiently, resulting in chronic cough and dyspnoea.  After stopping smoking, the decline 
in lung function is minimised but not restored fully and an increased airway resistance and 
inflammation persist (26, 28, 30-36).  It is believed that such decline in lung function is 
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probably due to airway fibrosis and inflammation that reduce the diameter of airway lumen.  
Other mechanisms which are thought to contribute to such (mal)adptation include oxidative 
stress and protease-antiprotease balance (37).  This may be due to genetic predisposition 
involving polymorphisms reported in various genes such as in glutathion-S-transferase, 
epoxide hydrolase, matrix metalloproeteinases (MMPs)-1, 9 or 12 as well as tissue inhibitor 
of metalloproteinase (TIMP)-2.  Additionally, an imbalance occurs due to chronic exposure 
to cigarette smoke and subsequent release of free radicals and proteases (elastase and 
MMPs) from activated inflammatory cells resulting in chronic state of tissue damage, repair 
and remodelling (38-40).  Frequent exacerbations in COPD patients may eventually result 
in increased airway inflammation with eosinophils and neutrophils and higher levels of 
inflammatory mediators like cytokines (40). 
 
In asthma, there is extensive infiltration of the airway with eosinophils and lymphocytes 
accompanied by vasodilatation, microvascular leakage and epithelial disruption (41).  
Inflammation of the bronchi, with associated plasma exudation, oedema, marked smooth 
muscle hypertrophy, mucus plugging and epithelial damage is thought to result in bronchial 
hyperreactivity; airflow limitation and airway hyperresponsiveness.  Trophic changes, 
which arise because of chronic inflammation and repeated cycles of injury and repair, may 
eventually lead to remodelling.  Therefore, the concept of airway remodelling caused by 
abnormal repair of the small airways and parenchyma has become more and more accepted 
(24). 
1.4 Airway remodelling 
Changes in the lung and airway anatomy (remodelling) tend to be context specific and 
elusive.  This process is characterized by structural changes that include alterations in the 
composition, size, mass, number and organization of the cellular and molecular component 
of the airway wall (42, 43).  An attempted repair process usually follows repetitive injury, 
secondary to the chronic inflammation during the progression of the chronic airway 
diseases.  This repair through an autocrine or paracrine mechanism involves highly dynamic 
interactions and cross talks between the resident cells (myofibroblasts, ASM, epithelial, and 
endothelial cells) (44).  Eventually these structural changes have functional consequences, 
as evidenced by clinical symptoms and signs.  There are several components to airway 
remodelling, such as epithelial abnormalities, reticular basement membrane (RBM) 
thickening, matrix abnormalities, increased smooth muscle mass, increased vascularity, 
General Introduction                                                                                                 Chapter 1 
 16 
hypersecretion and hypertrophy of mucous glands and thickening of the airway wall (42, 
43).  Remodelling in asthma involves fragile epithelium, significantly thicker RBM and 
marked smooth muscle enlargement, while in COPD it involves epithelial mucous 
metaplasia, airway wall fibrosis, increased ASM mass and alveolar destruction due to 
inflammation leading to emphysema (35).  Though asthma and COPD are supposedly 
pathologically distinct the remodelling aspects of these diseases have overlapping features 
(42).  Table 1.2 summarises the structural changes and functional consequences in airway 
remodelling.   
 
1.4.1 Epithelial injury and repair 
It is now well established that particles from cigarette smoke causes damage to the airways, 
particularly to the epithelial lining (45).  Both non-symptomatic smokers and patients with 
COPD and asthma show signs of damage and repair to the epithelial surface in the form of 
denuded epithelial lining and squamous metaplasia (35).  Epithelial changes include 
atrophy, squamous metaplasia and loss of ciliated epithelial cells and decrease of cilia 
length and function (24).  The processes of normal and abnormal wound healing as a 
response to injury have been studied extensively (46-50).  In general, wound healing 
involves a series of cellular and molecular events, which initiates after injury of the 
epithelial lining and disruption of the underlying vasculature.  This process is characterized 
by an influx of platelets and inflammatory cells, predominantly neutrophils, followed by 
macrophages and T-lymphocytes.  These platelets and inflammatory cells release many 
growth factors and cytokines, as well as fibrin and fibronectin that act to repair wounded 
tissue.  The environment of cytokines and growth factors, (myo)-fibroblast-derived 
extracellular matrix and adequate nutrient supply via angiogenesis facilitate epithelial cell 
proliferation and migration, leading to wound closure (50).  Within the airways, the 
bronchial epithelium, sub-epithelial myo-fibroblasts and ASM cells are the major cell types 
involved in tissue repair processes.  Figure 1.2 summarizes the cross talk between different 
cell types and eventual remodelling via bronchial epithelial repair and vessel remodelling. 
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Table 1.2: Structural changes and functional consequences in airway remodelling 
Structural Changes Functional Consequences 
Alterations in large airways 
• Epithelial injury 
• Reticular basement membrane thickness 
• Goblet cell hyperplasia 
• Submucosal gland hypertrophy 
• Increased smooth muscle 
Alterations in small airways and lung 
parenchyma 
• Chronic inflammation 
• Mucous metaplasia 
• Increased smooth muscle mass 
• Subepithelial fibrosis 
• Matrix abnormalities 
Alterations in vasculature 
• Vascular dilatation 
• Microvascular leakage 
• Angiogenesis 
• Vascular remodelling 
Increased Symptoms /frequency 
Perpetual inflammation 
Airway hyperresponsiveness 
Mucous hypersecretion 
Airflow limitation / obstruction 
Decreased airway distensibility 
Congestion /Oedema 
Swelling and stiffening of airway wall 
Decreased lung function 
Disease progression 
Irreversibility of airflow limitation 
Death 
 
 
 
1.4.2 Matrix abnormalities 
Altered ECM deposition contributing to the airway wall remodelling is an important feature 
of chronic airway diseases like asthma and COPD.  Proteinases, such as elastase released by 
neutrophils and macrophages, MMPs released by macrophages, eosinophils, lymphocytes, 
neutrophils, and fibroblasts and cathepsins released by macrophages destruct the tissue and 
modulate repair.  These proteinases are inhibited by antiproteinases such as α1-antitrypsin, 
α2-macroglobulin, elafin and TIMPs.  The balance between proteinases and their inhibitors 
is critical in tissue repair and remodelling.  Increased bronchial deposition of ECM proteins, 
such as collagen I and III, fibronectin and laminin has been demonstrated as part of the 
airway remodelling process in patients with COPD (51).  Staining for fibronectin was 
increased in bronchial blood vessels and for laminin in ASM as well as the 
microvasculature in patients with COPD as compared to controls (51).  
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Figure 1.1: Cross-section of normal human airway 
Schematic illustration (left panel) and representative photomicrograph (right panel) of a cross-
section of normal human airway showing the bronchial epithelium, smooth muscle, glands, 
microvessels (V) and cartilage. 
 
 
 
Figure 1.2: Dynamic interacting mechanisms during airway and vascular remodelling in 
chronic airway diseases 
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1.5 Bronchial vasculature in chronic airway disease 
The lung is unique in its double sources of perfusion from the pulmonary and systemic 
circulations and it is the only organ to receive the entire cardiac output.  The pulmonary 
vasculature seems to have much more limited capacity for angiogenesis than the bronchial 
vasculature (11).  In regional lung injury, pulmonary blood flow decreases to the injured 
regions, and anastomotic bronchial blood flow and total bronchial blood flow increase (52).  
Increased, oxygen-rich bronchial blood perfusing during injury may serve a nutrient rather 
than a gas-exchange function.  Acute bronchial artery dilatation observed with hypoxia is 
probably not due to release of dilator prostaglandins, and it is likely a direct effect of 
hypoxic blood on bronchial vascular smooth muscle, similar to the response of other 
systemic arteries (53).  Similarly, the bronchial circulation has angiogenic capacity, as all 
systemic arteries, whereas the pulmonary circulation seems relatively inert in this regard 
(11).  Although the pulmonary veins provide the common drainage pathway for both the 
pulmonary and bronchial circulations, little is known about its remodelling capabilities.  
Given the fact that the pulmonary veins have the capacity to narrow substantially the impact 
of such remodelling on lung pathology may be quite important (11).  In COPD, persistent 
alveolar hypoxia causes pulmonary vasoconstriction and increased muscularization of small 
arterial branches (54).  With sustained vasoconstriction of pulmonary arteries, arterioles and 
veins, the medial vascular smooth muscle (VSM) extends distally to vessels normally 
devoid of smooth muscle (54).  Recent observations indicate that muscular pulmonary and 
bronchiolar arteries have increased adventitial infiltration of CD8+ T-lymphocytes and 
intimal thickening that correlates with collagen deposition (55, 56). 
 
Qualitative and quantitative changes in airway blood vessel has been reported in asthma 
(57).  Oedematous bronchial mucosa with dilated and congested blood vessels along with 
increase in the vascular area has been reported in severe asthma (12, 57, 58).  Submucosal 
vascularity was increased in both the medium and small airways in asthmatic patients (59).  
Evidence suggests that the number and size of bronchial vessels is moderately increased in 
patients with asthma compared with normal individuals (12, 30, 44, 60).  The function of 
bronchial vessel has been extended beyond traditional view of supplying nutrients, 
temperature regulation, humidification of airways and being a portal for immune response 
to that of an important contributor to airflow obstruction and airway remodelling (61, 62). 
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1.6 Bronchial angiogenesis and vascular remodelling 
Angiogenesis and microvascular changes are documented features of chronic inflammatory 
diseases, including asthma and other airway diseases, of which the molecular mechanisms 
are not fully understood (63-66).  Advances in staining methods and availability of vascular 
markers have improved the ability to visualize vessels in tissue specimens.  The 
mechanisms and therapeutic implications of alterations in airway blood vessels are just 
beginning to be elucidated and changes in the microvasculature still represent an important 
gap in the understanding of the pathophysiology of asthma and other chronic inflammatory 
airway disease (63).  During the progression of chronic airway diseases, intimal thickening 
and emergence of smooth muscle cells within the intima of small pulmonary arterial 
branches has been attributed to a chronic inflammatory process accompanied by fibrosis, 
analogous to arteriosclerosis in cardiovascular disease (67, 68).  In COPD, persistent 
alveolar hypoxia causes pulmonary vasoconstriction and increased muscularization of small 
arterial branches (54).  With sustained vasoconstriction of pulmonary arteries, arterioles and 
veins, the medial vascular smooth muscle (VSM) extends distally to vessels normally 
devoid of smooth muscle (54).  Patients with moderate to severe COPD display elevated 
pulmonary vascular pressures during exercise and pathological changes in the pulmonary 
circulation (35, 69).  Wright et al. (69, 70) demonstrated increased wall thickness of small 
(<500 μm) pulmonary vessels in COPD subjects as compared to non-symptomatic smokers, 
which was correlated with the severity of the disease (declined FEV1).  Similar findings of 
vascular abnormalities in COPD have recently been reported with intimal but not medial 
thickening in mild COPD patients compared to non-smoking controls (55, 71). It has been 
postulated that emphysema actually may lead to loss of the pulmonary vascular bed and 
induce angiogenesis (54). 
Figure 1.3: Pulmonary 
vascular remodelling 
Vessel remodelling can occur 
either through adventitial 
(predominantly through 
hyperplasia/hypertrophy of 
fibroblasts) thickening or through 
the medial (mainly through 
vascular smooth muscle growth) 
thickening in different 
pathophysiological conditions of 
lungs. 
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Vascular abnormalities are associated with the development of COPD; conversely, 
advanced COPD leads to pathological changes in the pulmonary circulation (56, 69).  This 
is likely due, in part, to alveolar hypoxia, which is well known to cause pulmonary 
vasoconstriction and, if the hypoxic stimulus persists, pulmonary vascular remodelling takes 
place (54).  Several studies have commented on the importance of structural and functional 
abnormalities in the pulmonary vasculature of COPD patients (55, 56, 71).  Hypoxic 
vasoconstriction is considered to represent one of the major contributing factors of 
pulmonary hypertension and right-sided heart failure in COPD and other chronic pulmonary 
diseases (69, 72).   In addition, emphysema, accompanied by loss of elastic recoil, increased 
pulmonary pressure and destruction of part of the pulmonary microvasculature, may 
contribute to the increased vascular resistance observed in COPD (54, 70).  Thus, several 
phenomena acting in concert in COPD result in pulmonary vascular remodelling.  Yet, little 
is known about the molecular mechanisms underlying these processes in the context of 
COPD.  Figure 1.3 is a diagrammatic representation of two ways (medial or adventitial 
thickening) through which vascular remodelling could occur during chronic lung diseases.   
 
Changes in vasculature can be due to not only hypoxia or ischemia but also different 
pathophysiological process such as tissue hypertrophy (increased ASM mass), wound 
healing (epithelial damage and repair), chronic inflammation and would reflect the 
environment in which it takes place.  The complex molecular events of vascular 
remodelling could be structured into three processes.  The initiation is usually a trigger in 
the form of hypoxia, ischemia or inflammation.  The trigger is sensed by different 
components of the airway and a relay of signal starts within the cell and to adjacent cells.  
The signal induced by a variety of stimuli such as pro-inflammatory mediators, stretch, 
cytokines and growth factors acting in autocrine/paracrine fashion on different cellular 
components (ASM, VSM and epithelial cells) culminates in synthesis of factors (effectors) 
that potentially could take part in angiogenesis and vessel remodelling.  The effectors that 
include angiogenic factors, vasoactive substances, growth regulators and matrix modulators 
influence the growth, death and migration of respective cellular elements taking part in the 
remodelling process along with extra cellular matrix regulation.  Changes in the airway 
microvasculature have been described in many chronic respiratory diseases (63).  In our 
previous reports, we postulated a role for vascular abnormalities in the pathogenesis of 
COPD (51, 74).  Recent studies highlight distinct but interacting remodelling mechanisms 
in permutations of airway disease associated with asthma and COPD.  Some of these 
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mechanisms are generously supported by in vitro, in vivo, and clinical data, whereas others 
are intriguing but more speculative.  Figure 1.4 summarizes the potential scheme of events 
in angiogenesis and vascular remodelling in chronic respiratory diseases. 
 
Table 1.3: Endogenous regulators of angiogenesis* 
Angiogenesis inducers  Angiogenesis inhibitors 
Heparin binding peptide growth factors
VEGF, PlGF, FGF-1,  FGF-2, 
Pleiotrophin, HIV-tat, PDGF, HGF/SF 
Non-heparin binding peptide growth 
factors 
TGF-α,β, EGF, IGF-I 
Inflammatory mediators 
TNF-α, IL-8, IL-3, Prostaglandin E1, E2 
Enzymes 
PD-ECGF/TP, COX-2, Angiogenin 
Hormones 
Oestrogens, Proliferin 
Oligosaccharides 
Hyaluronan oligosaccharides, 
Gangliosides 
Haematopoietic factors 
Erythropoietin, G-CSF, GM-CSF 
Cell adhesion molecules 
VCAM-1, E-selectin 
Others 
Nitric oxide, Ang-1 
Protein fragments 
Angiostatin , Endostatin, ααAT (fragment of 
antithrombin 3),  Prolactin 
Soluble mediators 
TSP-1, Troponin I, IFN-α,γ, PEDF, IP-10,  
PF-4, IL-12, IL-4, VEGI, TIMP-1, -2,  PAI-1, 
Retinoic acid, Ang-2, 2-methoxyoestradiol 
Tumour suppressor genes 
P53, VHL 
VEGF: vascular endothelial growth factor; PlGF: Placental growth factor; FGF: fibroblast growth 
factor; HIV-tat: HIV-transactivating regulatory protein; PDGF: platelet-derived growth factor; 
HGF/SF: hepatocyte growth factor/scatter factor; TGF: transforming growth factor; EGF: 
epidermal growth factor; IGF: insulin-like growth factor; TNF: tumour necrosis factor; IL: 
interleukin; PD-ECGF/TP: platelet-derived endothelial cell growth factor/thymidine phosphorylase; 
COX: cyclo oxygenase; G-CSF: granulocyte colony-stimulating factor; GM-CSF: 
granulocyte-macrophage colony-stimulating factor; VCAM: vascular cell adhesion molecule; Ang: 
angiopoietin; TSP-1: thrombospondin-1; IFN: interferon;  PEDF: pigment-epithelium derived 
factor ; IP-10: interferon-gamma-inducible 10 kD protein; PF4: platelet factor 4; VEGI: Vascular 
endothelial growth inhibitor; TIMP: tissue inhibitor of metalloproteinases; PAI: plasminogen 
activator inhibitor; VHL: von Hippel-Lindau. *Based on reference (75) 
 
1.6.1 Mechanisms of angiogenesis 
Diseased or injured tissues produce and release angiogenic growth factors (proteins) that 
diffuse into the nearby tissues and bind to specific receptors located on the endothelial cells 
(EC) of nearby pre-existing blood vessels.  The activated endothelial cells send signals from 
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the cell's surface to the nucleus.  The endothelial cell's machinery begins to produce new 
molecules including enzymes that dissolve tiny holes in the sheath-like covering (basement 
membrane) surrounding all existing blood vessels.  The endothelial cells begin to divide 
(proliferate), and they migrate out through the dissolved holes of the existing vessel towards 
the diseased tissue.  Sprouting endothelial cells roll up to form a blood vessel tube.  A 
variety of adhesion molecules help the vessel to sprout forward.  Matrix metalloproteinases 
(MMPs) dissolve the tissue and remoulds it around the vessel.  Finally, newly formed blood 
vessel tubes are stabilized by specialized muscle cells (smooth muscle cells, pericytes) that 
provide structural support.  The switch to the angiogenic phenotype involves a change in the 
local equilibrium between positive and negative regulators (Table 1.3) of the growth of 
microvessels. 
 
Figure 1.4: Potential scheme of events in angiogenesis and vascular remodelling in 
chronic respiratory diseases 
Note the stages of trigger, signal transmission, activation of endothelial cells and initiation of the 
angiogenic process.  Adapted from reference (73). 
 
1.7 Role of growth factors 
Growth factors are small to large proteins that are divided in families based on their 
structural or functional homologies.  The main families include the epidermal growth factor 
(EGF) family, transforming growth factor (TGF)-β family, fibroblast growth factors 
(FGFs), insulin-like growth factor (IGF) family, platelet-derived growth factor (PDGF) 
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family, vascular endothelial growth factor (VEGF) family and hepatocyte growth factor 
(HGF).  Growth factors are involved in a variety of processes including cellular 
proliferation, differentiation, migration, metabolism and gene expression.  In airway 
epithelium of asthmatics, expression of EGFR but not of other c-erbB members or of EGF 
family members was enhanced as compared to epithelium from healthy control subjects (76, 
77).  As only the expression of EGFR was increased in airway epithelial cells in a wound 
repair model, it has been suggested that EGFR is involved in epithelial repair in asthmatics, 
while the altered expression also affects airway remodelling in asthma (78).  In the airway 
epithelium of patients with COPD, higher expression of EGFR, heregulin and EGF is 
reported as compared to control subjects (79) indicating that these EGF-like growth factors 
may be involved in pulmonary tissue remodelling in COPD. 
 
1.7.1 Growth factors in tissue repair and remodelling 
Several lines of evidence confirm the wound repair potential of growth factors, such as the 
PDGFs, FGFs, EGF, TGF-α, VEGF, PlGF, angiopoietins, IGFs, nerve growth factor 
(NGF), TGF-β, connective tissue growth factors (CTGF) and other chemokines, cytokines 
and leptins (77, 80-82).  IGF/IGFR-I system and FGF/FGFR-1 system as explored in detail 
in Chapter 2 and 3 respectively have the potential to enhance tissue repair and remodelling.  
 
Insulin like growth factors 
Endocrinologic disturbances and the levels of circulating of IGF-I have been linked with the 
disease processes, such as airway and vascular remodelling in patients with chronic airway 
disease (83).  IGF-I and IGF-II are single chain polypeptides, which play a pivotal role in 
regulating cell proliferation, differentiation and apoptosis.  The mitogenic effects of IGFs 
are primarily mediated through the type I IGF receptor (IGFR-I), which is a tetrameric 
tyrosine kinase receptor composed of two α-chains and two β-chains joined by disulfide 
linkages (84).  Insulin receptor and IGFR-I have 60% homology between them thus 
enabling the IGFs and insulin to cross-bind to each other’s receptor, though weakly (84).  
IGF-I has been reported to promote growth during post-natal life in various organs while 
IGF-II stimulates growth mainly pre-natally (85).  Recent reports suggest that, precise 
delivery on the need of the hour,  of IGF-I to a site-specific location may hasten, improve 
and facilitate the tissue recovery after an injury (86). 
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Fibroblast growth factor system 
The FGF family consists of 23 members in man and their functional receptors are 
designated FGFR1 to FGFR5 (87, 88).  These FGFs are mitogenic factors involved in 
development, tissue homeostasis and repair processes, while FGF-1 and FGF-2 are also 
angiogenic factors (89).  Differences in pulmonary expression of FGF-1, FGF-2 and FGFR1 
were found between non-smokers, or smokers with or without COPD (51, 90).  With regard 
to FGF-2, airway expression is higher in bronchial tissue from asthmatics as compared to 
healthy control subjects (91).  In COPD, expression levels of FGF-1, FGF-2 and FGFR1 
were observed to be increased in vascular and in epithelial compartments in lungs of 
patients with COPD as compared to subjects without COPD (74, 92).  FGF-1 can stimulate 
tissue remodelling by increasing collagenase expression and down-regulation of collagen I 
expression in lung fibroblasts (93).  These data support a role for the FGF-FGFR axis in 
tissue remodelling in COPD. 
 
1.7.2 Angiogenic growth factors 
Some of the heparin binding peptide growth factors (VEGFs, FGFs) and non-heparin 
binding peptide growth factors (TGFs, IGFs) are known angiogenic inducers (Table 1.3).  
Amongst the above mentioned and known factors, vascular endothelial growth factor 
(VEGF) family is the most potent and studied, direct angiogenic factor.  Moreover, 
cytokines (IL-6, oncostatin-M) and growth factors (IGF, TGF), which may be called 
indirect angiogenic factors, take part in angiogenesis via production of VEGF-like 
molecules. 
 
Vascular endothelial growth factor system 
The VEGF family consists of seven members (VEGF-A to VEGF-F and placenta growth 
factor PlGF), which bind to their respective cellular receptors VEGFR-1 (or Flt-1), 
VEGFR-2 (or KDR or Flk-1), and VEGFR-3 (or Flt-4).  VEGF is predominantly known as 
a paracrine angiogenic factor stimulating mitogenesis, migration and permeabilisation of the 
vascular endothelium.  Several studies support the idea that VEGF and its receptors 
contribute to tissue remodelling and disease severity in chronic lung diseases including 
asthma (92, 94).  In patients with COPD, higher pulmonary VEGF expression was found in 
bronchial and alveolar epithelial and vascular smooth muscle as well as alveolar 
macrophages, whereas higher VEGFR-1 and VEGFR-2 expression was found in the 
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endothelium as compared to patients without COPD (74).  Over expression of VEGF in 
mice caused pulmonary emphysema, aberrant structure of capillary endothelium, and 
pulmonary inflammation with macrophages (95).  Also transgenic over expression of PlGF 
caused apoptosis of pneumocytes, emphysema and a reduced endothelial cell number and 
VEGF expression (96).  Although not conclusive, data from these animal studies further 
support a role of VEGFs and their receptors in tissue and vascular remodelling as seen in 
patients with COPD. In addition, subjects with COPD showed an increased pulmonary 
vascular remodelling and thicker vessel walls (51).  In contrast, in subjects with 
emphysema, pulmonary VEGF and VEGFR2 expression is lower as compared to subjects 
without COPD.  Concomitant with the decreased expression, endothelial cell death and 
decreased endothelial proliferation occurred (97).  Supporting evidence for the role of 
VEGFR2 in emphysema was provided in an animal model in which VEGFR2 was blocked 
resulting in pulmonary endothelial cell apoptosis and emphysema (98).  Table 1.4 lists the 
expression patterns of some of the growth factors in COPD. 
 
Table 1.4: Expression of growth factors and cytokines in COPD* 
Molecule Product Compartment 
Expression/ 
Subtype Key references 
EGF protein lung tissue ↑  (CB) Vignola et al. (99) 
HER1 protein lung tissue ↑ (COPD) de Boer et al. (79)  
HER3 protein lung tissue ↑ (COPD) O’Donnell et al. (100) 
FGF-1 protein lung tissue ↑ (COPD) Kranenburg et al. (51, 90) 
FGF-2 protein lung tissue ↑ (COPD) Kranenburg et al. (51, 90) 
FGFR1 protein lung tissue ↑
  
(COPD) Kranenburg et al. (51, 90) 
TGFβ1 protein 
mRNA 
lung tissue 
lung tissue 
↑
↑
(COPD) 
(COPD) 
de Boer (101); Takizawa et al. (102) 
de Boer (101);Takizawa et al. (102) 
VEGF protein 
protein 
lung tissue 
lung tissue 
sp 
sp 
↓
↑
↓
↑
(emphys) 
(COPD) 
(emphys) 
COPD) 
Kasahara (97); Santos et al. (103) 
Kranenburg (74); Santos et al. (103) 
Kanazawa et al. (94) 
Kanazawa et al. (94) 
VEGFR1 protein lung tissue ↑
  
(COPD) Kranenburg et al. (74) 
VEGFR2 protein lung tissue ↓
↑
  
(emphys ) 
(COPD) 
Kasahara (97) 
Kranenburg et al. (74) 
sp = induced sputum; CB = chronic bronchitis; emphys = severe emphysema; EGF= epidermal 
growth factor; HER- EGF receptor; HER= EGF receptor; FGF=fibroblast growth factor; 
TGFb1= transforming growth factor-β1; VEGF=vascular endothelial growth factor; VEGFR= 
VEGF receptor.  *Based on reference (104) 
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1.8 Airway smooth muscle and beyond 
Airway smooth muscle research has gone a long way now after the acknowledgment that 
the ASM is not just a structural component in the chronic airway diseases.  Traditional view 
that ASM is a merely passive participant in inflammation and contracts and relaxes in 
response to inflammatory mediators and bronco dilators respectively has now changed 
(105).  It is now recognized that ASM, the most important cell type in airway remodelling, 
can be a rich source of biologically active chemokines, cytokines, matrix proteins, matrix 
metalloproteinases and their tissue inhibitors, adhesion molecules, bronchoprotective 
factors, surface receptors, lipid mediators, enzymes and growth factors; in short ASM is a 
biological factory (105-111).  Table 1.5 depicts the immunomodulatory molecules 
expressed by ASM cells in response to a variety of stimuli.   
 
Since the advent of human ASM cells in culture, the synthetic and highly proliferative 
properties of ASM cells have been discovered as well as the effects of various mitogens and 
the signal transduction pathways leading to ASM proliferation have been studied 
intensively (112).  Mitogenic effects in ASM cells are mediated through at least two distinct 
receptor systems: Receptor tyrosine-kinase (e.g. platelet derived growth factor, epidermal 
growth factor as well as acidic and basic FGF) and G protein-coupled receptors (e.g. 
thrombin) (112, 113).  Table 1.6 summarizes the known ASM cell mitogens. 
 
The synthetic response of ASM cells can vary both qualitatively and quantitatively in health 
and disease.  Moreover, the synthesized contractile, inflammatory, growth and angiogenic 
mediators are readily available not only to act in a paracrine fashion on the nearby cells but 
also via an autocrine mechanism could influence further the heterogeneity of ASM 
phenotype expression (107).  Mitzner (114), Seow and Fredberg (115) have discussed the 
possibility that the potential functions of airway smooth muscle are not essential to normal 
lung physiology.  However, the muscle is influenced by its dynamic microenvironment in 
the diseased state.  Figure 1.5 shows the various phenotypes exhibited by the ASM under 
the influence of mediators and an altered environment.  Moreover, the potential interaction 
between ASM cells and resident cells and infiltrating inflammatory cells (Figure 1.6) may 
indeed play a pivotal role in the vicious cycle of disease progression. 
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Table 1.5: Immunomodulatory molecules expressed by airway smooth muscle cells* 
Chemokines Cytokines Growth Factors 
Surface 
molecules/ 
receptors 
ECM 
Lipid 
mediators/
enzymes 
RANTES 
IL-8 
MCP-1,2,3 
Eotaxin 
IL-1β, 2, 
5, 6, 10, 
11, 13 
GM-CSF 
IFN-β 
LIF 
NGF 
PDGF-BB
FGF-1,2 
IGF-1 
TGF-β1, 
β2 
SCF 
CTGF 
VEGF 
 
 
VCAM-1 
ICAM-1 
α9β1 
α5β1 
ανβ6 
CD40, 44, 80, 
86 
IL-2R,4Rα6R, 
12R, 13Rα1, 
α2 
IFNγR 
FGF-1/2R 
VEGF-1/2R 
Fibronectin 
Laminin 
Pro-collagen 
Perlecan 
Tenascin-C 
MMPs-1,2,3,9,10,12 
TIMP-1,2 
Betaig-h3 
Chondroitin 
Thrombospondin 
Verisican 
Decorin 
PGE2 
PGD2 
PGF2α 
NOS 
TxA2 
*Adapted from References (105-107, 109, 111) 
 
Table 1.6: Airway smooth muscle cell mitogens 
Growth Factor Inflammatory mediators:  Cytokine /Cell derived Contractile agonist 
Intrinsic protein 
tyrosine kinase (RTK) Cell surface glycoprotein receptors 
G protein-coupled 
receptors (GPCRs) 
PI3K, ERK, protein kinase C- dependant and reactive oxygen-dependent pathways  
Epidermal Growth 
factor 
Insulin-like growth 
factors 
Platelet-derived growth 
factor 
Basic fibroblast growth 
factor  
Interleukin-1β 
Tumour necrosis factor-α 
Lysosomal hydrolases 
(β-hexosaminidases and 
β-glucuronidase) 
α-thrombin 
tryptase 
sphingosine 1-phosphate  
histamine 
endothelin-1 
Substance P 
phenylephrine 
serotonin 
thromboxane A2  
leukotriene D4 
Mechanical Stretch  
 
 
1.8.1 Cellular crosstalk with ASM 
It is now well established that the ASM cells interact with both infiltrating cells such as 
mast cells, neutrophils, eosinophils, macrophages and resident cells such as fibroblasts, 
epithelial cells and endothelial cells (Figure 1.6).  ASM cells have been shown to secrete 
regulated on activation, normal T cells expressed and secreted (RANTES), eotaxin, IL-8, 
monocyte chemotactic protein (MCP) 1, MCP-2, MCP-3, thymus and activation-regulated 
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chemokine, and GM-CSF (105, 108).  In addition to secreting chemokines that recruit 
leukocytes into the airways, ASM promote leukocyte retention and activation through the 
expression of cell adhesion molecules (108).  Thus, the intertwined relationship between the 
infiltrating cells and ASM cells helps to perpetuate the inflammatory processes. 
 
Evidences propose the cross talk between the damaged/activated epithelial cells and ASM 
cells in diseases such as asthma and COPD (35, 42).  We hypothesized that growth factors 
such as FGF and IGF expressed by ASM cells (90, 116, 117) most likely in response to 
epithelial injury would enhance the repair potential of the self-healing epithelium.  In vivo 
and in vitro data indicate that smooth muscle cells, and their cross-talk with myo-fibroblasts 
and inflammatory cells via growth factors and cytokines, are major actors in airway 
remodelling due to a variety of pathophysiological conditions (90, 93, 118-120). 
 
Attention has also been given recently to the bidirectional relationship between ASM cells 
and the ECM (121).  In addition to increased synthesis of ECM proteins, ASM cells can be 
involved in down regulation of matrix metalloproteinases (MMPs) and up regulation of 
tissue inhibitors of metalloproteinases (TIMPs) thus eventually contributing to the alteration 
in ECM.  In turn, ECM proteins promote the survival, proliferation, cytokine synthesis, 
migration and contraction of human airway smooth muscle cells.  Thus, the intertwined 
relationship of ASM and ECM and their response to stimuli like chronic inflammation in 
diseases like asthma and COPD contribute to the remodelling seen in airways of patients 
with these diseases (121). 
 
More recently, ASM cells and its interaction with endothelial cells in the perspective of 
angiogenesis in chronic respiratory diseases have come under limelight.  We (122) and 
others (123-125) have shown that sensitized ASM cells secrete VEGF which is readily 
available for acting on neighbouring endothelial cells.  Enhanced expression of VEGF in 
ASM and VSM has been reported in diseases such as COPD (74, 103), as investigated in 
Chapter 4 suggesting that ASM cells have an important role in vascular remodelling and 
angiogenesis in chronic airway diseases.  Thus, it is more likely that the active contribution 
of these cells (ASM) make to the development and perpetuation of chronic airway diseases 
may be in fact greater than what it has been recognised.  Several in vitro models have paved 
the way to decipher these molecular interactions. 
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Figure 1.5: Multifaceted airway smooth muscle cell 
Upon the influence of variety of mediators the airway smooth muscle cell exhibit versatile 
phenotypes such as proliferative, migratory, contractile and synthetic phenotype. 
 
 
 
Figure 1.6: Cellular crosstalk between airway smooth muscle cells with infiltrating cells 
and other resident cells in the airways 
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1.9 In vitro models of bronchial and vascular remodelling 
Recent advances in the field of molecular and cellular biology have enabled us to develop 
methodologies on which cells could be cultured and then manipulated to express phenotypic 
surface markers, to produce immunomodulatory cytokines and represent the molecular 
events in a given situation.  Excellent models (22, 126, 127) have been developed over the 
years which are simple and reproducible; important tools to reveal the molecular events and 
to deduce mechanisms of action.  Research has now massively adopted the low-cost, 
in vitro, molecular biology techniques in lieu of the idiosyncratic and expensive in vivo 
models.  Currently, in vitro models and experiments are a vital and highly productive 
research tool. 
 
1.9.1 Epithelial wound/repair model 
Three different wound models have been described: (A) straight mechanical scratch model, 
(B) crosshatch model and (C) circular wound model (Figure 1.7).  The mechanical scratch 
model and crosshatch model involved scraping the cells using a pipette tip.  However, 
taking into consideration the possible damage caused to the plate surface by the plastic 
pipette tips in the other models and the precision of taking images of the same wound area 
the circular wound repair model as reported previously has been explored in this thesis 
(126).  Images were collected using a digital camera after regular time intervals and 
analyzed using ImageJ 1.32j software (National institutes of health, Bethesda, USA) for 
percentage wound closure at various time points. This model represents a simple over view 
of how the repair process eventually takes place in a cell system with relevant factors and 
inhibitors. 
 
Figure 1.7: Examples of different in vitro wound repair models 
Representative examples of different wound repair models experimented.  Panel A represents a 
straight mechanical scratch model.  Original magnification: x20.  Panel B represents a crosshatch 
model, Original magnification: x10 and Panel C represents the circular wound model, Original 
magnification: x4. 
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1.9.2 Human ASM and endothelial cell based model of angiogenesis 
Airway smooth muscle cells in culture have been used as a successful model over the past 
few years.  They have provided new insights into the nature of smooth muscle function in 
disease and led to the recognition of multiple phenotypes: contractile, proliferative and 
synthetic (128).  We have extended this model further in order to explore the angiogenic 
potential of airway smooth muscle derived soluble factors.  Isolated and cultured primary 
human ASM cells and pulmonary artery endothelial cells have been characterized 
morphologically (hill and valley appearance: ASM, cobblestone appearance: endothelial 
cells) and immunohistochemically with respective specific markers for purity.  The 
conditioned media from stimulated or sensitised ASM cells, routinely collected and stored 
appropriately (-20 Cْ), were then used to stimulate the endothelial cells for different time 
and experimental conditions.  The proliferative potential of the angiogenic molecules 
secreted  in the conditioned medium by the sensitized ASM cells were assessed and was 
used as an indicator for angiogenesis (129, 130).  Respective inhibitors of the ASM derived 
factors confirm their angiogenic potential. 
 
1.9.3 In vitro cyclical stretch model 
ASM cells, in vivo, undergo cycles of stretching and shortening during respiration.  
However, in disease conditions like asthma and COPD due to airway narrowing and airflow 
limitation there is enhance stretch and a state of hypercontractility.  Stretching cells in 
culture simulates the in vivo environment causing dramatic morphologic and biochemical 
responses.  Many in vitro stretch models, using rat bronchial ring (131), bovine tracheas 
(132) or human ASM cells (127, 133-135), have been developed in order to mimic this 
pathophysiologic state.  This model applies a defined, controlled, static or cyclic 
deformation to cultured cells.  The pattern of cyclical stretch and the strength of the applied 
strain could be varied and fine-tuned in this model according to the disease condition using 
a computer-controlled vacuum.  Human ASM cells are plated onto type I collagen-coated 
wells made up of a flexible silastic membrane bottom.  The cells are subjected to cyclic 
strain at 1 Hz for different time intervals, using the Flexcer cell unit, FX 2000); Figure 1.8.  
Depending upon the culture plates the mechanical stretch may be uniaxial or biaxial (radial 
and circumferential). 
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Figure 1.8: Mechanical stretch apparatus 
Representative photograph of the mechanical stretch apparatus; Flexer cell unit (FX 2000) with 
attached base plate and a computer controlled vacuum system. Zoomed panel below shows the 
“BioFlex” 6 well, cell culture plate, coated with collagen-I and having a flexible bottom made up of 
silastic membrane, placed on the base plate inside the incubator under experimental conditions.  
 
The available evidence (131, 136, 137) suggests that upon in vitro mechanical stretch,  
ASM cells respond with increased proliferation, cell reorientation, protein production, 
reorientation of stress fibres and hence contribute to airway remodelling.  In this thesis, we 
have focused on the effect of cyclical mechanical stretch on angiogenic molecule secretion 
by the ASM cells in vitro. 
 
1.10 Aims of the thesis 
Increasingly, it has become clear that ASM cells are not only structural and contractile 
components of airways, rather they can express and release a large number of 
pro-inflammatory and mitogenic factors (e.g. IL-1β, TNF-α, IL-6, IL-8, TGF-β1, FGF, 
PDGF and VEGF) that may play a pivotal role in regulating the airway and vascular 
remodelling.  Thus we hypothesized that proliferating ASM cells produce angiogenic 
factors upon sensitization with mediators of Asthma and COPD and that the up-regulated 
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pulmonary expression of various growth factors could contribute via autocrine/paracrine 
pathways to epithelial repair, bronchial angiogenesis and vascular remodelling during 
chronic lung diseases. The central aim of the thesis is to investigate the molecular 
mechanisms involved in bronchial and vascular remodelling in chronic airway diseases.  
Employing the techniques of cell culture, immunohistochemistry, pharmacology and 
molecular biology, in this thesis we explored the following questions: 
 
1. Do IGF-I/IGFR-I and FGF/FGFR-1 systems play a pivotal role in epithelial repair in 
COPD (Chapter 2 and 3)? 
2. What is the expression pattern of various angiogenic molecules (VEGF, Flt-1 and 
KDR/Flk-1) in COPD and other chronic airway diseases (Chapter 4, 5)? 
3. Do ASM cells express and release angiogenic molecule, VEGF in response to 
pro-inflammatory cytokines (IL-1β and TNF-α; Chapter 6), vasoactive peptides 
(ANG-II and ET-1; Chapter 7) and if the secreted VEGF is biologically active as 
assessed by in vitro angiogenesis? 
4. Does nitric oxide play a role in pro-inflammatory cytokine (IL-1β) induced VEGF 
synthesis by ASM cells (Chapter 8)? 
5. Whether cyclic mechanical stretch leads to the expression and secretion of different 
pro-angiogenic molecules in human ASM cells (Chapter 9)? 
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Chapter 2:  Role of Insulin-Like Growth Factor-I and IGFR-I in Airway 
Epithelial Repair 
 
Summary 
Airway epithelial injury and repair and associated remodelling processes are common 
features in chronic obstructive pulmonary disease (COPD).  Insulin-like growth factors 
(IGF-I and II), exerting their mitogenic action primarily via IGF-I receptor (IGFR-I), could 
play a role in bronchial re-epithelialisation and airway remodelling.  We investigated the 
bronchial expression pattern of IGF-I and IGFR-I in COPD patients in relation to lung 
function data and further assessed the mitogenic potential of IGFs in an in vitro wound 
injury repair model.  Serial sections of lung tissue obtained from COPD (FEV1 <75%; 
n=14) and non-COPD (FEV1 >85%; n=15) patients were immunohistochemically stained 
for IGF-I and IGFR-I and the expression levels were correlated with lung function data.  
[3H]thymidine incorporation and cell counts assessed the mitogenic effects of IGFs, 
whereas mechanically injured confluent monolayer of NCI-H292 cells constituted the 
in vitro wound repair model.  Enhanced expression of IGF-I was localized in airway (ASM, 
p≤0.001) and vascular smooth muscle (VSM, p≤0.02) cells in patients with COPD as 
compared to controls and inversely correlated with respective lung function data 
(FEV1/FVC).  IGFR-I was localized in epithelial cells and its expression levels remained 
unaltered between two groups.  IGF-I and IGF-II induced cell proliferation (2-5 folds) and 
growth (2-4 folds) of ASM as well as NCI-H292 cells.  Repair experiments demonstrated 
accelerated wound closure after 72 h of IGFs treatment.  Taken together, our results suggest 
that IGF-I/IGFR-I system play a pivotal role in epithelial repair processes and hence 
contribute to the airway remodelling in COPD. 
 
2.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is characterized by reduced expiratory flow 
and airway inflammation.  This airflow limitation may be irreversible due to the narrowed 
airway lumen and alveolar destruction, while the release of multiple mediators and 
increased number of alveolar macrophages and neutrophils contribute to the airway 
inflammation.  Inflammation in COPD could further be perpetuated by the presence of high 
level of oxidative stress due to cigarette smoke which is an important etiological factor (1).  
The bronchial epithelium and airway smooth muscle are two major cell types involved in 
the airway remodelling (2).  Cellular events in these airways reveal selective bronchial 
epithelial cell damage and intense inflammation (3).  Studies have shown that repetitive 
injury and repair of the bronchial epithelium involves cell proliferation and migration that 
lead to the tissue remodelling and subsequent irreversible changes in the airways (4-7).  The 
repair of the damaged epithelium is crucial for restoration of barrier function and reduction 
of inflammation of which the molecular mechanisms are poorly understood.  A variety of 
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growth factors including insulin like growth factors (IGFs) could play a role in bronchial 
re-epithelialisation and airway remodelling during chronic airway diseases (8, 9). 
 
Both IGF-I and IGF-II are single chain polypeptides, which play a pivotal role in regulating 
cell proliferation, differentiation and apoptosis.  The mitogenic effects of IGFs are primarily 
mediated through the type I IGF receptor (IGFR-I), which is a tetrameric tyrosine kinase 
receptor composed of two α-chains and two β-chains joined by disulfide linkages (10).  
Insulin receptor and IGFR-I have 60% homology between them thus enabling the IGFs and 
insulin to cross-bind to each other’s receptor, though weakly (10).  Endocrinologic 
disturbances and the levels of circulating of IGF-I have been linked with the disease 
processes like airway and vascular remodelling in patients with chronic airway disease (11).   
In order to assess the role of IGFs/IGFR-I system in the pathogenesis of COPD, we 
examined the expression pattern of IGF-I and IGFR-I in lung tissue specimens obtained 
from patients with or without COPD and investigated the mitogenic effects of both IGF-I 
and IGF-II on cultured human airway epithelial and smooth muscle cells.  In addition, we 
examined the wound repair potential of IGFs in a cultured airway epithelial cell model. 
2.2 Materials and methods 
2.2.1 Selection of specimens 
The lung tissue specimens were taken from the bronchial airways, at a distance from the 
tumour in patients with or without COPD.   Based on lung function data (Table 2.1), 
subjects were assigned to the COPD (n=14) and non-COPD (15) groups (12, 13).  All lung 
tissues were fixed in 10% neutral buffered formalin for approximately 24 h after which the 
tissues were further processed for embedding in paraffin and immunohistochemical 
staining.  The patients in these two groups participated in a larger research project, part of 
which has been published previously (14, 15). 
 
All patients were free of symptoms of upper respiratory tract infection and they did not 
receive antibiotics preoperatively.  Except three in the COPD group, patients did not receive 
glucocorticosteroids in the period of three months prior to operation.  All selected lung 
tissues were checked histologically using the following exclusion criteria: (i) presence of 
tumour in the lung tissue specimen submitted for the study, (ii) presence of poststenotic 
pneumonia in the specimen, (iii) fibrosis of lung parenchyma, and (iv) obstruction of the 
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main bronchus of the resection specimen by tumour, regardless of the histology of the 
specimen intended for this study (12, 13). 
 
2.2.2 Pulmonary Function Tests 
All pulmonary function tests were performed within 3 months prior to surgery.  FEV1 and 
forced vital capacity (FVC) were measured by spirometry, total lung capacity and residual 
volume with the closed circuit helium dilution test and the Kco using the single 
breath-holding technique, as described by Quanjer and co-workers (16). 
 
Table 2:1 Parameters used to classify subjects as COPD and Non-COPD 
FEV1: Forced one-second expiratory volume calculated as % of predicted value before 
bronchodilatation, FEV1/Forced Vital Capacity (FVC) ratio <75%, reversibility in FEV1 
calculated as % of predicted after 400 μg inhaled salbutamol (12, 13), and Kco is transfer factor for 
carbon monoxide (diffusion capacity) per litre alveolar volume calculated as % of predicted value.  
In order to exclude accompanying lung disease leading to a restrictive function disorder, it was 
required that the total lung capacity (TLC) of each subject included in the study was over 80% of 
the predicted value (16). 
 
2.2.3 Immunohistochemistry 
Sections of paraffin-embedded lung tissue were cut at 4 μm, mounted on Super Frost Plus® 
microscopic slides (Meinzl-Gläser, Braunschweig, Germany) and processed for 
immunohistochemistry.  Serial sections were used to detect the expression of IGF-I and 
IGFR-I employing immunohistochemistry.  Sections were deparaffinised and rehydrated 
prior to incubation with specific purified mouse monoclonal antibodies raised against 
human IGF-I and IGFR-I (Neomarkers, Fremont, CA, USA), as described previously (17).  
The optimal dilutions for all antibodies were identified by examining the intensity of staining 
obtained with a series of dilutions: the optimum concentration resulted in specific and easily 
visible signal on paraffin sections of control specimens.  To block non-specific second 
antibody binding, sections were pre-incubated with 5% bovine serum albumin in phosphate 
Criteria COPD NON-COPD 
FEV1 <75%  >85% 
FEV1/FVC ratio  <75%, >85% 
Reversibility of FEV1 <12% <12% 
Kco <80% >80% 
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buffered saline (5% BSA/PBS, pH = 7.4).  Subsequently, sections were incubated overnight 
at 4 °C with primary antibodies diluted appropriately (IGF-I, 1:50 and IGFR-I, 1:1000).  
IGF-I immunostaining was performed after antigen retrieval by boiling in citrate buffer 
(10 mM citrate buffer, pH = 6.0) for 10 min in a microwave oven while IGFR-I was done 
using pronase pretreatment for 10 min.  Incubation for 30 min with post antibody blocking 
for power vision plus (Immunovision technologies, The Netherlands) and 30 min with poly 
HRP-GAM/ R IgG (Immunovision technologies, The Netherlands) were used to enhance the 
detection sensitivity.  Colour was developed by staining with 3,3-diaminobenzidine (Sigma, 
St Louis, USA) dissolved in PBS containing 0.03% H2O2.  Sections were subsequently, 
counter-stained with Mayer's haematoxylin.  Slides were mounted and studied 
light-microscopically.  Negative controls consisted of omission of the primary antibody. 
 
2.2.4 Quantification of staining 
To assess the expression levels of IGF-I and IGFR-I, a visual scoring method on 
immunostained tissue sections was applied.  Prior to screening, sections were coded so that the 
observers were unaware of the clinical details of the case under study.  Expression of IGF-I 
and IGFR-I was analyzed semi-quantitatively, using a visual scoring method with grades 
ranging from 0 to 3 (0 = no staining; 1 = moderate staining; 2 = intense staining; 3 = very 
intense staining) as previously described (12, 18, 19).  The entire slide of a tissue block was 
investigated and scored at the same magnification.  The staining intensity of IGF-I and IGFR-I 
was scored by three independent observers in bronchial airways as well as alveolar 
parenchyma in epithelial, smooth muscle cells and in macrophages.  Inter observer errors were 
tested by correlating the expression scores using Pearson’s analysis and found a high 
correlation ranging from 0.7 to 1.  In the bronchial airways staining for IGF-I and IGFR-I was 
assessed in the bronchial epithelium, airway smooth muscle (ASM) and vascular smooth 
muscle cells and macrophages in the bronchial airway wall.  Similarly, in peripheral lung 
tissues the staining of IGF-I and IGF-I receptor was analyzed in bronchiolar an alveolar 
epithelium, bronchiolar ASM and VSM cells, and alveolar macrophages. 
 
2.2.5 Isolation and culture of human airway smooth muscle cells 
Human airway smooth muscle cells were isolated and cultured as described previously (20, 
21).  Briefly, bronchial smooth muscle was dissected from a fresh macroscopically normal 
lobar or main bronchus.  After removal of the epithelium, parts of smooth muscle was 
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dissected free of adherent connective and peripheral lung tissue under aseptic conditions.  
Smooth muscle pieces were incubated in Hank's balanced salt solution (HBSS; Life 
Technologies BV, Breda, The Netherlands) containing bovine serum albumin (BSA, 10 
mg/ml), collagenase (type XI, 1 mg/ml) and elastase (3.3 U/ml; Sigma-Aldrich  BV, 
Zwijndrecht, The Netherlands) at 37°C in a humidified incubator containing 5% CO2 / 95% 
air.  After enzymatic digestion, the cell suspension was centrifuged and the pellet was 
washed in Dulbecco's modified Eagle's medium (DMEM) (Life Technologies BV, Breda, 
The Netherlands) containing 10% (v/v) heat-inactivated foetal bovine serum (FBS) 
(Bio-Whithaker BV, Verviers, Belgium) supplemented with sodium pyruvate (1 mM), 
nonessential amino acid mixture (1:100), gentamicin (45 μg/ml), penicillin (100 U/ml), 
streptomycin (100 μg/ml) and amphotericin B (1.5 μg/ml) (Life Technologies BV, Breda, 
The Netherlands).  Cells were subsequently seeded at 2x105 cells per 35 mm dish and 
maintained in culture by replacing the medium every 48 h.  After 10-14 days in culture, 
ASM cells grew to confluence and were then detached by trypsinization (0.5% trypsin; 
0.02% EDTA; Life Technologies BV, Breda, The Netherlands) and subcultured into 25 cm2 
and 75 cm2 tissue culture flasks.  Immunocytochemical staining of confluent 
serum-deprived primary cultures of human ASM cells, using monoclonal antibodies to 
smooth muscle α-actin and smooth muscle-myosin heavy chain (SM1 and SM2) 
(Sigma-Aldrich  BV, Zwijndrecht, The Netherlands) (20, 21), demonstrated that the cultures 
were essentially free (>95%) of other contaminating cell types. 
 
2.2.6 Culture of NCI-H292 cells 
NCI-H292 cells, a human pulmonary mucoepidermoid carcinoma cell line, were cultured in 
RPMI 1640 medium containing 10% foetal bovine serum (FBS; Bio-Whitaker BV, 
Verviers, Belgium) supplemented with sodium pyruvate (2 mM), gentamicin (50 μg/ml), 
L-glutamine (4 mM), HEPES (10 μM), penicillin (5 U/ml), streptomycin (5 μg/ml) at 37 °C in 
a 5% CO2-humidified atmosphere.  Cells were maintained in culture by replacing the medium 
every 48 h and when confluent were further passaged using trypsin/EDTA solutions into 
75cm2 tissue culture flasks.  Near confluent cells were used for all the experiments. 
 
2.2.7 Proliferation assays 
[3H]thymidine uptake: Serum deprived NCI-H292 and ASM cells (quadruplo in 96 wells 
plates) were incubated with 100 µl serum-free medium alone (negative control) or 
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supplemented with 10% FBS (positive control), 5 ng/ml human recombinant IGF-I, which 
has been reported to induce near maximal proliferation in NCI-H292 cells (4),  or 5 ng/ml 
IGF-II.   The NCI-H292 cells were stimulated for 8, 16 and 24 h while the ASM cells were 
stimulated for 8, 24 and 48 h.  Five hours prior to the end of the treatment 10 μl of 
[3H]thymidine (1 μCi/10 μl in HBSS; Amersham, Roosendaal, the Netherlands) was added 
to the wells, at a final concentration of 1 μCi/110 μl per well.  The medium was removed 
after the time points and the cells were washed twice with cold PBS.  The cells were 
detached with 50 μl trypsin for 10 min after which 50 μl PBS was added.  Cells were frozen 
overnight at –20°C and subsequently harvested on glass fibre filters using a Filtermate 
196 cell harvester (Packard, Meridan, USA).  Activity was counted using a Microplate 
Scintillation ß-counter (Topcount, Packard, Meridan, USA) and measured radioactivity was 
expressed as counts per min (CPM).  The mean CPM of quadruple wells was expressed as 
ratio as compared to control cells in serum free medium (fold-induction). 
 
Cell counts: In a parallel series of experiments, 200.000 cells were seeded in 24 well plates.  
Serum deprived NCI-H292 and ASM cells (in quadruplo) were stimulated for 24 and 48 h 
with IGF-I, or IGF-II or controls and cell numbers were determined using automated cell 
counting (Casy®1, Schärfe system GmbH, Reutingen, Germany).  After stimulation, the 
cells were trypsinized with 100 μl Trypsin/EDTA for 10 min.  Cells in suspension were 
added to 10 ml of Casy®1 isotonic solution (6.38 g/l NaCl, 0.2 g/l Na-tetraborate, 1.0 g/l 
Boric acid and 0.2 g/l EDTA).  Cell numbers, volumes and diameters were measured and 
analyzed using Casey®1 system software. 
 
2.2.8 Epithelial injury and repair model 
Circular wound repair model as described previously (22) was employed where three 
circular wounds (3 mm in diameter) were scraped in confluent monolayer of overnight 
serum deprived NCI-H292 cells.  The wounded monolayers were incubated in serum-free 
medium alone or supplemented with IGF-I or IGF-II (5 or 10 ng/ml) or 10%FBS (positive 
control).  Images were collected using a digital camera after 0, 24, 48 and 72 h and analyzed 
using ImageJ 1.32j software (National Institutes of Health, USA) by determining the 
percentage wound closure as compared with the time point of starting the stimulation (t = 0, 
Figure 2.1). 
 
IGF in Epithelial Repair                                                                                            Chapter 2
  
 50 
2.2.9 Statistical analysis 
Data were statistically analysed using the unpaired, two-tailed Students’ t-test as well as the 
non-parametric Mann-Whitney test when the distribution was not normal.  Data were 
expressed as mean±SEM.  Differences with p≤0.05 were considered statistically significant.  
Spearman’s correlation between FEV1/FVC values and expression of IGF-I and IGFR-I was 
analyzed using the SPSS 11.0 statistical package. 
 
Figure 2.1: Measurement of wound closure using image analysis software 
Representative example of the images taken of the wounded epithelial monolayer (NCI-H292) at 
different time points (t=0, 24, 48, 72 h).  ImageJ 1.32j software (National institutes of health, USA) 
was used to analyze the wound repair potential of the growth factors by calculating the remaining 
wound area at different time points and comparing with the wound area at t=0. 
 
2.3 Results 
2.3.1 Clinical parameters 
The clinical and lung function characteristics of all subjects included in the study are listed 
in Table 2.2.  All patients included in this study participated in a larger project (14).  The 
COPD group demonstrated lower FEV1 and FEV1/FVC values, (p≤0.001), whereas there was 
no significant difference between the two groups in age and smoking status (pack-years). 
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Table 2:2 A summary of the clinical characteristics of subjects with and without 
chronic obstructive pulmonary disease 
Group 
Sex 
(M/F) 
Age PY 
FEV1 
(% Pred) 
FEV1/FVC 
(%) 
Steroid 
treatment 
Non-COPD 12/3 59.3±14.8 34.2 ±24.7 97 ± 6.9 100 ±8.64 None 
COPD 13/1 63.5±8.8 39.7±14.5 57± 13.2 62.4 ± 8.75 3 
p-value  0.5 0.5 ≤0.001 ≤0.001  
Definition of abbreviations: COPD = chronic obstructive pulmonary disease; Forced expiratory 
volume in 1 s (FEV1) and Forced vital capacity (FVC) are given as percentages of the predicted 
values (% Pred.) before bronchodilatation.  M = Male; F = Female.  PY = number of pack years.  
Data shown represent means ± SD.  The patients in these two groups participated in a larger 
project, part of which has been published previously (14, 23). 
 
2.3.2 Expression of IGF-I and IGFR-I 
Representative examples of IGF-I and IGFR-I staining in non-COPD (Panel A, C) and 
COPD (Panel B, D) specimens are depicted in Figure 2.2 and 2.3 respectively.  
Immunoreactive IGF-I was localized (brown colour; DAB) in bronchial ASM and in VSM 
cells of the vessel wall and its level were significantly enhanced (Figure 2.4; Panels A and 
B) in COPD as compared to the non-COPD patients.  Unpaired two tailed t test (ASM 
staining scores: 1.38±0.25 vs. 0.39±0.13, p≤0.001 and VSM staining scores: 1.08 ±0.25 vs. 
0.40±0.12 p≤0.02) as well as non-parametric Mann-Whitney (ASM: p≤0.001 and VSM: 
p≤0.01) revealed significant levels for difference in staining scores of IGF-I respectively.  
Furthermore, IGF-I was localized in peripheral sections in ASM, VSM and in inflammatory 
cells (Figure 2.2; Panels C and D) though there was no significant difference in the 
expression pattern between the groups. 
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Figure 2.2: Expression of IGF-I in central and peripheral lung sections 
Photomicrographs of lung tissue sections from patients without COPD (A and C) and with COPD 
(B and D).  Panel A and B represents IGF-I staining in airway smooth muscle (ASM) in central lung 
sections, original magnification: x200.  Panel C and D is represents IGF-I staining in macrophages 
in peripheral lung sections, original magnification: x400.  Colour is developed with 
3,3-diaminobenzidine tetrahydrochloride (DAB) as chromogen (brown colour) and counterstained 
with Mayer's haematoxylin.  Arrows indicate sites of positivity for IGF-I.  Scale bar = 50 μm. 
 
Figure 2.3: Expression of IGFR-I in central and peripheral lung sections 
Photomicrographs of lung tissue sections from patients without COPD (A and C) and with COPD 
(B and D).  Panel A and B represents IGFR-I staining (brown) in bronchial epithelium in central 
lung sections, original magnification: x200.  Panel C and D represents IGFR-1 staining in 
macrophages in peripheral lung sections, original magnification: x400.  Scale bar = 50 μm. 
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Table 2:3 Comparing means: Independent Samples Test 
  Sig.   (p value)
Mean 
Difference
Std.  Error 
Difference 
95% Confidence 
Interval 
          Lower Upper 
IGF-I /ASM Equal variances assumed 000 1.10 0.26 0.57 1.63 
 Equal variances not assumed 0.001 1.10 0.27 0.54 1.66 
IGF-I/VSM Equal variances assumed 0.005 0.79 0.26 0.26 1.32 
 Equal variances not assumed 0.009 0.79 0.26 0.23 1.35 
IGFR-I/BE Equal variances assumed 0.990 000 0.21 -0.44 0.43 
 Equal variances not assumed 0.990 000 0.21 -0.44 0.43 
IGFR-I/IC Equal variances assumed 0.034 0.63 0.28 0.05 1.21 
 Equal variances not assumed 0.047 0.63 0.29 0.01 1.25 
Table depicts the mean difference between staining scores between the two groups (COPD and 
non-COPD) in bronchial airway sections.  Definition of abbreviations: IGF-I/ASM: IGF-I in airway 
smooth muscle; IGF-I/VSM: IGF-I in vascular smooth muscle; IGFR-I/BE: IGFR-I in bronchial 
epithelium; IGFR-I/IC: IGFR-I in inflammatory cells. 
 
 
Figure 2.4: Expression of IGF-1and IGFR-I in COPD and non-COPD 
Graphic representation of IGF-I expression in  (A) airway smooth muscle (ASM) and (B) vascular 
smooth muscle (VSM) and IGFR-I in (C) bronchial epithelium (BE) and  (D) macrophages (BM).  
Open and closed circles represent patients without and with COPD respectively.  Lines represent 
mean±SEM values.  # indicates a significant difference (p≤0.05, Student's t-test) as compared to 
non-COPD subjects. 
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IGFR-I was localized in bronchial epithelial cells, glandular epithelial cells and 
macrophages (Figure 2.3).  The expression of IGFR-I was not enhanced (Figure 2.3; Panels 
C and D) in COPD patients as compared to the non-COPD group in the bronchial and 
glandular epithelial cells as well as in the inflammatory cells (macrophages).  Similarly, in 
parenchymal lung sections, IGFR-I was localized in bronchiolar epithelium, alveolar 
epithelium and macrophages (Figure 2.3, Panels C and D), with no significant differences 
between the groups. 
 
 
Figure 2.5: Correlation of IGF-I and IGFR-I expression with lung function 
Correlation with FEV1 / FVC (% predicted) of IGF-I protein expression in (A) bronchial airway 
smooth muscle (ASM) and (B) bronchial vascular smooth muscle (VSM) and of IGF-I receptor in 
(C) bronchial epithelium (BE) and (D) macrophages (BM).  Open and closed circles represent 
patients without and with COPD respectively.  Correlation was assessed for the combined patient 
groups (non-COPD and COPD).  Correlation coefficient (r) was obtained using linear regression 
(Spearman’s) analysis.  Differences with p≤0.05 were considered statistically significant. 
 
2.3.3 Correlation with clinical data 
We examined the relation between the lung function (FEV1/FVC values) of patients in both 
groups and the expression (staining scores) of IGF-I and IGFR-I in the investigated areas 
with non-parametric Spearman’s correlation analysis.  Within the bronchial airways, 
FEV1/FVC values were inversely correlated with IGF-I staining sores in bronchial ASM 
cells (r = -0.58; p≤0.001, Figure 2.5A) and VSM cells (r = -0.50; p≤0.006, Figure 2.5B) if 
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all subjects were analyzed together.  However, FEV1/FVC values did not show any 
correlation with IGFR-I expression in the bronchiolar epithelium (r = -0.11; p≤0.5, 
Figure 2.5C) and in bronchial macrophages (r = -0.37; p≤0.06, Figure 2.5D) from the total 
group. 
 
2.3.4 Role of IGFs in ASM cell proliferation and growth 
[3H]thymidine incorporation assay was performed to assess the effect of IGF-I or IGF-II on 
DNA biosynthesis in human ASM cells.  Figure 2.5A shows the concentration response 
proliferation of ASM cells to incubation with IGF-I or IGF-II (0, 1, 5, 10 ng /ml).  Cell 
proliferation was near maximal at a concentration of 5 ng/ml for both the IGFs.  
Subsequently, all further experiments were done with 5 ng/ml of IGF-I or IGF-II.  Cell 
counts done with insulin in the medium showed increased cell numbers after 24 and 48 h 
compared to the controls however, the fold change was not significant (Figure 2.5 B).  In 
parallel, experiments were done with and without insulin in the medium to rule out its 
influence in the proliferation.  Interestingly, there was significant fold induction (Figure 2.5 
D) in cell number after stimulation with IGF-I (2.8 fold vs. control, p≤0.001) or IGF-II 
(3.02 fold vs. control, p≤0.001) without insulin supplement in the medium after 48 h.  
Moreover, there was significant difference in cell count between the controls with and 
without insulin (3.613 ±0.67 X 104 vs. 1.87 ±0.14 X 104 cells, p≤0.001).   
 
Similar experiments with ASM cells showed significant fold induction in DNA biosynthesis 
after 24 (IGF-I: 3.1 fold vs. control, p≤0.004) or IGF-II (5.4 fold vs. control, p≤0.05) and 
after 48 h (IGF-I: 2.67 fold vs. control, p≤0.001) or IGF-II (3.67 fold vs. control, p≤0.02) as 
assessed by [3H]thymidine incorporation assay (Figure 2.5 C). 
 
2.3.5 Role of IGFs in NCI-H292 cell proliferation and growth 
Similar sets of experiments, performed to assess the cell proliferation in NCI-H292 by 
[3H]thymidine incorporation assay at 8, 16 and 24 h (Figure 2.6 A) and cell count at 24 and 
48 h (Figure 2.6 B) after stimulation with both the IGFs revealed a significant fold induction 
of cell proliferation as compared to their respective controls.  NCI-H292 cells showed 
significantly increased DNA biosynthesis (IGF-I: 2.83 ± 0.30 fold increase, p≤0.0001 and 
IGF-II: 2.09 ± 0.19 fold increase, p≤0.0002) after 24 h and significantly higher cell numbers 
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after 48 h of stimulation.  (IGF-I: 3.17 ± 0.79 fold increase, p≤0.03 and IGF-II: 2.52 ± 0.48 
fold increase, p≤0.03). 
 
 
Figure 2.6: ASM cell proliferation in response to IGF stimulation 
A graphic representation of human airway smooth muscle (ASM) cell proliferation in relation to 
IGF-I or IGF-II and role of insulin in the medium.  Panel A:  Dose-dependent increases in 
[3H]thymidine uptake in ASM cells after 24 h stimulation with increasing concentrations (0, 1, 5, 
10 ng/ml) of IGF-I (straight line) or IGF-II (dotted line).  Panel B: Fold induction in ASM cells 
relative to control (open bar) after stimulation with 5 ng/ml IGF-I (striped bars) or IGF-II (closed 
bar) after 24 and 48 h with insulin in the medium as supplement.  Panel C: Time course of 
[3H]thymidine uptake in ASM cells after stimulation with 5 ng/ml of IGF-I (striped bar) or IGF-II 
(closed bar).  Panel D: Fold induction in ASM cells relative to control (open bar) after stimulation 
with 5 ng/ml IGF-I (striped bar) or IGF-II (closed bar) after 24 and 48 h without insulin in the 
medium as supplement.  Data is represented as mean fold increase in relation to control from three 
independent experiments performed in quadruplicate.  Values are mean±SEM and *P≤0.05 versus 
the control group. 
 
2.3.6 Enhanced epithelia wound closure by IGFs 
To investigate the effects of the mitogenic IGF-I or IGF-II on epithelial wound closure, 
mechanically wounded NCI-H292 cell monolayers were incubated with medium alone 
(negative control) or with IGF-I (5 or 10 ng/ml), IGF-II (5 or 10 ng/ml) or FCS, and the 
wound area was measured at various time points (24, 48, and 72 h).  Wounded monolayers 
incubated with 5 ng/ml of IGF-I or IGF-II did not show any significant wound closure as 
compared to negative control after 24, 48 or 72 h (Figure 2.7A).  However, parallel 
experiments with 10 ng/ml of IGFs showed enhancement in wound closure (IGF-I: 47% vs.  
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Figure 2.7: H292 cell proliferation in response to IGF stimulation 
A graphic representation of IGF-I or IGF-II stimulation on DNA biosynthesis and cell counts in 
NCI-H292 cells.  Panel A: Time course of [3H]thymidine uptake (fold change) in NCI-H292 cells 
after stimulation with 5 ng/ml of IGF-I (striped bar) or IGF-II (closed bar) in relation to control 
cells (open bar).  Panel B: Fold induction in ASM cell counts relative to control (open bar) after 
stimulation with 5 ng/ml IGF-I (striped bar) or IGF-II (closed bar) at 24 and 48 h.  Data are 
represented as mean fold change counts per min (CPM) and cell number values in relation to 
respective control from 3 independent experiments performed in quadruplicate.  Values are 
mean±SEM and *P≤0.05 versus the control group. 
 
Figure 2.8: Dose- and time-dependent enhancement of airway epithelial wound closure 
by IGF-I or IGF-II 
Mechanically wounded NCI-H292 monolayers were incubated with medium alone (closed square) 
or supplemented with 5 or 10 ng/ml of IGF-I (closed triangle) or IGF-II (closed circle) or 10% FCS 
(open square) and the percentage of closed wound area compared to t=0 h was measured after 24, 
48 and 72 h.  Panel A depicts the time-dependent wound closure with IGF-I or IGF-II at 5 ng/ml 
concentration and Panel B represents wound closure with IGF-I or IGF-II at 10 ng/ml 
concentration.  Data represent mean±SEM of three separate experiments, each performed in 
triplicate.  * P≤0.05 versus serum-free medium-treated cells. 
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29%, P≤0.02 and IGF-II: 44% vs. 29%, P≤0.05) after 72 h as compared with monolayers 
incubated with medium alone (Figure 2.7B).  In FCS-treated monolayers, 67% of the wound 
area was closed after 72 h. 
2.4 Discussion 
The result of our current study contributes to our insight into the role of IGFs in repair of 
injured airway epithelium and eventually airway remodelling in chronic airway diseases 
such as COPD.  Enhanced localization of IGF-I in ASM and VSM compartment of the 
bronchial airway in COPD patients along with the localization of the IGFR-I in the 
epithelium and in inflammatory cells (macrophages) point towards the possible role of IGFs 
in the whole milieu.  Additionally, the results from our cross-sectional study indicate that 
the expression of IGF-I in the bronchial airways increases as the lung function values 
(FEV1/ FVC) decreases.  Moreover we demonstrated the mitogenic effects of the IGFs on 
epithelial cells and also its wound repair potential in an in vitro model.  Taken together, our 
findings clearly indicate a role for IGF-I/IGFR-I system in the well-acknowledged 
remodelling processes of the airways in COPD patients. 
 
In the central airway sections, IGF-I protein was localized in the airway and vascular smooth 
muscle cells and the expression was enhanced in COPD patients as compared to respective 
controls.  Similarly, in parenchymal sections we could localize IGF-I to ASM, VSM and 
inflammatory cells particularly macrophages as recognized morphologically.  We did not 
observe any IGF-I staining in the bronchial epithelium in our study in both the groups (COPD 
and non-COPD patients).  In agreement with other studies reporting IGF-I localization to 
alveolar epithelium and macrophages in adult with fibrotic lung and acute respiratory distress 
syndrome (24-28), we also observed IGF-I staining in alveolar epithelium although only in a 
few sections with no significant difference.  Evidence suggests differential localization and 
expression pattern of IGF-I and IGF-II in foetus, infants and adults (24-26, 29).  In the study of 
Chetty et al. (29), it has been reported that with advancing gestational age the presence of 
IGF-I decreased in the mesenchyme and cuboidal epithelium.  However, IGF-I staining is 
markedly higher in neonates with bronchopulmonary dysplasia and respiratory distress 
syndrome.  This indicates that there may be an re-emergence of foetal pattern of IGF-I 
expression during intense repair after lung injury as also reported in hyperoxic rat lung injury 
(30).  Additional support for the involvement of IGF-1 comes from our observation that levels 
of IGF-I were inversely correlated with lung function, suggesting activation of repair 
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machinery that is also used during foetal development.  Similarly, in our previous study (23) 
we found up-regulated FGF-1, FGF-2 and FGFR-1 expression in bronchial epithelium 
indicating that such compensatory mechanisms are also active in COPD.  Whether this 
increased expression of these growth factors in COPD also contributes to squamous 
metaplasia and goblet cell hyperplasia in COPD remains to be determined. 
 
The localization of IGF-I receptor in the bronchial epithelium and macrophages in lungs of 
our patient groups is in agreement with earlier reports which describe a similar staining 
pattern in human normal adult lung as well as expression in human epithelial cell lines (9, 
31).  However, these studies found increased staining for total IGFR-I in fibroproliferative 
acute respiratory distress syndrome (9, 24) and squamous cell carcinoma (31) while we did 
not find any significant difference in expression between COPD and non-COPD.  
Interestingly, FGF-2 has been shown to enhance IGFR-I expression (24) while IGF-I by 
itself decreases the expression of receptor by auto regulation (32, 33).  This may explain the 
absence of any correlation of IGFR-I expression level with lung function data suggesting the 
possibility that IGF-I levels would be high in the vicinity (central airways) in COPD patients 
and hence decrease the receptor expression.  In support, the expression of IGFR-I is not 
enhanced in COPD patients as compared to the non-COPD group.  Both, IGF-I and IGFR-I 
were not discernible (localized) when other compartments like endothelium, fibroblast etc 
were looked at. 
 
Correlation of lung function data with staining pattern revealed a significant relationship 
with IGF-I expression in the smooth muscle compartment (ASM and VSM) in the central 
airways.  Exclusion of the patients, three in number, who were taking steroids 
peri-operatively, did not alter the data significantly.  Also subgroup analysis with patients 
with and without COPD indicates that the correlation was indeed related to the severity of 
disease and not just to the mere presence of the disease. 
 
Epithelial injury is normally followed by a complex repair process that comprises 
subsequent epithelial migration, proliferation, and differentiation (22).  The primary aim is 
to rapidly restore the denuded epithelium and this process has been reported to be mediated 
via growth factors such as Transforming Growth Factors-β (TGF-β), Keratinocyte Growth 
Factor (KGF), Epidermal Growth Factor (EGF) and their receptors (3, 7, 34).  It is 
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suggested that there may be an abnormal repair response in chronic airway disease leading 
to persistent activation and chronic secretion of cytokines and growth factors (8).  This can 
drive the remodelling process via alteration or activation of the adjacent 
fibroblasts/myofibroblasts, bronchial and vascular smooth muscles and mucus-secreting 
glands.  Our results add up to the available evidence that indeed IGFs have the potential to 
induce repair similar to EGFs (35, 36). 
 
At present, our knowledge of airway and vascular remodelling during the development of 
COPD is far from complete.  IGF-I has also been reported to contribute to vascularisation in 
developing lung through maintenance of endothelial cell population through its action as a 
survival factor (37).  Inflammation and subsequent local production of many growth factors, 
including IGFs, play an essential role in the epithelial repair in response to tissue injury.  
The increased bronchial IGF-I expression in COPD patients and its receptor localization in 
epithelium in addition to the wound repair potential of IGF-I advocate for its crucial role in 
tissue repair mechanism during smoke-induced airway injury.  Considering all data in this 
context, we conclude that ASM cells derived IGF-I act in a paracrine fashion on the IGFR-I 
positive epithelial cells resulting in their proliferation and thus contributing to airway 
remodelling in COPD. 
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Chapter 3:  Role of Fibroblast Growth Factor-Receptor System in 
Bronchial Epithelial Repair 
 
Summary 
Repeated injury/repair of the bronchial epithelium leading to aberrant airway remodelling 
is hallmark of chronic respiratory diseases.  Previously, we demonstrated enhanced 
bronchial epithelial expression of FGF-1, FGF-2 and FGFR-1 in COPD patients.  In this 
study, we explore the proliferative activity of bronchial epithelial cells in COPD in relation 
to lung function.  Moreover, the mitogenic activities, signalling mechanisms and wound 
closure potentials of FGF-1 and FGF-2 were assessed using NCI-H292 cells.  Proliferation 
marker, Ki-67 Labelling Index values showed significant doubling in COPD patients as 
compared to non-COPD and inversely correlated with FEV1 values (r = -0.43; p<0.03).  
Both FGF-1 and FGF-2 increased proliferation (3-7 folds) after 24h and cell counts (2 
folds) after 48 h.  Analysis of the injured epithelial monolayer’s showed enhanced wound 
closure with FGF-1 (67%, P <0.01) or FGF-2 (61%, P<0.01) as compared to controls 
(38%) after 72 h.  Specific inhibitors of ERK1/2 (U0126) and FGFR-1(SU5402) 
completely blocked FGF-1 or FGF-2 induced ERK1/2 activation after 15 min.  U0126 and 
SU5402 significantly blocked both FGF-1 (6% and 23% Vs 67%) and FGF-2 (9% and 19 
% Vs 61%) enhanced wound closure.  Similarly, the phosphatidylinositol-3-kinase 
inhibitor, LY294002 blocked epithelial repair in FGF-1(28%) and FGF-2 (22%) treated 
cells.  Taken together, our results suggest a potential role for the FGF/FGFR-1 system in 
bronchial epithelial repair and airway remodelling in patients with chronic airway diseases. 
 
3.1 Introduction 
Airway epithelial injury/repair and associated remodelling processes are common features 
in chronic airway diseases such as asthma and chronic obstructive pulmonary disease 
(COPD) (1, 2).  While there is genetic predisposition to COPD, we also know that smoking 
is a major determining factor that routinely leads to inflammation and damage, and those at 
risk lack the capacity to repair this damage (3).  One of the key pathological features 
involves an influx of neutrophils, macrophages and T-lymphocytes as a result of 
tobacco-induced injury to the bronchial epithelial lining (1, 4).  The bronchial epithelium 
consists of several cell types including basal, parabasal and ciliated cells, as well as Clara, 
some neuroendocrine and Goblet cells (5, 6).  Recent studies indicate that basal and 
parabasal cells are capable of cell division and are proposed as epithelial cell progenitor 
cells for ciliated cells, and these ciliated cells are sensitive for toxins from cigarette smoke 
(4, 5).  Attraction to and transmigration through the bronchial epithelial layer of 
predominantly neutrophils under influence of various cytokines such as tumour necrosis 
factor-α (TNF-α) and interleukin-8 (IL-8) may lead to additional damage to the bronchial 
epithelium by the release of granule components from neutrophils including human 
neutrophils proteases (7-9). 
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In addition to the bronchial epithelial cells, (myo-) fibroblasts are the other major cell type 
involved in the airway wall remodelling and thickening, which is thought to be in part a 
result of hyperplasia and hypertrophy of (myo-) fibroblasts and airway smooth muscle 
associated with an increased deposition of extra cellular matrix (1).  Growth factors that are 
released from these cells and that contribute to pathogenesis of airway remodelling include 
platelet–derived growth factor-B (PDGF-B), epidermal growth factor (EGF), transforming 
growth factor-β (TGF-β) and tumour necrosis factor (TNF)-α (10-12).  Co-culture studies 
with bronchial epithelial cells and myo-fibroblasts support the relationship between 
epithelial injury and enhanced airway remodelling as evidenced by increased epithelial cell 
proliferation and collagen expression due to interaction with several growth factors such as 
basic fibroblast growth factor (FGF-2), insulin-like growth factor-1, PDGF-B, TGF-β, 
endothelin-1 and EGF (13, 14).  Evidence suggests that members of EGF and FGF family 
contribute to chronic inflammatory and tissue repair processes including chronic respiratory 
diseases (15-18).  Given their function, FGFs may well play a pivotal role in regulating the 
airway wall remodelling in COPD as well.  Increased expression of FGF-1 and FGFR-1 has 
been shown during the development of lung fibrosis (19) and FGF-2 has been implicated in 
the pathogenesis of obliterative bronchiolitis in lung transplants (20).  We have previously 
demonstrated increased bronchial expression of fibroblast growth factors and their receptor 
in COPD patients (21).  In that study, we observed a highly significant correlation of 
FGF-1/FGFR-1 co-localization in bronchial epithelium and FGF-2/FGFR-1 in ASM cells.  
These findings indicate that FGF-1 and FGF-2 are differentially expressed and may regulate 
locally different events in the corresponding tissues. 
 
In order to further establish the role of the FGF receptorFGFR-1 and its ligands in the 
pathogenesis of COPD we examined the proliferative activity in the bronchial epithelium 
using the cell-cycle marker Ki-67.  We investigated the proliferative potential as well as the 
wound repair potential of FGF-1 and FGF-2 in vitro using a cultured bronchial epithelial 
cell line (NCl-H292 cells).  Finally, we explored partly, the signal transduction route of 
FGFR-1 by assessing the phosphorylation status of the downstream signalling protein 
Extracellular Regulated Kinase 1/2 (ERK1/2).  Specific inhibitors of FGFR-1, ERK1/2 and 
phosphatidylinositol-3-kinase (PI3K) were used to decipher the role of these pathways in 
FGFs induced wound repair. 
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3.2 Materials and methods 
3.2.1 Selection of specimens 
Anonymized bronchial tissue of current and ex-smokers, who underwent surgery for lung 
cancer (lobectomy or pneumonectomy), was obtained from the Pathology departments of 
the Leiden University Medical Center (LUMC, Leiden, The Netherlands) and Southern 
Hospital (Rotterdam, The Netherlands).  We examined routine formalin-fixed paraffin 
embedded lung tissue specimens from bronchial airways, taken distant from the tumour, in 
patients with or without COPD.  COPD (n=12) and non-COPD (n=14) subjects were 
selected based on lung function parameters (22).  Some of the tissue samples which belong 
to a larger database were also used in previous studies (21, 22). 
COPD group: Twelve subjects were assigned to this group on the basis of the following 
parameters: forced expiratory volume in one-second (FEV1) <75% of predicted value (23) 
before bronchodilatation, FEV1/Forced Vital Capacity (FVC) ratio <75%, a reversibility in 
FEV1 ≤12% of predicted after 400 μg inhaled salbutamol, and CO diffusion capacity (Kco) 
≤80% of predicted value. 
Non-COPD group: Fourteen subjects were assigned to this group based on the following 
data; a FEV1 >85% of predicted before bronchodilatation, FEV1/FVC ratio >85%, and 
reversibility in FEV1 ≤12% of predicted after 400 μg salbutamol inhalation.  In order to 
exclude accompanying lung disease leading to a restrictive lung function disorder, it was 
required that the total lung capacity (TLC) of each subject included in the study was over 
80% of the predicted value.  Clinical data of all patients were examined for possible 
co-morbidity and medication usage.  All patients were free of symptoms of upper 
respiratory tract infection and none received antibiotics perioperatively.  After the selection 
based on lung function, all the lung tissues were checked histologically using the following 
exclusion criteria (12, 22, 24): (i) presence of tumour in the lung tissue specimen submitted 
for the study, (ii) presence of poststenotic pneumonia in the specimen, (iii) fibrosis of lung 
parenchyma, and (iv) obstruction of the main bronchus of the resection specimen by 
tumour, regardless of the histology of the specimen intended for this study. 
Pulmonary function tests 
All pulmonary function tests were performed within 3 months prior to surgery.  FEV1 and 
FVC were measured by spirometry, total lung capacity and residual volume with the closed 
circuit helium dilution test and the Kco using the single breath-holding technique, as 
described by Quanjer and co-workers (23). 
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3.2.2 Immunohistochemistry 
Sections of paraffin-embedded lung tissue were cut at 4 μm, mounted on Super Frost Plus® 
microscopic slides (Meinzl-Gläser, Braunschweig, Germany) and processed for 
immunohistochemistry.  Serial sections were deparaffinised, rehydrated and blocked for 
endogenous peroxidase prior to incubation with specific purified mouse monoclonal 
antibodies.  To examine proliferation of cells in the airways, a monoclonal antibody against 
Ki-67 (Dako Corporation, Glostrup, Denmark) was used.   Ki-67 immunostaining was 
performed after antigen retrieval by boiling in citrate buffer (10 mM citrate buffer, pH 6.0) 
for 10 minutes in a microwave. To block non-specific second antibody binding, sections 
were preincubated with 10% normal goat serum diluted in 5% bovine serum albumin in 
phosphate buffered saline (5% BSA/PBS, pH = 7.4).  Subsequently, sections were incubated 
for 1 hour at room temperature with Ki-67 primary antibody at an appropriate dilution 
(1:400 v/v). To enhance sensitivity of detection, sections were incubated for 30 min30 
minutes with secondary biotinylated anti-immunoglobulins (Multilink®, 1:75 dilutions, 
Biogenex, San Ramon, USA) and tertiary complex of streptavidin conjugated with 
horseradish peroxidase was used.  Staining for FGF-1 and FGFR1 (kind gift from Dr.  J.  
Walters, Oxford, UK) and FGF-2 (Transduction Laboratories, Lexington, USA) in the 
bronchial epithelium were done as described previously (21, 22).  Colour was developed 
using 3,3-diaminobenzidine or New Fuchsin as chromogen.  Slides were counterstained 
with Mayer's haematoxylin.  Human breast carcinoma and placental tissue served as 
positive controls.  Omission of primary antibodies served as negative control.  The optimal 
dilutions for all antibodies were identified by examining the intensity of staining obtained 
with a series of dilutions: the optimal concentration resulted in specific and easily visible 
signal on paraffin sections of positive control specimens.  Slides were mounted and 
evaluated by light-microscopy. 
 
Quantitative analyses of immunostaining 
Digital images from each subject (pixel size: 736x574) were taken using a 3CCD camera 
(Hitachi) coupled to a light microscope (Leica, Rijswijk, The Netherlands) at a 
magnification of 400x.  Four randomly photographed sites of the airway section of each 
patient were analyzed using Leica Qwin system version 3.0 image analysis software (Leica 
B.V., Rijswijk, The Netherlands).  The nuclear localization of Ki-67 in epithelial cells was 
assessed by interactive computerized counting of individual nuclei.  Proliferation was 
FGF in Epithelial Repair      Chapter 3 
 68 
expressed as (number of stained nuclei/number of total nuclei) x 100% (labelling index, LI).  
The distribution of total nuclei divided by measured area was also assessed.  Data are given 
as mean±SEM. 
 
3.2.3 Culture of NCl-H292 cells 
NCl-H292 cells, a human pulmonary mucoepidermoid carcinoma cell line (purchased from 
American Type Culture Collection; ATCC, Manassas, VA), were cultured in 1640 medium 
containing 10% foetal bovine serum (FBS; Bio-Whitaker BV, Verviers, Belgium) 
supplemented with sodium pyruvate (2 mM), gentamicin (50 μg/ml), L-glutamine (4 mM), 
HEPES (10 μM), penicillin (5 U/ml), streptomycin (5 μg/ml) at 37 °C in a 5% CO2-humidified 
atmosphere.  Cells were maintained in culture by replacing the medium every h and when 
confluent were further passaged using trypsin/EDTA solution into 75 cm2 tissue culture flasks.  
Semi-confluent cultures were used for the experiments. 
 
3.2.4 Proliferation assays 
[3H]Thymidine uptake: Serum deprived (48 h) NCI-H292 cells (quadruplo in 96 wells 
plates from three different flasks) were incubated with 100 µl serum-free-medium alone 
(control medium serving as negative control) or supplemented with 10% FBS (positive 
control), 10 ng/ml human recombinant FGF-1 (Promega, Madison, USA) or FGF-2 
(Sigma-Aldrich  BV, Zwijndrecht, The Netherlands).  The optimal concentrations for FGFs 
were based on pilot experiments and from our previous study (21).  Three independent 
experiments, using different batches of cells, were performed in which cells were treated for 
8, 16 or 24 h.  Five hours prior to the end of the treatment 10 μl of [3H]thymidine 
(1 μCi/10 μl in HBSS; Amersham, Roosendaal, the Netherlands) was added to the wells, at 
a final concentration of 1 μCi/110 μl per well.  The medium was removed after 8, 16 and 
24 h and the cells were washed twice with cold PBS.  The cells were detached with 50 μl 
trypsin for 10 min after which 50 μl PBS was added.  Cells were frozen overnight at -20°C 
and subsequently harvested on glass fibre filters using a Filtermate 196 cell harvester 
(Packard, Meridan, USA).  Activity was counted using a Microplate Scintillation ß-counter 
(Topcount, Packard, Meridan, USA) and measured radioactivity was expressed as counts 
per min (CPM).  The mean CPM of quadruple wells and subsequently three different 
experiments were expressed as ratio as compared to control cells in serum free medium 
(fold-induction). 
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Cell counts: In a parallel series of experiments, 200,000 cells were seeded in 24-well plates.  
Serum deprived NCI-H292 cells (in quadruplo) were stimulated for 24 and 48 h with 
FGF-1, or FGF-2 or controls and cell numbers were determined using automated cell 
counting (Casy®1, Schärfe system GmbH, Reutingen, Germany).  After stimulation, the 
cells were trypsinized with 100 μl Trypsin/EDTA for 10 min.  Cells in suspension were 
added to 10 ml of Casy®1 isotonic solution (6.38 g/l NaCl, 0.2 g/l Na-tetraborate, 1.0 g/l 
Boric acid and 0.2 g/l EDTA).  Cell numbers, volumes and diameters were measured and 
analyzed using Casey®1 system software. 
 
3.2.5 Wound repair model 
In order to assess the wound repair potential of the FGFs, an in vitro model as described 
previously (25) was used.  Briefly, NCI-H292 cells were cultured to confluence in 6-well 
tissue culture plates.  After overnight serum deprivation, three circular wounds (3 mm in 
diameter) were scraped in each well using a sharpened silicone tube attached to a Pasteur 
pipette and a microscope.  After washing with PBS and allowing the cultures to recover for 
1 h in serum-free medium, the wounded monolayers were incubated in serum-free medium 
alone or supplemented with FGF-1 or FGF-2 (10 ng/ml) or 10% FBS (positive control).  To 
study the role of selected signalling pathways, wounded monolayers were incubated with 
U0126 (20 µM; Promega, Madison, WI), LY294002 (10 µM; Stratagene, La Jolla, CA) or 
SU5402 (20 µM; Calbiochem, UK) 1 h before addition of FGFs.  Possible cytotoxic effects 
of the inhibitors at concentrations used in these experiments were excluded by pilot studies 
and literature review.  Images were collected using a digital camera after 0, 24, 48 and 72 h 
and analyzed using ImageJ 1.32j software (National institutes of health, USA) by 
determining the percentage wound closure at various time points as compared with the time 
point of starting the stimulation (t = 0). 
 
3.2.6 ERK1/2 phosphorylation in NCI-H292 cells 
NCI-H292 cells were cultured to near confluence and subsequently serum-deprived 
overnight.  After incubation of cells with serum-free medium alone or supplemented with 
FGF-1 (10 or 100 ng/ml), FGF-2 (10 or 100 ng/ml) or 20 ng/ml transforming growth 
factor-α (TGFα; Sigma-Aldrich) for 15 or 30 min, cells were washed and lysed in 0.5% 
(v/v) Triton X-100, 0.1 M Tris-HCl pH 7.4, 100 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 1 
mM Na3VO4 and complete protease inhibitor cocktail (Roche, Basel, Switzerland) on ice.  
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The effects of the inhibitors U0261 and SU5402 on FGFs induced signalling pathway were 
assessed by pre-incubating NCI-H292 cells with these inhibitors for 1 h using 
concentrations as described for wound closure experiments.  Cell lysate protein samples 
(8 µg) were separated on a 10% acrylamide gel using standard SDS-PAGE procedures and 
transferred to polyvinylidene difluoride membranes using the Mini-transblot system 
(Biorad).  The membranes were then pre-incubated with 0.5% casein and 0.05% Tween-20 
in PBS for at least 1 h, followed by incubation with rabbit polyclonal antibodies directed to 
phospho-specific or native ERK1/2 (New England Biolabs, Beverly, MA) overnight at 4 °C.  
After incubation with horseradish peroxidase conjugated goat anti-rabbit (BD Transduction 
Laboratories, Franklin Lake, NJ, USA) polyclonal antibodies, immunoreactivity was 
visualized using electrochemiluminescent detection reagent (Amersham). 
 
3.2.7 Statistical analysis 
Data were analyzed for statistical significance using the unpaired, two-tailed Students’ t-test 
as well as Pearson’s correlation analysis wherever appropriate.  At p≤0.05 differences were 
considered statistically significant. 
 
3.3 Results 
3.3.1 Cell proliferation in bronchial epithelium 
Bronchial airways were stained for the cell cycle and proliferation marker, Ki-67 and Figure 
3.1A and 3.1B represents examples of the staining patterns in non-COPD and COPD 
subjects.  Ki-67 immunoreactivity was mainly observed in the nucleus of basal and 
parabasal epithelial cells, and also in some inflammatory cells.  Within the bronchial 
epithelium, the total number of bronchial epithelial cell nuclei and Ki-67 positive nuclei 
were measured and expressed as the labelling index (LI).  We observed a significant 
doubling of the LI in COPD patients (LI = 6.0%) as compared to non-COPD (LI = 3.0 %) 
(Figure 3.1C). 
 
3.3.2 Correlation with clinical data 
We examined the relation between the lung function (FEV1values) of patients in both 
groups and the expression (staining scores) of proliferation marker, Ki-67 in the bronchial 
epithelial cells in central airways. FEV1 values were inversely correlated with the Labelling 
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Index values of Ki-67 (r = -0.43; p<0.03, Figure 3.2) when all subjects were analyzed 
together. However, the Ki-67 values did not shown any significant correlation to the FGF-1, 
FGF-2 or FGFR-1 staining score in the bronchial epithelial cells. 
 
 
Figure 3.1: Immunohistochemical localization of Ki-67 in bronchial epithelium 
Photomicrographs of central bronchial tissue sections from patients without COPD (A) and with 
COPD (B) showing brown nuclear staining for cell proliferation marker, Ki-67.  Original 
magnification: x200.  (C) Graphic representation of Labelling index (L.I.) of Ki-67 staining in 
bronchial epithelium in COPD and non-COPD groups.  At P≤0.05 differences were considered as 
significant. 
 
Figure 3.2: Correlation analysis of 
Ki-67 expression in epithelial cells and 
lung function (FEV1) 
Graph represents correlation analysis 
between Labelling Index of Ki-67 expression 
in bronchial epithelial cells and FEV1.  Open 
and closed circles represent patients without 
and with COPD respectively.  Correlation 
coefficient (r) was obtained using linear 
regression (Pearson’s) analysis and P value.  
At P≤0.05 differences were considered as 
significant. 
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3.3.3 Localisation of FGF-1, FGF-2 and FGFR-1 in bronchial epithelium 
Immunohistochemical staining reveals localisation of FGF-1, FGF-2 and FGFR-1 in the 
bronchial epithelium in lung sections obtained from patients with (Figure 3.3) and without 
COPD.  We have reported earlier (21) the enhanced expression of these proteins in 
bronchial sections of COPD patients as compared to patients without COPD. 
 
 
Figure 3.3: Immunohistochemical localization of FGF-1, FGF-2 and FGFR-1 in 
bronchial epithelium. 
Photomicrographs of human central bronchial tissue sections showing localization of (A) FGF-1 
(red new-fuchsin), (B) FGF-2 (brown), (C) FGFR-1 (red new-fuchsin) and (D) α-smooth muscle 
actin (α-SMA, red new-fuchsin).  Original magnification: x200.  Scale bar = 50 µm.  Arrows 
indicate positive staining for respective ligands. 
 
3.3.4 Mitogenic effects of FGFs in cultured NCI-H292 cells 
Repair is a combination of proliferation, migration and cell death. Using bronchial epithelial 
NCI-H292 cells as a model system we further explored FGF-mediated proliferation and 
migration as well as intracellular signal transduction pathways thought to be involved in the 
repair process.  H292 cells were stimulated in vitro with FGF-1 or FGF-2 and proliferation 
was assessed. Both FGF-1 and FGF-2 stimulated proliferation and cell numbers after 24 and 
48 h of treatment. A graphic representation of the time dependent thymidine uptake 
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following incubation with FGF-1 or FGF-2 is presented in Figure 3.4A. After 8 hours of 
stimulation, we observed a statistically significant increase in thymidine incorporation upon 
FGF-2 treatment (2.21±0.11 Vs1.26±0.07 counts per minute (CPM) X 104) and after 16 and 
24 hours a statistically significant increase upon FGF-1 (3.4±0.19 and 6.8±0.4 CPM X 104) 
or FGF-2 treatment (4.3±0.28 and 7.6±0.48 CPM X 104) as compared to untreated cells 
(0.96±0.05 and 2.5±0.12 CPM X 104); Figure 4A. After 48h, FGF-1 and FGF-2 also 
induced significant increase in cell numbers 1.85±0.28 and 2.80±0.66 times, respectively; 
Figure 3.4B. 
 
Figure 3.4: Assessment of NCI-H292 cell proliferation in relation to FGF-1 and FGF-2 
Time course of [3H]thymidine uptake (8, 16, 24 h) in NCI-H292 cells after stimulation with 10 ng/ml 
of FGF-1(closed gray bar) and FGF-2 (closed black bar) (A).  Fold increase in cell counts of 
NCI-H292 cells upon stimulation with 10 ng/ml of FGF-1 (closed gray bar) and FGF-2 (closed 
black bar) for 24 h and 48 h relative to control (open bar) culture conditions (B).  Data are 
represented as mean values from three independent experiments performed in quadruplicate.  
Values are given as mean±SEM.  Differences were statistically significant at P≤0.05 (*) as 
compared to the control group. 
 
3.3.5 In vitro wound repair potential of FGFs 
To investigate the effects of the mitogenic FGF-1 or FGF-2 on epithelial wound closure, 
mechanically wounded NCI-H292 cell monolayers were incubated with medium alone 
(negative control, Figure 3.5A upper panels) or with FGF-1 (10 ng/ml, Figure 3.5A, middle 
panels) or FGF-2 (10 ng/ml, Figure 3.5A, lower panels) or 10% FCS. The wound area was 
measured at various time intervals (24, 48, and 72 h). Wounded epithelial monolayers 
showed enhanced wound closure in the presence of FGF-1 (67%, P <0.01) or FGF-2 (61%, 
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P<0.01) after 72 h as compared with monolayers incubated with medium alone (38%, 
Figure 3.5B). In FCS-treated monolayers, 58% of the wound area was closed after 72 h as 
compared to the control. 
 
Figure 3.5: Time-dependent enhancement of airway epithelial wound closure by FGF-1 
or FGF-2 
Representative images of wound closure treated with control medium alone (left panel), FGF-1 
(middle panel) and FGF-2 (right panel) after time period 0 and 72 h (panel A).  Mechanically 
wounded NCI-H292 monolayers were incubated with control medium alone (closed square) or 
supplemented with 10 ng/ml of FGF-1 (closed triangle) or FGF-2 (closed circle) or 10% FCS 
(closed diamond) and the percentage of closed wound area compared to t=0 h was measured after 
24, 48 and 72 h (panel B).   Data represent mean±SEM of three separate experiments, each 
performed in triplicate.  *: P≤0.05 versus serum-free medium-treated cells. 
 
 
3.3.6 Involvement of FGFR-1 receptor and MAPK signalling in 
FGF-induced ERK 1/2 activation 
FGF-1 and FGF-2 were demonstrated to stimulate both proliferation and migration of cells. 
Next we explored FGFR-1-dependent signal transduction pathways. We determined 
whether the intracellular signal transduction protein ERK1/2 was phosphorylated upon the 
induction of proliferation by FGF-1 and FGF–2. Incubation of NCI-H292 cells with 10 or 
100 ng/ml FGF-1 and FGF-2 for 15 and 30 min resulted in an increase of ERK1/2 
activation, as did the positive control TGFα (Figure 3.6A).  
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To further delineate the involvement of the FGFR-1 receptor signalling pathway, NCI-H292 
cells were incubated with inhibitors of FGF receptor-1 (SU5402) or ERK 1/2 (U0126) 1 h 
before addition of FGF-1 or FGF-2. Subsequently, cells were treated with either FGF-1 or 
FGF-2 for 15 minutes. Western blot analysis of phosphorylated ERK1/2 demonstrated that 
both the inhibitors completely blocked FGF-1 and FGF-2 induced ERK1/2 activation 
(Figure 3.6B). This point to FGFR-1 being the major effector receptor as SU5402 
specifically inhibits FGFR-1.  
 
Figure 3.6: ERK1/2 activation in NCI-H292 cells treated with FGF-1 and FGF-2 
(A) NCI-H292 cells were incubated with medium alone or supplemented with FGF-1 or FGF-2 (10 
or 100 ng/ml) or TGFα (20 ng/ml) for 15 or 30 min.  Activated and total ERK1/2 were determined 
in cell lysates by Western blot.  (B) Effect of inhibitors of the FGFR-1 and MEK signalling pathway 
on FGF-induced ERK1/2 activation.  NCI-H292 cells were preincubated with SU5402 (SU; 20µM) 
or U0126 (U; 20 µM), for 1 h before addition of 10 ng/ml FGF-1 or FGF-2 for 15 min.  Data are of 
one experiment (similar results were obtained in two separate experiments). 
 
3.3.7 Involvement of FGFR-1 and MAPK signalling in FGF-1, 2 enhanced wound 
closure 
To investigate whether the observed induction of epithelial wound closure by FGF-1 and 2 
is mediated via the FGFR-1 and ERK 1/2 pathway, the effect of the previously described 
inhibitors on FGFs enhanced wound closure was assessed. All individual inhibitors were 
shown to block the basal wound closure (Figure 3.7). Similar to the results on ERK1/2 
activation, U0126 and SU5402 significantly blocked both FGF-1 (showed 6% and 23% 
wound closure respectively as compared to 67%) and FGF-2 (9% and 19 % wound closure 
respectively as compared to 61%) enhanced wound closure.  PI-3K has been implicated in 
mediating cell migration and thereby may also contribute to wound repair (25). Inhibitors of 
these kinases, (LY294002) with or without SU5402, significantly blocked wound closure in 
FGF-1(28% Vs 67% wound closure) and FGF-2 (22% vs 61% wound closure) treated cells. 
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Figure 3.7: Effect of inhibitors of the FGFR-1, ERK 1/2 and PI3K signalling pathway on 
FGF–induced wound closure of NCI-H292 cells. 
Mechanically wounded NCI-H292 cell monolayer’s were preincubated with (A) SU5402 (20 µM), 
(B) U0126 (20 µM), (C) LY294002 (10 µM), or (D) LY294002 and SU5402 1 h before addition of 
10 ng/ml FGF-1 or FGF-2.  Data are mean±SEM of three experiments.  Closed square, medium; 
closed triangle, FGF-1; closed circle, FGF-2; open square, inhibitor; open triangles, 
inhibitor + FGF-1; open circles, inhibitor + FGF-2. 
 
3.4 Discussion 
In this study we showed an association between the expression of Ki-67 in the bronchial 
epithelium and the presence of chronic airflow obstruction. Several studies have used this 
marker to assess proliferating airway epithelial cells in biopsies of healthy, asthma and 
chronic bronchitis patients (6, 26). Our in vitro results indicate that FGF-1 and FGF-2 are 
potent mitogens for NCI-H292 cells associated with activation of ERK1/2. Additionally, 
our in vitro wound repair experiments revealed that FGF-1 and FGF-2 significantly 
enhanced wound closure. Using specific inhibitors of signalling pathways revealed that 
ERK1/2 and PI3-K are involved in FGF enhanced wound closure via activation of FGFR-1. 
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Taken together, these findings support the idea that the FGF/FGFR-1 system contributes to 
epithelial remodelling as seen in chronic lung diseases like COPD. 
 
In response to chronic injury there may be an abnormal persistent activation and chronic 
secretion of growth factors. Previously, we showed that there is an increased expression of 
growth factors such as vascular endothelial growth factors (VEGF) and FGFs in COPD 
patients (21, 27). This expression pattern also correlated with the severity of the disease or 
the lung function indicating that the repair machinery was activated. We observed that 
FGF-1, FGF-2 and FGFR-1 are constitutively expressed in non-COPD human lungs, 
particularly in bronchial epithelium, alveolar macrophages and monocytes, as well as in the 
intima and media of pulmonary blood vessels. Expression of these molecules was enhanced 
in COPD patients in the bronchial epithelium (21). FGF-1 and FGF-2 in the bronchial 
epithelium may be involved in proliferation and repair of epithelial layers after injury. Our 
findings of increased Ki-67 expression in bronchial epithelium and its correlation with the 
lung function data (FEV1) indicate that such compensatory mechanisms are active in COPD 
(28).  
 
Many experimental and clinical studies have shown the importance of exogenous growth 
factors in wound repair (29). Recently the functions of endogenous growth factors in the 
healing process are being addressed.  Our in vitro data confirm the mitogenic potential  of  
FGF-1 and FGF-2  on epithelial cells (30) and  was similar to our previous results (21) on 
human airway smooth muscle cells. Our data suggest that FGF-1 and 2–enhanced wound 
closure requires activation of the FGFR-1 and involves the ERK 1/2 pathway, suggesting 
pivotal role of cell proliferation in the FGF-enhanced wound closure.  It supports previous 
reports on ERK1/2 activation upon FGF-2 stimulation as early as 15 minutes in lens 
epithelial cells (30).  However, in contrast to that report, we did not see correlation of the 
ERK 1/2 phosphorylation with the dose of FGFs. 
 
 The observation that the MEK inhibitor, U0126 blocked airway epithelial cell proliferation 
(31) and given the importance of ERK1/2 signalling pathway in the induction of epithelial 
cell, suggests a role for ERK1/2 signalling in wound repair. FGF induced epithelial cell 
proliferation has been shown to be ERK dependant. In addition, inhibition of this pathway 
has been reported to result in delayed epithelial wound healing (32). ERK1/2 and PI-3K 
pathways have also been implicated in cell migration during wound repair (25)  and is 
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further supported by the current demonstration that inhibitors of ERK1/2, PI3K, and FGFR-
1 block FGF-enhanced wound closure suggesting involvement of cell migration in FGF-
enhanced wound repair. Previous reports on FGF-2 induced endothelial cell migration after 
injury support the role of PI3K pathway in this process (33). 
 
In asthma and COPD injury of the epithelium is a common feature and this injury is 
followed by the activation of the remaining epithelial cells. Besides releasing pro-
inflammatory cytokines, they also secrete factors that help in restoring the epithelial barrier 
through active repair (34). Among these secreted factors many growth factor/receptor 
systems are involved in tissue remodelling, including the EGF/EGFR, TGF-β/TGF-βR and 
IGF-1/IGFR-1. These growth factors have been suggested to regulate repair of airway 
epithelial injury by induction of extra cellular matrix deposition, cell migration, 
proliferation and differentiation (2, 4). Our results add up to the available evidences that 
FGF-1 and FGF-2 have the potential to induce airway epithelial repair similar to EGFs, 
IGFs and keratinocyte growth factor (15, 35-37).  
 
Taken together, our results support the notion that increased bronchial expression of FGF-1, 
FGF-2 and FGFR-1 in patients with COPD could contribute to epithelial proliferation (as 
observed in the present study) and remodelling in COPD. Our observation that FGFs 
promote epithelial wound repair and that these growth factors are over expressed in the 
lungs of COPD patients, is in line with the hypothesis that excessive repair following injury 
may underlie epithelial remodelling in COPD. Modulation of the signalling pathways 
identified in the current study could provide a new therapeutic target for the treatment of 
COPD.  
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Chapter 4:  Bronchial Vascular Remodelling in Chronic Bronchitis/ 
Emphysema 
 
Summary 
At present, our knowledge of airway and vascular remodelling in COPD is far from complete. 
COPD is often called “emphysema and chronic bronchitis” since over time, alveolar 
destruction results in emphysema, and chronic bronchial inflammation leads to chronic 
bronchitis. Increased adventitial infiltration of inflammatory cells in pulmonary and 
bronchiolar arteries has been reported.  Many growth factors, among them VEGF and FGF, 
play an essential role in maintaining pulmonary and vascular viability and in tissue repair.  
Based on the available evidence, we hypothesize that in chronic bronchitis, expression of 
VEGF and VEGFR-2 expression leads to increased vascular remodelling, which is 
inefficiently compensated by the low expression of VEGFR-1. In subjects with emphysema, 
however, VEGFR2 expression is lower. Preferential activation of VEGFR-1 results in 
higher MMP activity, alveolar destruction and endothelial apoptosis. Hence, the balance 
between VEGF, VEGFR-1 and VEGFR-2 are critical in the pathogenesis of COPD 
subtypes. 
 
4.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is global health problem with increasing 
morbidity and mortality (1).  COPD is characterized by airflow limitation that is not fully 
reversible, usually progressive and associated with an abnormal inflammatory response of 
the lungs following exposure to noxious particles and gases and inhaled cigarette smoke (2, 
3).  One important pathological feature of COPD is airway inflammation, characterized by 
an influx of neutrophils, macrophages and CD8+ T-lymphocytes in the lumen and wall of 
bronchial and bronchiolar airways and parenchyma (4-6).  Over time, alveolar destruction 
results in emphysema, and chronic bronchial inflammation leads to chronic bronchitis, 
which is why COPD is often called “emphysema and chronic bronchitis” (7).  Interestingly, 
only ten to twenty percent of all smokers develop symptomatic COPD; yet the causes of this 
variability in response of the airways and lung parenchyma to tobacco smoke exposure 
remain largely unclear. 
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4.1.1 Emphysema 
The development of emphysema and its different pathological patterns is likely the result of 
interactions between external risk factors and intrinsic host susceptibility factors.  The 
parenchymal destruction seen in emphysema may be caused by an inflammatory process 
due to imbalances in protease-antiprotease and oxidant-antioxidant levels (8) and also by 
activation of innate and adaptive immune responses (9).  The protease-antiprotease theory 
has been further refined to an elastase-anti-elastase theory of pathogenesis of emphysema, 
as neutrophil elastase and macrophage-derived proteases are primarily implicated (10, 11).  
The role of cigarette smoke-induced free radicals in structural damage and inhibition of 
protease inhibitors also has been studied extensively (12-14).   However, theories of 
antiprotease deficiency do not fully explain why only 10-20 % of all smokers develop 
emphysema (14).  One additional possibility is the vascular atrophy model of Leibow (15), 
as has been suggested (16, 17).  Leibow proposed that a reduction in the blood supply of the 
small precapillary blood vessels might induce the disappearance of alveolar septa and hence 
may result in the development of emphysema. 
 
4.1.2 Chronic bronchitis 
Mucous gland hypertrophy and goblet cell hyperplasia occur in chronic bronchitis and 
contribute to excess mucus production.  Although the exact pathogenesis of chronic 
bronchitis remains unclear, bacterial colonization and the resulting inflammatory response 
are thought to be of central importance.  The generation of pro-inflammatory cytokines and 
chemotactic stimuli by the airway epithelium are likely to play a central role in propagating 
the inflammatory response in patients with chronic bronchitis (18).  Smokers with chronic 
sputum production have an increased infiltration of neutrophils and macrophages and an 
increased proportion of CD8+ T-lymphocytes in their bronchial glands, supporting the 
important role of bronchial-gland inflammation in the pathogenesis of chronic bronchitis 
(19), which results in epithelial disruption, smooth muscle hypertrophy and fibrosis (20).  It 
has been reported that there are increased macrophage counts in chronic bronchitis patients 
with airflow limitation compared to patients without airflow limitation (21).  In addition, 
neutrophils, compartmentalized in the mucosal surface of the airways and CD8+ T cells, 
distributed along the subepithelial zone of the airways and lung parenchyma are consistently 
associated with the chronic airflow limitation found in COPD (22).  The number of 
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neutrophils further increases in the submucosa of patients with severe COPD, suggesting a 
role for these cells in the progression of disease (22). 
 
Several studies have described changes consistent with airway remodelling in COPD, 
characterized by a thickened bronchiolar wall, an increase in airway smooth muscle (ASM) 
mass (5, 23, 24) and increased deposition of extracellular matrix (25), associated with 
peribronchiolar fibrosis.  Airway remodelling and abnormal repair of small airways may 
explain the changes in small airways and parenchyma in these diseases (14). 
4.2 Airway remodelling 
4.2.1 Injury and repair 
It is now well established that particles from cigarette smoke causes damage to the airways, 
particularly to the epithelial lining (26).  Both non-symptomatic smokers and patients with 
COPD show signs of damage and repair to the epithelial surface in the form of denuded 
epithelial lining and squamous metaplasia (4).  The processes of normal and abnormal 
wound healing as a response to injury have been studied extensively (27-31).  In general, 
wound healing involves a series of cellular and molecular events, which initiates after injury 
of the epithelial lining and disruption of the underlying vasculature.  This process is 
characterized by an influx of platelets and inflammatory cells, predominantly neutrophils, 
followed by macrophages and T-lymphocytes.  These platelets and inflammatory cells 
release many growth factors and cytokines, as well as fibrin and fibronectin, which act to 
repair wounded tissue.  The environment of cytokines and growth factors, 
(myo)-fibroblast-derived extracellular matrix and adequate capillaries facilitate epithelial 
cell proliferation and migration, leading to wound closure (31).  Within the airways, the 
bronchial epithelium, sub-epithelial myo-fibroblasts and ASM cells are the major cell types 
involved in tissue repair processes.  Some of the important cellular and molecular events in 
the epithelial repair process and potential mechanisms leading to the remodelling of the 
airway are summarized in Figure 4.1. 
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Figure 4.1: Cigarette smoke and airway injury leading to tissue remodelling 
On exposure tobacco smoke, epithelial cells are damaged.  Epithelial cells and resident 
macrophages produce inflammatory mediators such as tumour necrosis factor (TNF)-α, interleukin 
(IL)-1β and IL-8.  In turn, inflammatory mediators stimulate migration of monocytes/macrophages, 
neutrophils, CD8+ T-lymphocytes to the airway.  Both TNF-α and IL-8 cause degranulation of 
neutrophils with production and release of serine-proteinases, metalloproteinases (MMPs), as well 
as free radicals that can cause matrix and epithelial damage.  In turn, TNF-α and growth factors 
like vascular endothelial growth factor (VEGF) and fibroblast growth factors (FGF-1 and FGF-2) 
orchestrate epithelial repair.  Ongoing inflammation and tissue breakdown trigger the release of 
growth factors like transforming growth factor-β1 (TGF-β1) inducing ECM production by 
myofibroblasts.  Repetitive tissue damage and repair leads to excessive ECM deposition and 
subepithelial fibrosis, and ultimately to airway and vascular remodelling.  Neu = neutrophil; Mφ = 
macrophage.  Based on Refs (32, 33). 
 
4.3 Vascular remodelling in COPD 
Changes in the airway microvasculature have been described in many chronic respiratory 
diseases (34).  Advances in staining methods and availability of vascular markers have 
improved the ability to visualize vessels in tissue specimens.  The mechanisms and 
therapeutic implications of alterations in airway blood vessels are just beginning to be 
elucidated and changes in the microvasculature still represent an important gap in the 
understanding of the pathophysiology of asthma and other chronic inflammatory airway 
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disease (34).  Patients with moderate to severe COPD display elevated pulmonary vascular 
pressures during exercise and pathological changes in the pulmonary circulation (4, 35).  It 
has been postulated that emphysema actually may lead to loss of the pulmonary vascular 
bed and induce angiogenesis (36). 
 
Vascular abnormalities are associated with the development of COPD; conversely, 
advanced COPD leads to pathological changes in the pulmonary circulation (35, 37).  This 
is likely due, in part, to alveolar hypoxia, which is well known to cause pulmonary 
vasoconstriction and, if the hypoxic stimulus persists, pulmonary vascular remodelling (36).  
With sustained vasoconstriction of pulmonary arteries, arterioles and veins, the medial 
vascular smooth muscle (VSM) extends distally to vessels normally devoid of smooth 
muscle (36).  Intimal thickening due to fibrosis and emergence of smooth muscle cells 
within the intima of small pulmonary arterial branches has also been reported (38).  Several 
studies have commented on the importance of structural and functional abnormalities in the 
pulmonary vasculature of COPD patients.   Hypoxic vasoconstriction is considered to 
represent one of the major contributing factors of pulmonary hypertension and right-sided 
heart failure in COPD and other chronic pulmonary diseases (35, 39).  In addition, 
emphysema, accompanied by loss of elastic recoil, increased pulmonary pressure and 
destruction of part of the pulmonary microvasculature, may contribute to the increased 
vascular resistance observed in COPD (36, 38).  Thus, several phenomena acting in concert 
in COPD result in pulmonary vascular remodelling.  Yet, little is known about the 
molecular mechanisms underlying these processes in the context of COPD. 
 
4.3.1 Angiogenesis 
Mature endothelial cells are quiescent cells with an extremely low proliferative index.  
Smoke-induced injury with hypoxia, however, induces VEGF-A mRNA expression via 
hypoxia inducible transcription factors (HIF 1 to 3), (40, 41).  This initiates angiogenesis by 
increasing endothelial permeability and stimulates endothelial cells to secrete several 
proteinases, such as MMPs including collagens and elastin degrading MMP-1, MMP-2, 
MMP-3 and MMP-9, and heparinase acting on HSPGs (42).  This, in turn, leads to ECM 
breakdown and the liberation of additional growth factors, predominantly VEGF-A, as well 
as FGF-2 and insulin-like growth factor-1 (IGF-1) sequestered within the surrounding 
matrix (40, 42).  Proliferating endothelial cells migrate to distant sites in wounded or 
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inflamed tissue, guided by the actions of VEGF and FGF-2 in close contact with the 
collagen and heparan-sulfate proteoglycan matrix, thus resulting in endothelial tube 
formation (43). 
 
4.3.2 Arteriogenesis and vascular remodelling 
Of great importance is the recruitment of a stable vascular smooth muscle coating to newly 
formed vessels.  This is initiated by VEGF in combination with angiopoietins (ANGs) 
produced by endothelial cells, of which currently four ligands are known (ANG-1 to 
ANG-4) that bind to two receptors expressed by endothelial cells, tie-1 and tie-2 (44).  
Binding ANG-1 to tie-2 induces endothelial cells to recruit fibroblasts or VSM, whereas 
ANG-2 binding to tie-2 inhibits this event (44).  TGF-β1 and TGF-βR2 are involved in 
vessel maturation by inhibiting endothelial cell proliferation and inducing smooth muscle 
differentiation and stimulating of ECM deposition by VSM cells and fibroblasts, thereby 
solidifying the endothelial-mural connections (42). 
 
Pathological arteriogenesis involves hypoxia, tissue ischemia and increased sheer stress, 
which damage both endothelial and VSM cells (42).  Inflammatory cells such as monocytes, 
macrophages and CD8+ T-lymphocytes infiltrate the vessel wall, causing additional damage 
to the vessel wall through release of mediators.  Growth factors such as FGF-2, PDGF and 
TGF-β1 are released by endothelial and VSM cells in response to inflammatory mediators.  
Eventually dysregulated repair leads to fibrosis and vascular remodelling (42).  Taken 
together, vascular remodelling and angiogenesis in peripheral, as well as in central airways 
could also be associated with the pathogenesis of COPD. 
 
4.3.3 Bronchial vessels 
Intimal thickening and emergence of smooth muscle cells within the intima of small 
pulmonary arterial branches has been attributed to a chronic inflammatory process 
accompanied by fibrosis, analogous to arteriosclerosis in cardiovascular disease (45, 46).  In 
COPD, persistent alveolar hypoxia causes pulmonary vasoconstriction and increased 
muscularization of small arterial branches (36).  With sustained vasoconstriction of 
pulmonary arteries, arterioles and veins, the medial vascular smooth muscle (VSM) extends 
distally to vessels normally devoid of smooth muscle (36). 
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Recent observations indicate that muscular pulmonary and bronchiolar arteries have 
increased adventitial infiltration of CD8+ T-lymphocytes and intimal thickening that 
correlates with collagen deposition (37, 47).  We studied pulmonary vascular remodelling, 
assessed as the ratio of α-smooth muscle actin staining and vascular wall (VW) area to 
lumen diameter (48).  Vascular medial thickness, assessed by video image analysis, was 
significantly increased in pulmonary vessels of various sizes in patients with COPD.  Others 
used expression of the smooth muscle marker α-SMA to investigate whether the ratio of 
smooth muscle (α-SMA/VW area) in the vascular wall had changed during the progression 
of COPD (49).  Surprisingly, the ratio of α-SMA stained area to VW area remained 
unchanged.  Approximately 42% of cells in all vessels stained positive for α-SMA, 
indicating that the increase in wall thickness could be attributed to the deposition of 
extracellular matrix proteins and medial accumulation of inflammatory cells and fibroblasts.  
Recently, we demonstrated expression staining for extracellular matrix proteins, like 
fibronectin (Figure 4.2D) and collagen subtypes (Figure 4.2C) in the intimal vascular cells 
of these pulmonary vessels indicating for ongoing intimal fibrosis in COPD patients.  Wall 
thickness of vessels 200 μm or more in diameter was increased in COPD (Figure 4.2A and 
B).  Our results on pulmonary vascular remodelling particularly in terms of intimal and 
medial thickening (Figure 4.2) are in agreement with several earlier reports (35, 38, 47, 50, 
51).  Wright and coworkers (35, 38) also observed a correlation with the severity of disease 
with mild to moderate COPD with intimal thickening and in severe cases with medial 
thickening.  Taken together, the data from this study indicate that vascular remodelling in 
COPD could be a contributing event in the pathogenesis of pulmonary hypertension in these 
patients.  Furthermore, the observed changes in the intimal fibrosis as well as medial 
thickening could narrow the vessel calibre and may eventually lead to more severe vascular 
obstruction in COPD patients.  Additionally, an inverse correlation of FEV1 with medial 
thickening was found in pulmonary vessels of larger calibre, indicating that the degree of 
pulmonary vascular remodelling is related to the severity of obstructive lung function 
defect.  Wright et al. (35, 38) also demonstrated increased wall thickness of small 
(<500 μm) pulmonary vessels in COPD subjects as compared to non-symptomatic smokers, 
which was correlated with the severity of the disease (as indicated by a decline in FEV1). 
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Figure 4.2: Histopathology of airway and vascular remodelling 
Photomicrographs of lung tissue sections from patients without COPD (A) and with COPD (B) 
showing α-smooth muscle actin staining (red new-fuchsine) in airway and vascular smooth muscle 
cells (ASM and VSM).  Panel C and D represents the expression of Collagen III and Fibronectin 
respectively in a bronchial vessel of COPD patient depicting vascular intimal fibrosis and 
remodelling. 
 
Similar findings of vascular abnormalities in COPD were recently reported by Peinado and 
coworkers, who showed intimal but not medial thickening in the vasculature of mild COPD 
patients compared to non-smoking controls (47, 50).  Furthermore, observations from the 
same group indicated that muscular pulmonary and bronchiolar arteries have increased 
adventitial infiltration of inflammatory cells, predominantly CD8+ T-lymphocytes and 
displayed VSM heterogeneity in relation to desmin as well as intimal thickening that 
correlated to the amount of total collagen deposition (37, 47). 
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Table 4.1: Major growth factors in vascular remodelling 
Growth factor Source Target Function 
FGF-1 ECM 
Fibroblast 
Fibroblast 
ASM 
VSM 
Epithelium 
Proliferation, 
Collagen production 
Proliferation 
Collagen production 
FGF-2 ECM 
Endothelial cell 
ASM 
VSM 
Macrophages 
Endothelial cell 
Fibroblast 
ASM 
VSM 
Epithelium 
Proliferation 
Proliferation 
Proliferation 
Proliferation 
Proliferation 
VEGF Epithelium 
ASM 
Endothelial cells 
VSM 
Macrophages 
ECM 
Endothelial cell 
 
Epithelial cells 
Fibroblast 
 
Macrophages 
Proliferation, 
Migration 
Proliferation 
Proliferation 
Recruitment 
Recruitment 
TGF-ß ECM 
Platelets, 
Macrophages 
Fibroblast 
ASM 
Fibroblast 
ASM 
VSM 
Endothelial cell 
Epithelium 
Neutrophil, 
T-lymphocytes 
Monocyt/macrophage 
ECM production 
Recruitment 
ECM production 
ECM production 
Differentiation 
ECM production 
Apoptosis 
Differentiation 
ECM production 
Chemotaxis 
PDGF Platelets, 
Endothelial cell 
Macrophages 
Fibroblast 
ASM 
Epithelium 
ASM 
Epithelium 
Fibroblast 
 
Proliferation 
Proliferation 
Recruitment 
Proliferation 
IGF-1 ECM 
Fibroblast 
Fibroblast 
ASM 
VSM 
Proliferation and 
Differentiation 
Collagen synthesis 
IGF-2 ECM 
Fibroblast 
 
Fibroblast 
 
Proliferation 
Differentiation 
Collagen synthesis 
Abbreviations; Transforming growth factor beta (TGF-ß), Fibroblast growth factor (FGF), 
Vascular endothelial growth factor (VEGF), Platelet-derived growth factor (PDGF), Insulin-like 
growth factors (IGF), Airway and Vascular smooth muscle (ASM and VSM), Extracellular matrix 
(ECM).  References (27, 28, 52-54). 
4.4 Growth factors involved in vascular remodelling 
A variety of growth factors and cytokines released from various sites of airway and vascular 
walls have the potential to contribute to the pathogenesis of vascular remodelling in COPD.  
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The major sources, target cells and effects for several growth factors implicated in chronic 
lungs diseases are listed in Table 4.1.  The main families of growth factors include the 
vascular endothelial growth factor (VEGF) family, fibroblast growth factors (FGFs), 
epidermal growth factor (EGF) family, transforming growth factor (TGF) β family, 
insulin-like growth factor (IGF) family, platelet-derived growth factor (PDGF) family and 
hepatocyte growth factor (HGF). 
4.5 Vascular remodelling in Emphysema and Chronic Bronchitis 
4.5.1 Expression of angiogenic growth factors in COPD 
In patients with COPD, higher expression of VEGF is found in bronchial and alveolar 
epithelium and VSM as well as in alveolar macrophages, whereas higher VEGFR-1 and 
VEGFR-2 expression is found in the endothelium, compared to patients without COPD 
(55), (56).  These data suggest a role for VEGF in tissue and vascular remodelling seen in 
COPD.  One intriguing possibility is that functional differences exist for VEGFRs in the 
pathogenesis of COPD.  For example, activation of VEGFR-2 is involved in angiogenesis 
by stimulating mitogenesis of endothelial cells during vascular damage-repair processes 
(57).  In contrast, VEGFR1 is involved in stimulating vascular smooth muscle expression of 
MMP and endothelial expression of plasminogen activator and its inhibitor, activities 
needed for blood vessel maturation (58, 59).  As VEGFR-1 has a higher affinity for VEGF 
than VEGFR-2, it is thought that VEGFR-1 is involved in resolving the angiogenic process 
(59, 60).  Pulmonary vascular smooth muscle expression of VEGF and VEGFR-2 are 
increased in smokers with COPD or chronic bronchitis, whereas VEGFR-1 expression did 
not differ between smokers with or without COPD in these compartments (37, 55).  In 
contrast to Kasahara et al (61) who showed that VEGF and its receptor VEGFR-2 were 
decreased in total lung extracts of emphysematous lungs as measured by ELISA or western 
blot analysis, we (55) found that the epithelial and endothelial cells in the alveolar spaces 
and in the most distal airways were intensely positive for VEGF and VEGFR-2 in patients 
with COPD.  In our study the patients could be considered as having mild to moderate 
COPD whereas the lungs studied by Kasahara et al (61) were solely emphysematous.  
Likewise, in COPD, expression levels of FGF-1, FGF-2 and FGFR1 are increased in 
vascular and in epithelial compartments in patients with COPD compared to subjects 
without COPD (48, 62).  Table 4.2 summarises the expression levels of angiogenic growth 
factors in COPD patients. 
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Table 4.2: Pulmonary expression of angiogenic growth factors in COPD, chronic 
bronchitis and emphysema 
Growth Factor Expression* Disease 
EGF 
EGFR 
Increased 
Increased 
Chronic Bronchitis 
COPD 
FGF-1 
FGF-2 
FGFR1 
Increased 
Increased 
Increased 
COPD 
COPD 
COPD 
TGFβ-1 Increased COPD 
VEGF 
VEGF 
VEGFR1 
VEGFR2 
VEGFR2 
Increased 
Decreased 
Increased 
Increased 
Decreased 
COPD 
Emphysema 
COPD 
COPD 
Emphysema 
*Pulmonary expression or circulating levels of various growth factors in comparison to age 
matched controls 
 
4.5.2 Role of VEGF and its receptors in pathogenesis of Emphysema and 
Chronic Bronchitis 
The destruction of lung tissue in emphysema may involve the progressive loss of capillary 
endothelial and epithelial cells through the process of programmed cell death, apoptosis.  
Several lines of evidence suggest that VEGF induces the expression of anti-apoptotic 
proteins and thus acts as an endothelial survival factor (63-65).  A recent study 
demonstrated that patients with emphysema had decreased levels of VEGF messenger RNA 
and protein, as well as decreased expression of VEGFR-2.  Furthermore, decreased VEGF 
and VEGFR-2 expression were associated with endothelial and epithelial cell death in 
alveolar septa (61).  Several recent animal studies have demonstrated that VEGFR-2 
blockade, in combination with chronic hypobaric hypoxia, destroys lung capillaries by 
inducing endothelial cell apoptosis and at the same time causes occlusion of precapillary 
pulmonary arteries by proliferating endothelial cells (66-69).  Chronic treatment of animals 
with SU5416, a VEGFR-2 inhibitor, results in increased pulmonary artery pressure in both 
normoxic and hypoxic animals, widespread endothelial cell apoptosis and emphysema, 
when compared with drug vehicle treated controls (17).  Similar findings of emphysema 
have been reported in mice depleted of pulmonary VEGF by a Cre/LoxP-targeted deletion 
technique (70) and in animals treated with a soluble Flt-Fc chimaeric protein (71).  Thus, the 
expression of VEGF may be protective against signals leading to apoptosis such as toxic 
agents from tobacco smoke.  Cigarette smoke, possibly by inducing nitric oxide (72), may 
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also act to decrease the expression of VEGF and VEGFR-2, thus resulting in lung septal 
endothelial cell death (61). 
 
In chronic bronchitis, increased VEGF levels may be due, in part, to ongoing repair 
processes (55, 73).  Small airway changes are associated with thickening of the airway wall 
and disruption of mucociliary clearance, resulting in the accumulation of inflammatory 
exudates in the airway lumen.  In addition, Hogg et al. postulated that colonization and 
infection of the lower airways was associated with an adaptive immune response that 
accounts for the increase in lymphocytes and their organization into lymphoid follicles in 
patients with severe COPD (74).  Thus, both the innate mucociliary clearance system (75), 
the adaptive immune responses (74) appear to be important for the repair process. 
 
Kanazawa et al. (73) examined VEGF levels in the induced sputum of patients with 
emphysema, chronic bronchitis and asthma and found correlations with both forced 
expiratory volume in 1 s [FEV1] and diffusing capacity of lung for carbon monoxide 
(DLco).  In emphysema patients, lower FEV1 or DLco directly correlated with lower VEGF 
levels in sputum.  In contrast, patients with chronic bronchitis or asthma demonstrated an 
inverse correlation between VEGF levels and FEV1.  These data suggest a positive 
association between the severity of airway inflammation and VEGF secretion in these two 
diseases.  Given the scarcity of evidence, however, it is difficult to conclude that there is a 
differential role for VEGF in the pathogenesis of emphysema or chronic bronchitis.  As 
Wagner rightly points out, it is unknown whether VEGF expression is below a critical 
threshold level and indeed the cause of emphysema, or whether reduced expression is 
merely a marker of the disease process, without functional importance (7).  However, 
emerging evidences gives us a clear indication that there is modulation of angiogenic 
factors like VEGF in COPD patients that appears to correlate with the underlying 
pathophysiology. 
 
Signalling through VEGFR-1/flt-1 may also be important to the pathogenesis of 
emphysema.  A recent study of PlGF transgenic mice demonstrated enlarged airspaces 
without airway inflammation (76).  Over expression of PlGF resulted in apoptosis of type II 
pneumocytes, leading to decreased VEGF secretion and subsequent endothelial cell death.  
These authors hypothesize that a positive feedback loop exists between type II pneumocytes 
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that secrete VEGF and integrity of the septal microcirculation that promotes pneumocyte 
survival (76). 
 
4.5.3 Angiogenic growth factors as potential therapeutic targets 
VEGF and its receptors are critical regulators of angiogenesis, tumorigenesis and 
metastasis.  Several drugs have been developed to reduce tumour growth by impairing 
neovascularization.  Among those in clinical trials are VEGF-Trap, bevacizumab (Avastin), 
CEP-7055, SU6668 and PTK787 (77).  Avastin is a humanized monoclonal IgG1 antibody 
against VEGF that inhibits receptor binding.  CEP-7055 is a small molecule, water-soluble 
indenopyrrolocarbazole derivate inhibitor of pan-VEGFR tyrosine kinase activity.  It has 
been shown to inhibit pulmonary VEGFR-2 activation in vivo, capillary formation by 
human and rat endothelial cells in vitro and in vivo, granuloma formation and 
vascularisation in a chronic inflammation model, and tumorigenesis (78).  VEGF Trap is a 
soluble VEGFR constructed from VEGFR1 and VEGFR2 binding domains linked to an 
IgG1 constant region.  In vivo animal models have demonstrated that VEGF Trap reduce 
haemangiogenesis, lymphangiogenesis, and tumour growth (79, 80).  SU6668 is an IgG2a 
fusion protein inhibiting the receptor tyrosine kinase activity of FGFR1, KDR and 
PDGF-Rβ.  SU6668 has been shown to inhibit tumour growth, lung cancer metastasis and 
tumour vascularisation (81).  Many other small molecule VEGFR inhibitors are being 
developed for clinical therapy (82). 
 
Recent studies support a role for VEGF/VEGFR in pulmonary and vascular remodelling 
and inflammation.  For example, VEGF transgenic mice exhibit alveolar vascular and 
airspace remodelling as well as a Th2-type airway inflammation in a murine model of 
experimental asthma (83, 84).  In this study, the VEGF-R inhibitor SU1498, as well as 
VEGF-TRAP, decreased airway inflammation and airway hyperresponsiveness (83, 84).  
Therefore, VEGF inhibitors may be of potential use for the treatment of inflammation and 
neovascularization seen in asthma or specific subtypes of COPD, like chronic bronchitis.  
However, the redundancy of the VEGF-VEGFR system may limit the applicability and 
efficacy of VEGF/VEGFR inhibitors (85).  In contrast, in patients with emphysema, therapy 
may need to be targeted more towards inhibition of apoptosis or stimulation of VEGF 
expression, in order to overcome endothelial and epithelial cell death and maintain alveolar 
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septal integrity (86).  Hence, treatment with VEGF/VEGFR inhibitors should be further 
investigated and may be restricted to specific chronic lung diseases. 
 
Figure 4.3: The potential role of airway smooth muscle cells in bronchial vascular 
remodelling 
The expression and secretion of cytokines, chemokines and growth factors by ASM cells can alter 
the proliferative response of vascular endothelial and smooth muscle cells.  These complex 
interactions may contribute to the overall airway and vascular remodelling process by promoting 
increased vascularity, endothelial permeability and airway wall oedema and trafficking of 
inflammatory cells during chronic lung diseases. 
4.6 Conclusion 
Current in vivo and in vitro data indicate that cross-talk between smooth muscle cells, 
endothelium, myofibroblasts and inflammatory cells via growth factors and cytokines, are 
major contributing factors to vascular remodelling during different pathophysiological 
conditions (49, 87-89).  Figure 4.3 summarizes the possible interactions between the 
ASM-derived mediators and the adjacent endothelial and vascular smooth muscle cell 
compartment in the bronchial blood vessels and how they contribute to the remodelling 
process.  At present, our knowledge of airway and vascular remodelling in COPD is far from 
complete.  Increased adventitial infiltration of inflammatory cells, predominantly CD8+ 
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T-lymphocytes, in muscular pulmonary and bronchiolar arteries has been reported (47, 90).  
Many growth factors, among them VEGF and FGF, play an essential role in maintaining 
pulmonary and vascular viability and in tissue repair.  Based on the available evidence, we 
hypothesize that in chronic bronchitis, expression of VEGF and VEGFR-2 expression leads 
to increased vascular remodelling, which is inefficiently compensated by the low expression 
of VEGFR-1.  In subjects with emphysema, however, VEGFR2 expression is lower.  
Preferential activation of VEGFR-1 results in higher MMP activity, alveolar destruction and 
endothelial apoptosis.  Hence, the balance between VEGF, VEGFR-1 and VEGFR-2 are 
critical in the pathogenesis of COPD subtypes. 
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Chapter 5:  Vascular Endothelial Growth Factor and its Receptors in 
COPD 
 
Summary 
Ongoing inflammatory processes resulting in airway and vascular remodelling characterize 
chronic obstructive pulmonary disease (COPD).  Vascular endothelial growth factor 
(VEGF) and its receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) could play a role in 
tissue remodelling and angiogenesis in COPD.  We examined the cellular expression pattern 
of VEGF, Flt-1 and KDR/Flk-1 by immunohistochemistry in central and peripheral lung 
tissues obtained from (ex-) smokers with (FEV1 <75% predicted; n=14) or without COPD 
(FEV1 >85% predicted; n=14).  The immunohistochemical staining of each molecule was 
quantified using a visual scoring method with grades ranging from 0 (no), 1 (weak), 2 
(moderate) to 3 (intense). VEGF, Flt-1 and KDR/Flk-1 immunostaining was localized in 
vascular and airway smooth muscle (VSM and ASM) cells, bronchial, bronchiolar and 
alveolar epithelium and macrophages.  Pulmonary endothelial cells abundantly expressed 
Flt-1 and KDR/Flk-1 but not VEGF.  In COPD patients, bronchial VEGF expression was 
higher in microvascular VSM cells and ASM cells as compared to non-COPD patients (1.7 
and 1.6 fold, p≤0.01, respectively).  VEGF expression in intimal and medial VSM (1.7 and 
1.3 fold, p≤0.05) of peripheral pulmonary arteries associated with the bronchiolar airways 
was more intense in COPD, as well as in small pulmonary vessels in the alveolar region (1.5 
and 1.7 fold, p≤0.02).  In COPD patients, KDR/Flk-1 expression was enhanced in 
endothelial cells, intimal and medial VSM (1.3, 1.9 and 1.5 fold, p≤0.02), whereas 
endothelial Flt-1 expression was 1.7 times higher (p≤0.03).  Furthermore, VEGF expression 
was significantly increased in bronchiolar and alveolar epithelium as well as bronchiolar 
macrophages (1.5 fold, p≤0.001).  Additionally, expression of VEGF in bronchial VSM and 
mucosal microvessels as well as bronchiolar epithelium inversely correlated with FEV1 
(r<-0.45; p≤0.01).  Our results suggest that VEGF and its receptors Flt-1 and KDR/Flk-1 are 
involved in peripheral vascular and airway remodelling processes in an autocrine and/or 
paracrine manner.  This system may also be associated with epithelial cell viability during 
airway wall remodelling in COPD. 
 
5.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is a disease state characterized by airflow 
limitation that is not fully reversible, usually progressive and associated with an abnormal 
inflammatory response of the lungs in response to noxious particles and gases (1).  COPD is 
a major health problem with cigarette smoking as its main cause.  One important pathological 
features of COPD is chronic airway inflammation characterized by an influx of inflammatory 
cells predominantly neutrophils, macrophages and CD8+ T-lymphocytes in the lumen and wall 
of bronchial and bronchiolar airways and parenchyma (2-4).  Furthermore, several studies 
reported a thickened bronchiolar wall and airway remodelling with peribronchiolar fibrosis, an 
increase in airway smooth muscle (ASM) mass and emphysema (3, 5, 6). 
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Vascular abnormalities have been associated with the development of COPD (7, 8).  Wright 
et al. found an increase in wall area of small (<500 μm) pulmonary vessels, by intimal 
thickening in mild to moderate COPD patients and medial thickening in severe cases as 
well, which was correlated with a decline in FEV1 (7, 9).  Furthermore, recent observations 
indicated that muscular pulmonary and bronchiolar arteries have increased adventitial 
infiltration of CD8+ T-lymphocytes and have intimal thickening that was correlated to the 
amount of total collagen deposition (8, 10).  Finally, emphysema may lead to loss of the 
pulmonary vascular bed and induce angiogenesis (11).  Yet, little is known about the 
molecular mechanisms underlying these processes in the context of COPD. 
 
One of the potent proteins involved in vascular remodelling is vascular endothelial growth 
factor (VEGF).  The VEGF family currently comprises six members (VEGF-A to F), of 
which the originally identified VEGF-A165 variant is the predominant form of five 
additional spliced variants (12).  VEGFs are heparin-binding proteins and act via their high 
affinity, transmembrane receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1).  The 
receptors belong to the family of tyrosine kinases and are predominantly expressed by 
endothelial and epithelial cells (12).  VEGF promotes an array of responses in the 
endothelium including hyperpermeability, endothelial cell proliferation and angiogenesis 
with new vessel tube formation in vivo (12, 13).  The expression of VEGF can be induced 
under a variety of pathophysiological conditions, including pulmonary hypoxia and 
pulmonary hypertension with increased sheer stress (13, 14).  Both hypoxia and pulmonary 
hypertension are pathological features often seen in advanced COPD patients (2).  We 
hypothesize, that increased VEGF expression perhaps under an influence of 
hypoxia-inducible transcription factors (HIFs) may contribute to increased and abnormal 
proliferation of endothelial and VSM cells in pulmonary vessels leading to vascular 
remodelling. 
 
Although the role of VEGF in the vascular biology is thoroughly studied, it has become 
clear that VEGF and its receptor system are involved in various other cellular events as 
well, including epithelial proliferation and survival, and the recruitment of mast cells, 
neutrophils and macrophages to sites of fibrosis (13, 15, 16).  Recent studies indicate that 
VEGF is expressed in the lung by bronchiolar, submucosal glandular and alveolar type I and II 
epithelial cells, alveolar macrophages, airway and vascular smooth muscle (ASM and VSM) 
cells as well as myo-fibroblast in fibrotic lung lesions (14, 17, 18). 
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In order to assess the role of VEGF and its receptors VEGFR-1 (Flt-1) and VEGFR-2 
(KDR/Flk-1) in the pathophysiology of COPD, we first examined the expression of 
VEGF-A, Flt-1 and KDR/Flk-1 in central and peripheral lung tissue from (ex-) smokers 
with or without COPD.  Furthermore, we investigated the relation of lung function with the 
expression data of VEGF and its receptors. 
5.2 Materials and methods 
5.2.1 Selection of patients 
Central and peripheral lung tissues were obtained from current or ex-smokers who 
underwent lobectomy or pneumonectomy for lung cancer.  Fourteen subjects with COPD 
(FEV1 < 75% predicted) and fourteen subjects without COPD (FEV1 > 84% predicted) were 
included as previously described (19-21).  Total lung capacities (TLC) were not below 
normal levels (TLC >80% predicted).  All patients lack upper respiratory tract infection and 
did not receive antibiotics perioperatively.  None of the patients had received 
glucocorticosteroids during 3 months period before resection, but four patients received 
glucocorticosteroids perioperatively.  Based on these criteria, subjects with COPD could not 
be subdivided into patients with either chronic bronchitis or emphysema alone.  Clinical 
data are given in Table 5.1.  Subjects were excluded if the obstruction of the central bronchi 
was due to the tumour, or if diffuse pulmonary inflammation or fibrosis was present, or if 
no tissue free from tumour could be obtained.  Lung tissue specimens used in this study 
were obtained from the archival collection at the Department of Pathology (LUMC, Leiden, 
NL).  Medical Ethics Committee of LUMC approved the study.  The patients in these two 
groups participated in a larger research project, part of which has been published previously 
(19-21).  Lung tissue specimens were routinely fixed in 10% neutral buffered formalin by 
inflation-immersion fixation and embedded in paraffin for histopathological examination 
and immunohistochemistry. 
 
5.2.2 Immunohistochemistry 
Paraffin sections (4 μm thick) of the lung tissues were cut and mounted on silane-coated 
glass slides.  Immunohistochemistry was performed using a method as described earlier (20, 
22, 23).  In brief, after deparaffinization in xylene and rehydration through graded alcohol, 
slides were rinsed with phosphate buffered saline (PBS).  Endogenous peroxidase was 
blocked with 0.3% hydrogen peroxidase.  For VEGF, VEGFR-1, VEGFR-2 and Ki-67 
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staining, slides were pre-treated by boiling in citrate buffer (10 mM citrate buffer, pH = 6.0) 
for 10 min in a microwave oven.  Subsequently, sections were preincubated with 10% 
normal goat serum diluted in 5% bovine serum albumin in phosphate buffered saline (5% 
BSA/PBS, pH = 7.4), and afterwards incubated for 30 min at room temperature with 
affinity-purified rabbit polyclonal VEGF antibody in a dilution of 1:200 v/v.  The VEGF 
antibody used was raised against a 20 amino acid synthetic peptide corresponding to 
residues 1-20 of the amino terminus of human VEGF (Santa Cruz Biotechnology Inc., Santa 
Cruz, CA, USA).  A different series of slides were incubated with a rabbit polyclonal 
antibody against a synthetic peptide corresponding to aa 1312-1328 of human Flt-1 
(NeoMarkers, RB-1526, Fremont, CA, USA) in a dilution of 1:100 v/v.  For VEGFR-2, a 
rabbit polyclonal antibody against aa 1326-1345 of mouse KDR/Flk-1 (NeoMarkers, 
RB-1527, Fremont, CA, USA) in a dilution of 1:200 v/v was used.  To examine 
proliferation of cells in the airways, an antibody against Ki-67 (Dako Corporation, Glostrup, 
Denmark) of 1:400 v/v at 4oC overnight for was used as a marker.  Consecutive tissue 
sections were also stained with a monoclonal mouse anti-human alpha-smooth muscle actin 
(α-SMA) antibody (clone 1A4: Biogenex, San Ramon, USA) in a dilution of 1:1000 v/v.  
The optimal dilution of the first antibody was identified by examining the intensity of 
staining obtained with a series of dilutions of the antibody from 1:50 to 1:1000.  Negative 
controls were prepared by omission of the primary antibody.  After washing with tris-base 
buffered saline (TBS, pH = 7.4), the test and control slides were incubated for 15 min with 
Powervision+ΤΜ Post-antibody blocking solution (Immunovision Technologies, Daly City, 
CA, USA).  Next, slides were washed and incubated with Powervision+TM polymerized 
horseradish peroxidase conjugates (Immunovision Technologies, Daly City, CA, USA).  
Finally, the sections were stained with 3,3’-diaminobenzidine tetrahydrochloride (Sigma-
Aldrich , Zwijndrecht, NL) as chromogen, counterstained with Mayer's haematoxylin and 
visualized with light microscopy. 
 
5.2.3 Quantitative scoring analysis of immunohistochemistry 
Prior to screening, sections were coded so that the observers were unaware of the clinical 
details of the case under study.  Expression of VEGF, Flt-1 and KDR/Flk-1 was analyzed 
semi-quantitatively, using a visual scoring method with grades ranging from 0 to 3 (0 = no 
staining; 1 = moderate staining; 2 = intense staining; 3 = very intense staining) as previously 
described (8, 19, 20, 24).  The entire section of a tissue block was investigated and scored at 
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the same magnification.  The staining intensity of VEGF, Flt-1 and KDR/Flk-1 was scored 
blindly by two independent observers, who were unaware of the clinical data of the case 
under study, in bronchial and bronchiolar airways as well as alveolar parenchyma in cells of 
epithelial, endothelial and smooth muscle origin as well as macrophages.  We examined 
errors within and between observers by correlating the expression scores using Pearson’s 
analysis and found a very high correlation ranging from 0.8 to 0.9.  In the bronchial airways 
staining was assessed in the bronchial epithelium, mucosal microvasculature, submucosal 
bronchial wall vessels, airway smooth muscle (ASM) cells and macrophages in the 
bronchial airway wall.  In peripheral lung tissues the staining of VEGF and receptors was 
analyzed in bronchiolar an alveolar epithelium, bronchiolar ASM cells, and bronchiolar and 
alveolar macrophages.  The vasculature in the peripheral lung was further subdivided into 
the larger pulmonary vessels associated with the bronchiolar airways and smaller vessels 
situated within the alveolar parenchyma.  In each the VEGF and receptor staining of 
endothelial, intimal and medial VSM cells were assessed.  Since TGF-β1 may also induce 
VEGF expression in epithelial cells (25, 26), we assessed the correlation between the 
epithelial VEGF expression from the current study and  epithelial TGF-β1 expression from 
one of our previous studies (20).  In both studies the same patient groups were used and the 
staining was performed on adjacent or near sections. 
 
5.2.4 Statistical analysis 
Data were analyzed for statistical significance using the unpaired, two-tailed Students’ t-test 
as well as the non-parametric Mann-Whitney test, where appropriate.  The expression data 
for VEGF and its receptors were expressed as mean±SEM.  Furthermore, VEGF and its 
receptors staining for different compartments were correlated with FEV1 using Pearson’s 
correlation analysis.  Differences with p ≤ 0.05 were considered to be statistically 
significant. 
5.3 Results 
5.3.1 Clinical parameters 
The clinical and lung function characteristics of all subjects included in the study are listed 
in Table 5.1.  As defined, the COPD group demonstrated decreased FEV1 and FEV1/FVC 
values, (p≤0.001) as has been described previously (19-21).  The subjects in the two groups 
did not differ significantly in age and smoking status (pack-years) or steroid use (Table 5.1). 
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Table 5.1: A summary of the clinical characteristics of subjects with and without 
chronic obstructive pulmonary disease 
Group Sex 
(M/F) 
Age PY FEV1 
(% Pred.) 
FEV1/FVC 
(%) 
Steroid 
treatment  
Non-COPD 10/4 64 (3.7) 42 (7.7) 101 (3.3) 0.72 (0.02) None 
COPD 14/0 64 (2.3) 44 (0.8) 63 (2) 0.54 (0.02) 4 
p-value  0.84 0.82 ≤0.001 ≤0.001  
Definition of abbreviations: COPD = chronic obstructive pulmonary disease; Forced expiratory 
volume in 1 s (FEV1) and Forced vital capacity (FVC) are given as percentages of the predicted 
values (% Pred.) before bronchodilatation.  M = Male; F = Female.  PY = number of pack years.  
Data shown represent means with standard deviation in brackets.  The patients in these two groups 
participated in a larger project, part of which has been published previously (19-21). 
 
5.3.2 Immunolocalisation of VEGF, Flt-1 and KDR/Flk-1 
 
Bronchial airways 
 
Examples of VEGF expression in central airways of non-COPD and COPD subjects are 
given in Figure 5.1A and 5.1B, whereas 5.1C and 5.1D (both taken from COPD subjects) 
show the VEGF receptors Flt-1 and KDR/Flk-1, respectively.  In all subjects, within the 
airways VEGF, Flt-1 and KDR/Flk-1 were localized in the bronchial epithelium and airway 
smooth muscle (ASM) cells, bronchial microvasculature of mucosa and submucosa and on 
inflammatory cells, predominantly macrophages, (Figure 5.1A-D).  In the vessel wall, 
vascular smooth muscle (VSM) cells were positive for VEGF, Flt-1 and KDR/Flk-1, 
whereas endothelial cells did not stain for VEGF protein but were positive for the Flt-1 and 
KDR/Flk-1 (Figure 5.1).  To assess the intensities of VEGF, Flt-1 and KDR/Flk-1 
expression in various bronchial airway compartments, we opted for a visual scoring method 
as previously described (8, 19, 20, 24).  VEGF expression was increased in bronchial 
airway smooth muscle cells of COPD patients as compared to non-COPD subjects (1.6 fold, 
p≤0.01) but not in bronchial epithelial cells and macrophages (Figure 5.2A).  In the central 
airways of patients with COPD as compared to non-COPD subjects, VEGF staining was 
more intense in VSM of microvasculature the bronchial mucosal (lamina propria) (1.7 fold, 
p≤0.001) and bronchial VSM in the submucosa (1.4 fold, p≤0.01, Figure 5.2A).  No 
significant differences were observed when considering the expression levels of KDR/Flk-1 
and Flt-1 between COPD subjects and non-COPD patients (Figure 5.2B and 5.2C, 
respectively).  In all subjects VEGFR-2 (KDR/Flk-1) expression was more intense than 
VEGF in COPD  Chapter 5 
 110 
VEGFR-1 (Flt-1) expression, except for the expression in endothelial cells of bronchial 
microvessels and on bronchial macrophages, which were comparable (Figure 5.2B and 
5.2C). 
 
Bronchiolar airways 
 
Figure 5.3 shows photographs of peripheral lung tissues from non-COPD and COPD 
subjects for VEGF (5.3A and 5.3B), KDR/Flk-1 (5.3C and 5.3D) and Flt-1 (5.3E and 5.3F), 
respectively.  In bronchiolar epithelial cells VEGF (1.5 fold, p≤0.001, Figure 5.4A) and 
Flt-1 expression (1.4 fold, p≤0.04, Figure 5.4C) were increased in COPD patients as 
compared to non-COPD subjects, whereas the staining for KDR/Flk-1 was unchanged 
between both patient groups (Figure 5.4B). 
D
BA
C
 
Figure 5.1: Expression of VEGF and its receptors in bronchial tissues 
Immunohistochemical localization of VEGF (A-B), KDR/flk-1 (C) and flt-1 (D) in bronchial tissues 
from non-COPD (ex-) smoking subjects (A) and patients with COPD (B, C, D).  Immunoreactive 
VEGF, KDR/flk-1 and flt-1 were localized in bronchial epithelial cells, airway smooth muscle 
(ASM) cells and in macrophages, endothelial and vascular smooth muscle (VSM) cells.  Colour is 
developed with 3,3-diaminobenzidine tetrahydrochloride (DAB) as chromogen (brown colour) and 
counterstained with Mayer's haematoxylin.  Arrows indicate sites of positivity for VEGF, flt-1 or 
KDR/flk-1.  Original magnification: x100; Scale bar = 50 μm. 
 
VEGF in COPD  Chapter 5 
 111
Airway smooth muscle cells showed slightly increased VEGF expression in bronchiolar 
region (1.3 fold, p≤0.05), whereas the expression of both the receptors remained unchanged 
in two patient groups.  However, the expression of KDR/Flk-1 was more intense than Flt-1 
in all patients (Figure 5.4B and 5.4C). 
 
 
Figure 5.2: Quantification of expression pattern of VEGF, KDR/flk-1 and flt-1 in COPD 
Graphic representations of VEGF (panel A), KDR/flk-1 (panel B) and flt-1 (panel C) protein 
expression in different cell types in bronchial airways using visual scoring.  The immunostaining 
score ranges from 0 (no staining) to 3 (very intense staining).  Open and closed bars represent mean 
data from subjects without and with COPD, respectively.  Data are presented as mean±SEM.  An 
asterisk indicates a significant difference (p≤0.05, Student's t-test) as compared to non-COPD 
subjects.  Abbreviations: bronchial epithelium (Epi), bronchial microvessels (MV) in the mucosa, 
bronchial vascular smooth muscle cells (VSM) in the submucosa, airway smooth muscle (ASM) and 
macrophages (Mφ). 
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Figure 5.3: Expression of VEGF and its receptors in peripheral lung tissues 
Immunohistochemical localization of VEGF (A-B), KDR/flk-1 (C-D) and flt-1 (E-F) in peripheral 
tissues from non-COPD (ex-) smoking subjects (A, C, E) and patients with COPD (B, D, F).  
Immunoreactive VEGF, flt-1 and KDR/flk-1 were localized in bronchiolar and alveolar epithelial 
cells, airway smooth muscle (ASM) cells, macrophages and in endothelial and intimal/medial 
vascular smooth muscle (VSM) cells.  Colour is developed with 3,3-diaminobenzidine 
tetrahydrochloride (DAB) as chromogen (brown colour) and counterstained with Mayer's 
haematoxylin.  Arrows indicate sites of positivity for VEGF, flt-1 or KDR/flk-1.  Original 
magnification: x100; Scale bar = 50 μm. 
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Figure 5.4: Quantification of expression pattern of VEGF, KDR/flk-1 and flt-1 in 
bronchiolar airways and pulmonary arteries 
Graphic representations of VEGF (panel A), KDR/flk-1 (panel B) and flt-1 (panel C) protein 
expression in different cell types in bronchiolar airways and associated pulmonary arteries using 
visual scoring.  Open and closed bars represent mean data from subjects without and with COPD, 
respectively.  Data are presented as mean±SEM.  An asterisk indicates a significant difference 
(p≤0.05, Student's t-test) as compared to non-COPD subjects.  Abbreviations: bronchiolar 
epithelium (Epi), endothelial cells (EC), intimal and medial vascular smooth muscle cells (VSM int. 
and med), airway smooth muscle (ASM) and bronchiolar macrophages (Mφ). 
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When considering the expression of VEGF in the larger pulmonary arteries associated with 
the bronchiolar airways, the fold in intimal and medial VSM staining was 1.7 and 1.3 
(p≤0.05, Figure 5.4A) between COPD and control subjects respectively, whereas 
endothelial cells did not express VEGF.  KDR/Flk-1 expression was enhanced in 
endothelial cells, intimal and medial VSM (1.3, 1.9 and 1.5 fold, p≤0.02, Figure 5.4B), 
whereas the corresponding value in endothelial cells for Flt-1 expression is 1.7 (p≤0.03, 
Figure 5.4C).In both patient groups, the intimal VSM stained 2-3 times less intense than 
medial VSM for VEGF, Flt-1 and KDR/Flk-1.  Moreover, the vascular Flt-1 expression was 
lower than KDR/Flk-1 and VEGF in each of the investigated vessel wall areas (p≤0.002, 
Figure 5.4).  Staining of VEGF in bronchiolar macrophages (1.5 fold, p≤0.001, Figure 
5.4A) was increased in COPD as compared to non-COPD subjects, whereas the staining on 
macrophages of Flt-1 or KDR/Flk-1 expression in bronchiolar airways as well as VEGF, 
Flt-1 or KDR/Flk-1 in the alveolar region remained unchanged (Figure 5.5). 
 
Alveolar parenchyma 
 
Staining of alveolar epithelial cells (type I and II) for COPD was more intense than for 
non-COPD controls (1.5 fold, p≤0.0001, Figure 5.5A).  KDR/Flk-1 and Flt-1 expression 
were not changed in alveolar epithelial cells (Figure 5.5B and 5.5C).  VEGF expression was 
increased in intimal and medial VSM (1.5 and 1.7 fold, p≤0.01, Figure 5.5A) of small 
pulmonary vessels in the alveolar region whereas the corresponding values for KDR/Flk-1 
were 2.0 and 1.8 (p≤0.02), respectively (Figure 5.5B).  Furthermore, the expression of both 
KDR/Flk-1 and Flt-1 were increased in endothelial cells of small pulmonary vessels in lung 
parenchyma (1.7 and 2.1 fold, p≤0.001, Figure 5.5B and  5.5C). 
 
5.3.3 Correlation between staining and clinical data 
We examined the relation between FEV1 values of patients in both groups and the staining 
scores of VEGF, Flt-1 and KDR/Flk-1 in the investigated areas.  Within the bronchial 
airways, FEV1 values were inversely correlated with VEGF staining sores in bronchial 
mucosal microvasculature (r = -0.65; p≤0.001, Figure 5.6A), bronchial ASM cells (r = 
-0.45; p≤0.01, Figure 5.6B) if all subjects were analyzed together. 
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Figure 5.5: Quantification of expression pattern of VEGF, KDR/flk-1 and flt-1 in 
alveolar parenchyma 
Graphic representations of VEGF (panel A), KDR/flk-1 (panel B) and flt-1 (panel C) protein 
expression in different cell types in alveolar parenchyma and pulmonary vasculature using visual 
scoring.  Open and closed bars represent mean data from subjects without and with COPD, 
respectively.  Data are presented as mean±SEM.  An asterisk indicates a significant difference 
(p≤0.05, Student's t-test) as compared to non-COPD subjects.  Abbreviations: bronchiolar 
epithelium (Epi), endothelial cells (EC), intimal and medial vascular smooth muscle cells (VSM int. 
and med.), and alveolar macrophages (Mφ). 
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Figure 5.6: Correlation of lung function with VEGF expression in airway 
Correlation with FEV1 (% predicted) of VEGF protein expression in microvessels  (MV) in the 
bronchial mucosa (A), bronchial airway smooth muscle (ASM) cells (B), bronchiolar epithelial 
(Epi) cells (C) and medial vascular smooth muscle (VSM) cells of pulmonary arteries associated 
with the bronchiolar airways (D).  Correlation was assessed for the combined patient groups 
(non-COPD and COPD).  Correlation coefficient (r) was obtained using linear regression 
(Pearson’s) analysis. 
 
The bronchiolar epithelium (r = -0.67; p≤0.001, Figure 5.6C) and medial VSM of larger 
pulmonary arteries associated with bronchiolar airways (r = -0.50; p≤0.01, Figure 5.6D) 
also showed an inverse correlation with FEV1 values from the total group.  Additionally, 
VEGF expression in medial VSM was correlated with KDR/Flk-1 expression in 
endothelium of pulmonary arteries (r = 0.41; p≤0.01) as well as smaller alveolar vessels (r = 
0.48; p≤0.01).  Furthermore, we found correlation for the expression pattern of KDR/Flk-1 
and Flt-1 in the endothelium of pulmonary arteries (r = 0.67; p≤0.001) as well as in alveolar 
vessels (r = 0.80; p≤0.0005). 
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Additionally, we examined correlation between the epithelial VEGF expression from the 
current study and epithelial TGF-β1 expression from one of our previous studies (20).  In 
both studies the same patient groups were used and the staining was performed on adjacent 
or near sections.  With regard to the bronchiolar epithelium, Pearson’s analysis revealed a 
significant positive correlation between the VEGF protein and TGF-β1 protein levels (r = 
0.55; p≤0.004) and VEGF protein and TGF-β1 mRNA expression (r = 0.45; p≤0.02).  With 
regard to the alveolar epithelium, the VEGF protein levels correlated significantly with the 
TGF-β1 mRNA expression only (r = 0.58; p≤0.002), but not with the TGF-β1 protein levels 
(r = 0.31; p≤0.12). 
5.4 Discussion 
In this study we show that COPD is associated with an increased expression of VEGF in the 
bronchial, bronchiolar and alveolar epithelium and in bronchiolar macrophages as well as 
ASM and VSM cells in both bronchiolar and alveolar region.  KDR/Flk-1 and Flt-1 were 
increased in COPD as compared to non-COPD in endothelial, intimal and medial VSM cells 
of larger pulmonary arteries and of smaller calibre alveolar vessels.  Interestingly, we 
observed a significant inverse correlation of VEGF with FEV1 in bronchial mucosal 
microvessels and ASM cells, bronchiolar epithelium and medial VSM of larger pulmonary 
arteries associated with bronchiolar airways.  TGF-β1 staining in the bronchiolar epithelium 
also correlated with VEGF in the same patients as described in our previous study (20). 
 
Our results indicate that VEGF and its receptors Flt-1 and KDR/Flk-1 are localized within 
the airways and vasculature in endothelial and epithelial cells as well as smooth muscle cell 
origin and furthermore on various inflammatory cells, predominantly macrophages.  The 
localization of VEGF and its receptors in the lungs of our patient groups is in agreement 
with earlier reports, which described a similar staining pattern in human developing and 
normal adult as well as in emphysematous lungs (17, 27, 28).  In contrast to Kasahara et al. 
(28), where authors showed in emphysematous lungs that VEGF and its receptor VEGF-R2 
were decreased in total lung extracts, as measured with ELISA or western blot analysis, we 
found that the epithelial and endothelial cells in the alveolar spaces and in the most distal 
airways were intensely positive for VEGF and KDR/Flk-1 in COPD patients.  Furthermore, 
our patient groups could be considered as mild to moderate COPD, whereas in the study of 
Kasahara (28) the selected patients were solely emphysematous in origin.  Our findings of 
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increased VEGF expression in viable cell populations represent in part a successful attempt 
to repair sustained damage and perhaps contribution to vascular remodelling and their 
participation in the establishment and maintenance of the functional blood-gas interface, 
maturation, survival and proliferation of capillary endothelial cells (29).  In adult lungs, 
VEGF and its receptor system could contribute in the maintenance of endothelial and 
epithelial cell viability in response to injury (30). 
 
Interestingly, immunoreactivity for VEGF in intimal and medial VSM cells and for Flt-1 as 
well as KDR/Flk-1 in endothelial cells of pulmonary arteries and alveolar vessels was 
elevated in patients with COPD.  The highest levels of VEGF expression in the pulmonary 
vasculature were observed in the medial VSM cells and of KDR/Flk-1 in endothelial cells 
of arteries with a diameter of approximately 200 μm which are known to play an important 
role in pulmonary blood pressure regulation and vascular resistance (14, 31).  Pulmonary 
hypoxia and hypertension with increased sheer stress are pathophysiological conditions that 
have been shown to increase the expression of VEGF in VSM cells (13, 14).  Blockade of 
KDR/Flk-1 is associated with obliterative endothelial cell proliferation in pre-capillary 
arterioles with abnormal vessel development and at the same time with induction of 
capillary endothelial and cell death by apoptosis, together leading to death in rat embryos, 
similar to that seen in human primary pulmonary hypertension subjects (13, 18, 30, 32).  In 
a follow-up study they found that after VEGFR-2 blockade apoptosis predominated in areas 
of oxidative stress and that apoptosis blockade by a broad spectrum caspase inhibitor 
markedly reduced the expression of markers of oxidative stress (33).  Hypoxia, oxidative 
stress and pulmonary hypertension are pathological features often seen in advanced COPD 
patients and increased VEGF expression may lead to increased or even abnormal 
proliferation of endothelial and VSM cells in pulmonary vessels.  This suggests a potential 
role of this endothelial mitogen in peripheral angiogenesis and vascular remodelling, 
possibly in orchestration with other smooth muscle specific growth factors like FGF-2, 
PDGF and TGF-ß1 (12, 34-36). 
  
We observed increased expression for VEGF and unchanged expression levels for Flt-1 and 
KDR/Flk-1 in bronchiolar and alveolar epithelial cells as well as in airway smooth muscle 
cells in COPD.  It has been previously documented that the expression of VEGF and 
receptor KDR/Flk-1 can also be induced by stimuli like hypoxia and oxidative stress in 
other than endothelial cells, such as epithelial and smooth muscle cells (33, 37, 38).  In a 
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recent report, Kanazawa and colleagues (39) have demonstrated that VEGF levels in 
induced sputum were higher in patients with bronchitis and lower in emphysema as 
compared to normal controls.  Moreover, VEGF levels in bronchitis patients were inversely 
correlated with FEV1 values.  Our data on inverse correlation of VEGF levels in various 
airway and vascular cells is in agreement with this report.  In our study subjects with COPD 
could not be subdivided into patients with either chronic bronchitis or emphysema alone.  
Furthermore, the nature of the human material examined (sputum) in the study of Kanazawa 
and colleagues is different than the lung tissue where we immunohistochemically localize 
and quantify the VEGF and its receptor levels. 
  
Recent studies indicated that the expression of VEGF was increased in bronchial and 
alveolar epithelial cells and also was induced in α-SMA positive (myo-)fibroblasts in 
bleomycin induced fibrosis in the rat and in human patients with pulmonary fibrosis and 
that these fibrotic regions were densely populated by mast cells and macrophages with 
elevated KDR/Flk-1 expression (15, 38).  We have shown earlier that mast cells and 
macrophages were increased in bronchiolar airway epithelium and reported an increased 
expression of TGF-ß1 in bronchiolar and alveolar epithelial cells in patients with COPD (20, 
21).  We found a  significant correlation between VEGF expression in epithelial cells with 
the expression of  TGF-ß1 published on same patient groups earlier (20) suggesting that the 
VEGF/Flk-1 system, possibly together with TGF-ß1, represents a molecular link between 
inflammatory cell accumulation and proliferation of myo-fibroblasts.  Summarizing, the 
elevated VEGF and TGF-ß1 expression on bronchiolar epithelial cells and macrophages and 
the presence of KDR/Flk-1 and Flt-1 suggests a mechanism of initiating and perpetuating 
fibrosis at sites of tobacco induced injury contributing to airway remodelling in COPD.  As 
inhaled corticosteroids could decrease the VEGF expression levels (40), but this was not the 
case in our study as none of the patient received inhaled corticosteroid therapy except 4 
patients received corticosteroids perioperatively.  However, caution must be exercised in 
extrapolating the expression data based on fourteen patients in each group as the increased 
trend of VEGF expression in bronchial airways and KDR/Flk-1 in bronchial and 
bronchiolar airway smooth muscle could reach significance if more patients would have 
been examined. 
  
Taken together, these findings strongly suggest a role for VEGF and its receptors in airway 
and vascular remodelling, and thereby in the development of airway obstruction in COPD.  
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At present, our knowledge of airway and vascular remodelling during the development of 
COPD is far from complete.  Probably, many growth factors, among them VEGF, play an 
essential role in the pulmonary and vascular viability and repair in response to tissue injury.  
The increased pulmonary VEGF expression in airways, parenchymal lining and 
small-diameter pulmonary vessels in COPD may reflect an, in part unsuccessful, attempt to 
stimulate tissue repair mechanisms caused by tobacco-induced injury. 
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Chapter 6:  Pro-inflammatory Cytokines and Vascular Remodelling 
 
Summary 
Airflow obstruction in chronic airway disease is associated with airway and pulmonary 
vascular remodelling of which the molecular mechanisms are poorly understood.  Paracrine 
actions of angiogenic factors released by resident or infiltrating inflammatory cells 
following activation by pro-inflammatory cytokines in diseased airways could play a major 
role in the airway vascular remodelling process.  Here, the pro-inflammatory cytokines, 
IL-1β and TNF-α were investigated on cell cultures of human airway smooth muscle 
(ASM) for their effects on mRNA induction and protein release of the angiogenic peptide, 
vascular endothelial growth factor (VEGF).  IL-1β (0.5 ng/ml) and TNF-α (10 ng/ml) each 
increased VEGF mRNAs (3.9 and 1.7 kb) expression in human ASM cells, reaching 
maximal levels between 16-24 h and 4-8 h, respectively.  Both cytokines also induced time 
dependent release of VEGF, which was not associated with increased ASM growth.  
Pre-incubation of cells with 1 μM dexamethasone abolished enhanced release of VEGF by 
TNF-α.  Data suggest that human ASM cells express and secrete VEGF in response to 
pro-inflammatory cytokines and may participate in paracrine inflammatory mechanisms of 
vascular remodelling in chronic airways disease. 
 
6.1 Introduction 
Airway remodelling is a common feature of both asthma and chronic obstructive pulmonary 
disease (COPD) and is characterized by structural changes including increased airway 
smooth muscle (ASM) mass, subepithelial fibrosis, glandular hypertrophy and peribronchial 
fibrosis, widely believed to culminate in poorly reversible airway narrowing.  Recently, it 
has been demonstrated that vascular changes also occur during airway remodelling (1-6).  
For instance, in asthma there is hyperaemia of the bronchial vasculature and increased 
number and size of blood vessels.  These changes correlate with the severity of disease in 
asthma (7, 8) and the release of angiogenic growth factors such as vascular endothelial 
growth factor (VEGF) from infiltrating inflammatory or resident structural cells has been 
implicated in their induction (9). 
 
It is well established that ASM cells exhibit functions in addition to their structural and 
contractile properties, rather they proliferate and can express a wide range of adhesion 
molecules and pro-inflammatory or mitogenic factors, including, but not limited to tumour 
necrosis factor-α (TNF-α), interleukin (IL)-1β (10-12).  TNF-α is an important cytokine in 
chronic inflammation, its presence may further perpetuate airway inflammation by inducing 
the secretion of other pro-inflammatory cytokines from multiple cells types in the airways 
during chronic lung diseases (13, 14).  Elevated levels of TNF-α are found in bronchial 
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tissues during chronic airway diseases.  Similarly, IL-1β is found in high levels in 
bronchoalveolar fluid and in the airway epithelium of asthmatic patients (13).  Many of the 
actions of IL-1β are similar to those of TNF-α and the signal transduction pathways of these 
cytokines may interact closely often resulting in synergism (15). 
 
In many tissues, angiogenesis and increased vascular permeability are characteristic features 
of the wound healing process and of inflammation (16).  VEGF is a potent endothelial cell 
mitogen, which is reported to regulate vasculogenesis and postnatal vascular remodelling 
(17).  Its expression in the lung is increased in COPD and asthma (6), as well as during 
hypoxia (18) and  levels of VEGF are reported to correlate with the increased size and 
number of blood vessels found in these conditions (8).  Moreover, the degree of VEGF 
expression correlates with levels of airway hyperresponsiveness in subjects with asthma (2).  
VEGF is highly mitogenic for endothelial cells and induces their survival leading to nearby 
angiogenesis or bronchial vascular remodelling.  It is also associated with increased 
endothelial permeability and induction of endothelial cell expression of chemokines (IL-8), 
adhesion molecules (ICAM-1) and proteolytic enzymes (matrix metalloproteinases) that 
promote changes in tissue ECM composition required for endothelial and inflammatory cell 
migration.  Thus, VEGF may play an important role in chronic airway diseases like asthma 
by contributing to airway and vascular remodelling (19).  Consistent with this possibility, in 
an animal model, VEGF receptor inhibition prevents both airway inflammation and 
hyperresponsiveness induced by toluene diisocyanate (20). 
 
The molecular mechanisms underlying the expression and release of VEGF during airway 
inflammation are largely unknown.  The aim of the present study was to investigate whether 
ASM cells release VEGF when stimulated with the proinflammatory cytokines TNF-α or 
IL-1β and might therefore contribute to paracrine mechanisms of bronchial vascular 
remodelling during inflammation in chronic airways disease. 
6.2 Materials and methods 
6.2.1 Materials 
All cell culture reagents were obtained from Invitrogen (Life Technologies BV, Breda, The 
Netherlands).  Sigma-Aldrich BV (Zwijndrecht, The Netherlands).  Recombinant human 
(rh) TNF-α was purchased from Knoll AG (Ludwigshaven, Germany).  Foetal bovine 
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serum (FBS) was obtained from Bio-Whitaker BV (Verviers, Belgium).  
[Methyl-3H]thymidine and [Methyl-3H]leucine were from Amersham Nederland BV 
('s-Hertogenbosch, The Netherlands).  Human specific antibodies and the enzyme-linked 
immunosorbent assay (ELISA) kits were from R & D Systems Europe Ltd (Abingdon, UK).  
All other reagents including rhIL-1β were from Sigma-Aldrich BV (Zwijndrecht, The 
Netherlands). 
 
6.2.2 Human ASM cell culture 
Human ASM cells were obtained in accordance with procedures approved by the Erasmus 
University Hospital Research Ethics Committee from the lobar or main bronchus of 
non-asthmatic patients undergoing lung resection for carcinoma of the bronchus using cell 
isolation and culture methods described previously (21).  Fluorescent immunocytochemical 
labelling confirmed that near confluent, FBS-deprived human ASM cells stained >95% for 
smooth muscle-α-actin.  Under these conditions approximately 87% of propidium-iodide 
labelled cells remained in the G0/G1 phase of the cell cycle.  Confluent cells in the 4th - 6th 
passage were used for all experiments. 
 
6.2.3 Cytokine stimulation of human ASM cells in vitro 
The ASM cell growth was synchronized prior to treatment by washing the cell monolayers 
twice in phosphate buffered saline (PBS, 140 mM NaCl, 2.6 mM KCl, 1.4 mM KH2PO4, 
8.1 mM Na2HPO4.2H2O, pH 7.4) and then replacing the medium with serum free DMEM 
supplemented with 1 μM insulin, 5 μg/ml transferrin and 100 μM ascorbate for 60 h.  
Growth-arrested cell monolayers were treated with TNF-α (10 ng/ml) or IL-1β (0.5 ng/ml) 
in fresh FBS-free DMEM for 1, 2, 4, 8, 16, 24 h.  In additional sets of experiments, ASM 
cells were pretreated with 1 μM dexamethasone for 1 hr and then TNF-α was added and the 
incubation continued for 24 h.  Cells were harvested for total RNA isolation and the 
conditioned media were collected after each time point.  Cell-conditioned media were 
stored at -80°C until assayed for VEGF levels by ELISA. 
 
6.2.4 [3H]Thymidine and [3H]leucine incorporation assay 
Effects of pro-inflammatory cytokines on DNA biosynthesis and total protein biosynthesis 
were evaluated by incorporation of [methyl-3H]thymidine and [methyl-3H]leucine, 
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respectively.  Sub-confluent cell monolayers were growth arrested as described above.  
Cells were incubated with [methyl-3H]thymidine or [methyl-3H]leucine (1 μCi/well) in 
either fresh FBS-free DMEM or similar containing TNF-α, IL-1β or 10% FBS for 8, 24 or 
48 h.  Following stimulation cells were washed in PBS, fixed with ice-cold methanol and 
exposed to ice-cold trichloroacetic acid (5% w/v).  The acid-insoluble fraction was lysed in 
0.3 M NaOH and the incorporated radioactivity determined in a Packard 1500 Tri-carb 
liquid-scintillation counter (Packard-Becker BV, Delft, The Netherlands).  Data are 
expressed as counts per min of [3H]thymidine or [3H]leucine incorporation. 
 
6.2.5 Isolation of total cellular RNA and Northern blot analysis 
Treated and untreated human ASM cells were washed in PBS and directly lysed in 
guanidinium thiocyanate buffer.  Genomic DNA was sheared by passing lysates repeatedly 
through 23-gauge needles.  Total cellular RNA was then isolated using as described 
previously (21).  Total RNA (10 μg) was denatured at 65°C in formaldehyde containing 
loading buffer and size fractionated on a 1% agarose gel containing 2.2 M formaldehyde.  
Ethidium bromide stained gels were photographed and RNA was transferred onto hybond-N 
membrane (Amersham Nederland BV, 's-Hertogenbosch, The Netherlands) by the alkaline 
downward capillary transfer method (21).  Filters were air-dried and UV cross-linked 
(Biorad Laboratories B.V., Veenendaal, The Netherlands) and blots hybridized at 42°C.  
cDNA insert (950 bp DNA fragment encoding human VEGF) was labelled using 32P-dCTP 
with a multiprime labelling system.  A glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) cDNA probe (American Type Culture Collection, Rockville, USA) was used to 
rehybridize membranes for reference purposes.  Filters were washed under stringent 
conditions and subsequently exposed to Kodak X-OMAT AR films (Amersham Nederland 
BV, 's-Hertogenbosch, The Netherlands) at -80°C.  Hybridisation signals were quantified by 
scanning laser densitometry using the Ultroscan XL enhanced laser densitometer (LKB, 
Bromma, Sweden) and normalised against GAPDH mRNA values and expressed as relative 
optical density (OD) in stimulated cells versus controls. 
 
6.2.6 Measurement of VEGF protein by ELISA 
Conditioned media were collected from TNF-α- or IL-1β-treated human ASM cells after 1, 
2, 4, 8, or 24 h and VEGF levels assessed using a human VEGF specific solid-phase 
sandwich enzyme-linked immunosorbent assay (ELISA) kit.  Cell-conditioned medium 
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samples were diluted until VEGF levels were within the linearity limits of the assay 
standard curve.  The concentration of VEGF was expressed in pg/ml.  The detection limit of 
the ELISA assay was 20 pg of VEGF/ml. 
 
6.2.7 Statistical analysis 
All data in the figures are given as mean±SEM.  Statistical analysis was performed by using 
two-tailed, independent sample "t"-test.  Significance was accepted at p≤0.05. 
6.3 Results 
6.3.1 Effect of pro-inflammatory cytokines on human ASM cell growth 
There are reports that TNF-α and IL-1β can act as mitogens for ASM cells in culture (14, 
22).  Moreover, VEGF is a potent mitogen, particularly for endothelial cells but also 
indirectly for ASM cells (23, 24).  Thus, we examined whether TNF-α or IL-1β, acting 
either directly or possibly indirectly via VEGF production, induced significant changes in 
DNA synthesis ([3H]thymidine incorporation) or total protein synthesis ([3H]leucine) in 
human ASM cells.  However, treatment of the cells with TNFα (10 ng/ml) or IL-1β 
(0.5 ng/ml) for 8, 24 or 48 h did not induce significant changes in [3H]thymidine or 
[3H]leucine uptake when compared with unstimulated cells (Figure 6.1). 
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Figure 6.1: Growth of ASM cells treated with TNF-α or IL-1β 
Thymidine (Panels A and C) and Leucine (Panels B and D) incorporation measured after 8, 24 and 
48 h in semi-confluent, growth arrested, human ASM cells stimulated with 10 ng/ml of TNF-α 
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(upper panels) or 0.5 ng/ml IL-1β (lower panels).  Values were calculated from quadruplicate 
experiments and expressed as mean counts per min (CPM)±SEM.  No significant differences were 
found between stimulated and unstimulated control cells. 
 
6.3.2 VEGF mRNA expression in relation to TNF-α or IL-1β 
To examine VEGF mRNA expression human ASM cells were treated with TNF-α 
(10 ng/ml) or IL-1β (0.5 ng/ml) for 1, 2, 4, 8, 16 or 24 h.  Using Northern blot 
hybridization, two mRNA species of 3.9 and 1.7 kb encoding VEGF were detected in 
cultured human ASM cells treated with TNF-α (Figure 6.2, Panel A) or IL-1β (Figure 6.2, 
Panel B), which were absent in unstimulated cells.  TNF-α-induced VEGF mRNA levels 
were maximal during 4-8 h; whereas IL-1β-dependent VEGF mRNA content peaked at 16 h 
and remained elevated after 24 h, when compared with unstimulated cells.  10% FBS also 
induced the mRNA expression of VEGF in human ASM cells in vitro (not shown). 
 
Figure 6.2: Pro-inflammatory cytokines induce expression of VEGF mRNAs in human 
airway smooth muscle cells 
Representative Northern blots showing a major 3.9 and a minor 1.7 kb mRNA band for VEGF.  
Total RNA samples from control (C) and TNF-α (Panel A) or IL-1β (Panel B) treated human ASM 
cells were hybridized with a cDNA insert encoding human VEGF.  Human ASM cells were 
incubated with TNF-α or with IL-1β or left unstimulated for the time points as indicated on top of 
the blot.  Panel C and D show the densitometric analysis for the blots represented as fold change in 
VEGF expression relative to GAPDH (as compared to control).  Data represent the mean± SEM of 
triplicate values from independent blots.  * Significant values (P ≤ 0.05) compared with controls. 
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6.3.3 Release of VEGF protein from human ASM cells in response to TNF-α 
or IL-1β 
Conditioned medium from human ASM cells treated with varying concentrations of TNF-α 
(0.2, 1, 2, 5, 10, 20 and 100 ng/ml) for 24 h revealed a concentration-dependent release of 
VEGF (Figure 6.3).  TNF-α induced VEGF secretion, as measured by ELISA, was 20±3 
pg/ml, 110±0.5 pg/ml and 78.5±12.5 pg/ml after 0, 20 and 100 ng/ml stimulation, 
respectively.   VEGF release reached maximal levels (166 ±4 pg/ml) after stimulation with 
10 ng/ml of TNF-α. 
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Figure 6.3: Concentration-dependent production of VEGF protein by TNF-α 
Growth-arrested human ASM cells were stimulated with 0.2, 1, 2, 5, 10, and 20 ng/ml of TNF-α for 
24 h.  Data represent the mean±SEM of triplicate values from independent experiments using 
conditioned medium from ASM cells cultured from three patients.  *Significant values (p ≤ 0.05) 
compared with unstimulated cells. 
 
Likewise, the release of VEGF protein from human ASM cells treated either with TNF-α 
(10 ng/ml) or IL-1β (0.5 ng/ml) was time-dependent.  TNF-α-induced VEGF secretion 
(Figure 6.4, panel A) was 40.67±6.8 pg/ml, 88.67±11.7 pg/ml and 162.3±59 pg/ml at 1, 4 or 
8 h, respectively.  TNF-α-dependent VEGF release was maximal at 24 h (173.3±33.9 
pg/ml), compared with unstimulated cells (37.67±7.2 pg/ml).  Incubation with IL-1β 
resulted in 66 ±18 pg/ml, 267.3±15.5 pg/ml and 356.7±31.9 pg/ml at 1, 4 and 8 h and was 
maximal after 24 h where levels reached 668±116.4 pg/ml (Figure 6.4, panel B).  
Additionally, FBS induced a modest release of VEGF at 24 h (290.67±53.9 pg/ml). 
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Figure 6.4: Time-dependent production of VEGF protein by pro- inflammatory cytokines 
Growth arrested human ASM cells were stimulated with TNF-α or with IL-1β for varying times (1, 
2, 4, 8, 24 h).  Control cells (Con) received only serum free medium.  Data represent the mean±SEM 
of triplicate values from independent experiments using conditioned media from ASM cells cultured 
from three patients.  *P ≤ 0.05 as compared with controls. 
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Figure 6.5: Effect of Dexamethasone on TNF-α induced VEGF release 
Growth arrested human ASM cells were stimulated with 10 ng/ml of TNF-α for 24 h.  Human ASM 
cells were pretreated with 1 μM dexamethasone for 1 h prior to stimulation with TNF-α for 24 h.  
Control cells received only serum free medium.  Data represent the mean±SEM of triplicate values 
from independent experiments using conditioned medium from ASM cells cultured from three 
patients.  *P ≤ 0.05 as compared with controls; # compared with TNF-α stimulated cells. 
 
6.3.4 Effect of dexamethasone on TNF-α induced expression of VEGF 
To assess whether anti-inflammatory glucocorticoids could inhibit release of VEGF by 
TNF-α (10 ng/ml), ASM cells were pretreated with dexamethasone (1 μM).  Under these 
conditions, VEGF release was abolished by dexamethasone (Figure 6.5). 
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6.4 Discussion 
Changes in airway microvasculature and the presence of angiogenesis in inflammatory 
respiratory diseases are now being documented (3).  Our study provides insight into 
possible mechanisms through which the angiogenic events may take place in chronic airway 
disease.  We confirmed that human ASM cells express mRNA encoding VEGF and secrete 
VEGF protein and found that VEGF expression was increased by the proinflammatory 
cytokines, TNF-α and IL-1β, important modulators of airway function in asthma, and 
suppressed by anti-inflammatory glucocorticoids.  We speculate that paracrine actions of 
VEGF derived from ASM cells could perpetuate the chronic inflammatory process in 
asthma or COPD in several ways.  For example, VEGF is highly mitogenic for endothelial 
cells and induces their survival leading to nearby angiogenesis or bronchial vascular 
remodelling.  It is also associated with increased endothelial permeability and induction of 
endothelial cell expression of chemokines (IL-8), adhesion molecules (ICAM-1) and 
proteolytic enzymes (matrix metalloproteinases) that promote changes in tissue ECM 
composition required for endothelial and inflammatory cell migration (20, 25, 26). 
 
Recent reports describe the secretion of VEGF by human ASM cells in response to 
bradykinin and prostanoids (9) as well as by Th2 cytokines, such as IL-4, IL-5 and IL-13 
(21).  Other reports reveal only a modest effect of these cytokines on VEGF secretion by 
bronchial fibroblasts (27).  Cytokines including IL-1 and IL-6 have also been shown to 
upregulate VEGF protein expression, but their effects appear variable and species or tissue 
specific.  In the present study, up regulation of VEGF by human ASM cells occurred both at 
the mRNA and protein level, corroborating recent similar findings with IL-1β (24, 28).  We 
also report that TNF-α, another major proinflammatory cytokine, increased VEGF mRNA 
and protein secretion in human ASM cells.  Induction of VEGF secretion by these cytokines 
was time dependent, peaking at 24 h and was concentration-dependent in case of TNF-α 
with optimum concentration being 10 ng/ml.  Our findings with IL-1β showing a relatively 
slow induction of mRNA and release of protein are in broad agreement with those of others 
(24) where IL-1β-dependent VEGF secretion was increased at 16 h after stimulation.  
However, accumulation of VEGF mRNA after stimulation by TNFα appeared more rapid 
occurring within 2 to 4 h and contrasts with Kazi and colleagues (24), who reported no 
increase in VEGF by TNFα.  Reasons for this discrepancy are unclear, but our observation 
that neither TNFα nor IL-1β induced proliferation of ASM cells under these conditions 
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suggests the increased VEGF levels we observed were not artificially increased due to 
increased cell numbers. 
 
Increasing experimental evidence suggests inhibition of VEGF activity via blockade of its 
receptors has potential therapeutic value as an intervention method for decreasing 
angiogenesis and vascular remodelling (29).  This approach reverses pathophysiological 
symptoms including airway hyper-responsiveness and inflammation in a mouse model of 
asthma (30).  One likely mechanism for the effectiveness of this approach could be 
prevention of VEGF-induced vascular permeability, thereby suppressing inflammation by 
reducing vascular leakage and migration of cells and mediators into the airways.  However, 
the VEGF inhibition could be both beneficial and detrimental in different forms of chronic 
airway diseases.  For example, some reports suggest increased levels of VEGF are 
associated with airflow limitation in bronchitis, whilst decreased levels are also associated 
with airflow limitation and alveolar destruction in patients with emphysema (31, 32).  
Likewise, recent evidence demonstrates that long-term glucocorticoids treatment in patients 
with asthma significantly affects airway remodelling by reducing basement membrane 
thickness, and reducing indices of submucosal vascularity including blood vessel number 
and total vascular area (33, 34).  Our finding that dexamethasone completely inhibits the 
release of the angiogenic factor VEGF would support this notion.  The inhibitory action of 
dexamethasone on TNF-α induced VEGF release may be mediated by several mechanisms, 
including the reduction of cAMP levels or inhibition of p38 MAPK phosphorylation (35).  
Dexamethasone suppresses TNF-α-induced AP-1 DNA binding suggesting that 
glucocorticoids may exert their inhibitory effect on TNF-α by trans-repression of AP-1 
(36).  The effect of glucocorticoids on airway remodelling, however, remains controversial.  
Inhibition of VEGF production by ASM cells suggests one mechanism by which 
glucocorticoids might affect tissue remodelling. 
 
Localization studies in the airways of asthmatics suggest VEGF is expressed by both 
infiltrating inflammatory and resident cell types including submucosal glandular and alveolar 
type I and II epithelial cells, myofibroblasts, eosinophils, macrophages and CD34+ cells (2).  
The relative importance of each cell type for release of VEGF under pathophysiological 
conditions is unknown.  However, consistent with ASM also participating in these processes 
we and others have demonstrated that human ASM cells express VEGF both in vitro and in 
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vivo in the intact myobundles of patients with COPD (6, 37, 38).  These latter findings 
suggest that VEGF release by cultured human ASM cells is not a simple culture artifact 
rather ASM represents a possible pathophysiological important pool of VEGF available 
during airways inflammation that may be amenable to therapeutic intervention. 
 
In summary, VEGF is secreted by ASM cells in response to the proinflammatory mediators, 
IL-1β and TNFα acting via pathways that are sensitive to inhibition by anti-inflammatory 
glucocorticoids.  The current study supports the hypothesis that ASM cells are active 
sources of mediators relevant to the pathogenesis of airway disease.  Proinflammatory 
cytokines such as IL-1β and TNF-α that associated with chronic inflammation of the 
airways may drive production of VEGF by ASM cells, which via paracrine mechanisms in 
the vicinity of bronchial endothelial cells may perpetuate the bronchial vascular remodelling 
that characterizes asthma and COPD. 
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Chapter 7:  Vasoactive Peptides and Bronchial Vascular Remodelling 
 
Summary 
Airway remodelling and associated angiogenesis are documented features of asthma, of 
which the molecular mechanisms are not fully understood.  Angiotensin II (ANG II) and 
endothelin-1 (ET-1) are potent vasoconstricting circulatory hormones implicated in asthma.  
We investigated the effects of ANG II and ET-1 on human airway smooth muscle (ASM) 
cells proliferation and growth and examined the mRNA expression and release of the 
angiogenic peptide, vascular endothelial growth factor (VEGF).  Serum deprived (48 h) 
human ASM cells were incubated with ANG II (100 nM) or ET-1 (10 nM) for 30 min, 1, 2, 
4, 8, 16 and 24 h and the endogenous synthesis of VEGF was examined in relation to 
control cells receiving serum free culture medium.  ET-1 induced time dependent DNA 
biosynthesis as determined by [3H]thymidine incorporation assay.  Using northern blot 
hybridisation, we detected two mRNA species of 3.9 and 1.7 kb encoding VEGF in the 
cultured smooth muscle cells.  Both ANG II and ET-1 induced the mRNA expression (2-3 
fold) and secretion (1.8-2.8 fold) of VEGF reaching maximal levels between 4-8 h of 
incubation.  Induced expression and release of VEGF declined after 8 h of ANG II 
incubation while levels remained elevated in the case of ET-1.  The conditioned medium 
derived from ET-1 treated ASM cells induced [3H]thymidine incorporation and cell number 
in porcine pulmonary artery endothelial as well as human umbilical vein endothelial cells.  
Moreover, the VEGF tyrosine kinase receptor inhibitor blocked the conditioned medium 
induced mitogenesis in endothelial cells.  Our results suggest a potential role for ANG II 
and ET-1 in ASM cell growth and up-regulation of VEGF that may participate in 
endothelial cell proliferation via paracrine mechanisms and thus causing pathological 
angiogenesis and vascular remodelling seen during asthma. 
 
7.1 Introduction      
Increased airway smooth muscle (ASM) mass and airway remodelling is a common feature 
in chronic airway diseases such as asthma (1).  Airway remodelling is accompanied with 
angiogenesis and microvascular changes wherein the ongoing inflammation seems to be the 
main contributing factor (2-5).  Evidence suggests that the number and size of bronchial 
vessels is moderately increased in patients with asthma as compared with normal 
individuals (6-9).  Moreover, Salvato and colleagues (10) found that patients with severe 
asthma had significantly more vessels than those with a mild or moderate disease.  
Previously, we reported that fibroblast growth factors (FGFs) and vascular endothelial 
growth factor (VEGF) play a pivotal role in the pathogenesis of chronic obstructive 
pulmonary disease (COPD) (2, 3).  Similarly, enhanced bronchial localization of various 
angiogenic growth factors has been observed in patients with asthma and COPD (2, 3, 11, 
12).  However, the molecular mechanisms underlying bronchial angiogenesis and vascular 
remodelling remain unclear. 
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VEGF is a potent endothelial cell mitogen that regulates vasculogenesis and postnatal 
vascular remodelling (13).  Expression of VEGF is upregulated under a variety of 
pathophysiological conditions, including hypoxia in the lung (14) and during angiogenesis 
in other biological systems (15, 16).  The most important role of VEGF in inflammation 
may be in mediating the angiogenic response (17).  Since angiogenesis and increased 
vascular permeability are characteristic features of wound healing, VEGF may play an 
important role in airway remodelling in asthma where wound healing after injury is a 
common phenomenon (12).  VEGF is expressed by human airway smooth muscle cells in 
culture and in lungs under pathophysiological conditions (2, 9, 18, 19) and we have shown 
that COPD is associated with an increased expression of VEGF in both ASM and vascular 
smooth muscle (VSM) cells in bronchiolar as well as alveolar regions; this  increased 
expression is inversely co-related with the lung function data (2). 
 
Angiotensin II (ANG II) and endothelin-1 (ET-1) are potent vasoconstricting circulatory 
hormones implicated in asthma (20-24).  Angiotensin II has been reported to induce VEGF 
mRNA expression in rat heart endothelial cells (25) and mitogenesis in human ASM cells 
(26).  Evidence suggests that ET-1 acts as a co-mitogen with EGF and that its action is 
mediated through activation of ETA receptors in lungs (27).  However, the underlying 
molecular mechanisms of mitogenic and subsequent signalling elicited by ET-1 in human 
ASM cells are not yet characterised.  We therefore investigated the responses to ANG II and 
ET-1 in human ASM cells in vitro and examined the expression and release of VEGF that 
may contribute to pulmonary vascular remodelling in chronic airway diseases.  
Furthermore, we assessed the conditioned medium obtained from human ASM cells treated 
with ANG II and ET-1 for in vitro angiogenic potential by examining endothelial cell 
proliferation and growth. 
7.2 Materials and methods 
7.2.1 Human ASM cell isolation and culture  
Human ASM cells were isolated and cultured as described previously (28).  Briefly, 
bronchial smooth muscle was dissected from fresh macroscopically normal lobar or main 
bronchi.  After removal of the epithelium, parts of smooth muscle was dissected, free of 
adherent tissue under aseptic conditions.  Smooth muscle pieces were incubated in Hank's 
balanced salt solution (HBSS; Invitrogen, Breda, The Netherlands) containing bovine serum 
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albumin (BSA, 10 mg/ml), collagenase (type XI, 1 mg/ml) and elastase (3.3 U/ml; Sigma-
Aldrich BV, Zwijndrecht, The Netherlands) at 37 °C in a humidified incubator containing 
5% CO2/95% air for 30 min.  After enzymatic digestion, the cell suspension was centrifuged 
and the pellet was washed in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, 
Breda, The Netherlands) containing 10% (v/v) heat-inactivated foetal bovine serum (FBS; 
Cambrex, Verviers, Belgium) supplemented with sodium pyruvate (1 mM), nonessential 
amino acid mixture (1:100), gentamicin (45 μg/ml), penicillin (100 U/ml), streptomycin 
(100 μg/ml) and amphotericin B (1.5 μg/ml) (Invitrogen, Breda, The Netherlands).  Cells 
were subsequently seeded at 2x105 cells per 35 mm dish and maintained in culture by 
replacing the medium every 48 h.  After 10-14 days in culture, ASM cells grew to 
confluence and were then detached by trypsinization (0.5% trypsin; 0.02% EDTA; 
Invitrogen, Breda, The Netherlands) and subcultured into 25 cm2 and 75 cm2 tissue culture 
flasks.   
 
7.2.2 Immunocytochemical characterization of cultured human ASM cells 
Immunocytochemical staining of confluent serum-deprived primary cultures of human 
ASM cells, using monoclonal antibodies to smooth muscle α-actin and smooth 
muscle-myosin heavy chain (SM1 and SM2; Sigma-Aldrich BV, Zwijndrecht, The 
Netherlands) demonstrated that the cultures were essentially free (<5%) of other 
contaminating cell types (26, 28). In order to perform immunocytochemistry, monoclonal 
antibodies against -smooth muscle actin were used as markers.  In brief, cells were allowed 
to attach to multiwell slides for 24 h in FBS-containing medium and were subsequently 
growth-arrested by incubating for 60-72 h in FBS-free DMEM supplemented with apo-
transferrin (5 µg/ml), ascorbate (100 µM), and insulin (1 µM) prior to fixation and staining.  
Following two washes in ice-cold phosphate-buffered saline (PBS; 140 mM NaCl, 2.6 mM 
KCl, 1.4 mM KH2PO4, 8.1 mM Na2HPO4 · 2 H2O, pH 7.4), the cells were fixed in ice-cold 
methanol and permeabilized in PBS containing 0.1% Tween-20.  Non-specific bindings 
were blocked by incubating the cells in 1% BSA in PBS, and the cells were then washed 
and subsequently incubated with anti-  smooth muscle actin antibodies. The cells were then 
washed twice in PBS and further incubated with affinity purified FITC-conjugated 
antimouse antibody. Unbound antibody was washed away using distilled water and the 
sections were dehydrated and mounted in glycerol. Specimens were visualized under a 
fluorescence microscope (Carl Zeiss BV, Weesp, The Netherlands) and photographed. 
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Human ASM cells stained positive for anti-  smooth muscle actin (Figure 7.1, upper right 
panel). Under the light microscope, the human ASM cells appeared elongated and spindle-
shaped with central oval nuclei containing prominent nucleoli. Confluent human ASM cells 
in culture showed a specific pattern, aligned in parallel so that the broad nuclear region of 
one cell lies adjacent to the thin cytoplasmic area of another, giving rise to a typical "hill 
and valley" appearance (Figure 7.1, upper left panel).   
 
Figure 7.1: Representative examples of human ASM and pulmonary artery endothelial 
cells in culture 
Photomicrograph depicts the monolayer (upper left panel) of human ASM cells with the 
characteristic hill and valley appearance.  Smooth muscle α−actin (fluorescence) antibody (upper 
right panel) characterizes the staining in longitudinal actin filaments and assures the purity of the 
human ASM cells. Photomicrograph depicts the monolayer (lower left panel) of porcine pulmonary 
artery endothelial cells (PAEC) with the characteristic cobble stone appearance.  CD31 (brown) 
antibody staining (lower right panel) characterizes the purity of the endothelial cells. 
 
7.2.3 Porcine pulmonary artery endothelial cell isolation and culture 
The lungs were obtained from Yorkshire x Landrace female pigs after sacrifice and the 
major pulmonary artery was identified and dissected free of all connective tissue and 
cleaned with HBSS.  After incubation with collagen I for 30 min endothelial cells were 
isolated by scraping gently the inner surface of the artery with a surgical blade and cultured 
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up to fourth passage in M-199 medium containing 10% foetal calf serum (FCS; Cambrex, 
Verviers, Belgium) at 37 °C in a 5% CO2-humidified atmosphere.  Cells were maintained in 
culture by replacing the medium every 48 h and when confluent was further passaged using 
trypsin/EDTA solution into 75 cm2 tissue culture flasks.  Porcine pulmonary artery 
endothelial cells had the characteristic cobblestone appearance when cultured in monolayer.  
Cells were characterized immunocytochemically, using monoclonal antibodies against 
CD31 and visualised under the light microscope.  Porcine pulmonary artery endothelial 
cells in culture revealed cobblestone appearance (Figure 7.1, lower left panel).  
Immunocytochemical staining of confluent serum-deprived primary cell cultures of using 
monoclonal antibodies against CD31 (Figure 7.1, lower right panel) demonstrated that the 
cultures were essentially free (<5%) of other contaminating cell types. 
 
7.2.4 Stimulation of human ASM cells in vitro with ANG II or ET-1 
Human ASM cells were added in 500µl medium to 24 wells multiplate (Corning BV, 
Schiphol, The Netherlands), at a final concentration of 3x104 cells/well. After 72 h, cells 
were serum deprived for 60 h and subsequently incubated with ANG II (100 nM), optimal 
concentration based on our previous report (26) or ET-1 (10 nM), optimal concentration 
based on pilot experiments,  for 30 min, 1, 2, 4, 8, 16 and 24 h.  Control cells were cultured 
in serum free medium (24 h). 
 
7.2.5 Isolation of total cellular RNA and Northern blot analysis 
Total RNA was extracted from the cells incubated with ANG II (100 nM) or ET-1 (10 nM) 
for 30 min, 1, 2, 4, 8, 16 and 24 h by the guanidinium thiocyanate-phenol-chloroform 
method.  For Northern hybridization, 10 µg of total RNA was electrophoresed on 1% 
agarose gel containing 2.2 M formaldehyde.  RNA was transferred to hybond-N 
membranes, which were eventually UV cross-linked and hybridized at 42 °C.  cDNA insert 
(950 bp DNA fragment encoding human VEGF) was labelled using (32P)dCTP with a 
multiprime labelling system.  Filters were washed under stringent conditions and 
subsequently exposed to Kodak X-OMAT AR films at -80 °C.  A 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probe was used to 
rehybridize membranes for reference purposes.  After autoradiography and densitometric 
measurement of signals, the optical density (OD) of the VEGF signal was divided by OD of 
the corresponding GAPDH signal and relative mRNA levels were calculated.  Values were 
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expressed as fold induction (mean±SEM) from four different autoradiograms.  Statistical 
significance was accepted at p≤ 0.05. 
 
7.2.6 Measurement of VEGF protein by ELISA 
Conditioned media were collected from human ASM cells treated with ANG II or ET-1 and 
VEGF levels were assessed using a commercial ELISA kit according to the manufacturer’s 
instruction (R&D Systems, Abington, UK).  As a control, conditioned medium from human 
ASM cells incubated with only serum-free medium were was used.   A standard curve using 
recombinant VEGF protein was first established and subsequently (100 μl) of conditioned 
medium was used to assay VEGF.  Subsequently, the samples were pre-incubated with VEGF 
capture antibody followed by biotinylated VEGF detecting antibody.  After addition of the 
streptavidine-peroxidase conjugate tetramethylbenzidine (TMB) was added and the absorbance 
of the resulting coloured product was measured using an automated spectrophotometer (Biorad 
Laboratories BV, Veenendaal, The Netherlands).  The concentration of VEGF was expressed 
in ng/ml.  The detection limit of the VEGF ELISA method was 20 pg of VEGF/ml. 
 
7.2.7 Cell proliferation assays 
7.2.8 [3H]Thymidine incorporation assay in human ASM cells treated with ET-1 
Effects of ET-1 on human ASM DNA biosynthesis were evaluated by incorporation of 
[methyl-3H]-thymidine.  Confluent cells were washed in PBS, loosened by trypsinisation and 
transferred into 96-well plates at a seeding density of 1x104 cells/well.  After 24 h in culture 
the sub-confluent cell monolayers were growth arrested by 48 h serum deprivation and 
incubated with different concentrations of ET-1 (1, 10 and 100 nM) for 48 h.  Additionally, 
cells were incubated with ET-1 (10 nM) for varying time periods from 24 to 96 h.  Five 
hours prior to the end of the treatment periods, 10 μl (1 μCi/10 μl in HBSS) of 
[3H]thymidine was added to the wells, at a final concentration of 1 μCi/110 μl per well.  The 
plates were frozen overnight at -20 °C after which the cells were harvested on glass fibre 
filters using a Filtermate 196 cell harvester (Packard, Meridan, USA) and the activity was 
counted using a Microplate Scintillation ß-counter (Topcount, Packard, Meridan, USA).  
Measured radioactivity was expressed as counts/min (CPM).  Data represented is the mean 
CPM of experiments performed with three different cell isolations. 
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Endothelial cell proliferation assay 
Porcine pulmonary artery endothelial cells were added in 100 µl medium to 96 wells 
multiplate (Corning BV, Schiphol, the Netherlands), at a final concentration of 1 x 104 cells 
per ml. After 48 hours, the cells were serum deprived for 24 hours and subsequently 
incubated with the conditioned medium from human ASM cells treated for 8 h with ANG II 
(100 nM) or ET-1 (10 nM) and positive controls with VEGF (5 ng/ml) or PlGF (5 ng/ml) in 
100 μl serum-free M199 medium for 24 h.  Control incubations consisted of cells that were 
incubated with serum-free M199 medium alone.  DNA biosynthesis was measured 
employing [3H]thymidine incorporation assay as described above. 
 
Endothelial cell count 
In a parallel series of experiments, serum-deprived porcine pulmonary artery endothelial 
cells were stimulated with the same factors as above for 48 h and processed for cell 
counting in the Casy®1 system (Schärfe system GmbH, Reutelingen, Germany).  After 
stimulation, cells were harvested with mild trypsinisation.  Cells in suspension were added 
to 10 ml of Casy®1 isotonic solution (6.38 g/l NaCl, 0.2 g/l Na-tetraborate, 1.0 g/l Boric 
acid and 0.2 g/l EDTA), counted and further analyzed using Casy®1 system software. 
 
7.2.9 VEGF receptor blockade and endothelial cell growth 
Human umbilical vein endothelial cells (HUVEC) were isolated from normal human 
umbilical cords as described earlier (29). Briefly, cells were cultured in fibronectin-coated 
tissue culture flasks in culture medium (human endothelial-SFM, Invitrogen), with 20% 
newborn calf serum, 10% human serum (Cambrex, Verviers, Belgium), 20 ng/ml basic 
fibroblast growth factor, and 100 ng/ml epidermal growth factor (Peprotech, London, UK).  
Passages 5 to 7 were used for the experiments.  Cells were plated in fibronectin-coated 
96-well plates and allowed to grow for 24 h and then serum deprived and cultured in 
DMEM for 24 h.  Serum deprived cells were incubated for 48 h with control medium 
(DMEM alone) or the conditioned medium from ET-1 (10 nM)-treated (8 h) human ASM 
cells in 1:1 dilution. Control HUVEC was exposed to medium from untreated ASM cells. 
Activity of VEGF present in the conditioned medium on the growth of HUVEC cells was 
assessed by pre-treating the cells with 10 μM VEGF tyrosine kinase receptor blocker 
4-[(4′-Chloro-2′-fluoro)phenylamino]-6,7-dimethoxyquinazoline (Calbiochem, Darmstadt, 
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Germany).  The growth of HUVEC cells was measured using the sulforhodamine-B (SRB) 
assay as described earlier.  In short, cells were washed twice with PBS, incubated with 10% 
trichloric acetic acid (1 h, 4 °C), and washed in distilled water.  Cells were stained with 
0.4% SRB (Sigma-Aldrich  BV, Zwijndrecht, The Netherlands) for 15 to 30 min, washed 
with 1% acetic acid, and were allowed to dry.  Protein-bound SRB was dissolved in TRIS 
(10 mmol/l, pH 9.4).  The absorbance was read at 540 nm. Growth was calculated using the 
formula: percentage growth = (absorbance test well / absorbance control well) x 100%.  
 
7.2.10 Statistical analysis 
All data in the figures are given as mean±SEM.  Statistical analysis was performed by using 
two-tailed, independent sample "t"-test.  Significance was accepted at p≤0.05. 
7.3 Results 
7.3.1 Effect of ET-1 on human ASM cell proliferation 
In order to investigate the role of ET-1 on airway smooth muscle cell proliferation  and 
remodelling, isolated human airway smooth muscle cells were stimulated in vitro with 
increasing concentrations of ET-1 (1, 10 and 100 nM).  Graphic representations of dose-
dependent increase in [3H]thymidine incorporation are shown in Figure 7.2 (Panel A).  ET-1 
significantly increased cell numbers at all concentrations after 48 h of incubation. There was 
no significant difference in the increase in cell proliferation in relation to increase in dose of 
ET-1.  Figure 7.2 (Panel B) is a graphic representation of time-dependent [3H]thymidine 
incorporation at a concentration of 10 nM of ET-1.  After 48 h of stimulation, we found 
significantly increased cell proliferation as measured by thymidine incorporation as 
compared to the control cells (13.6±1.9 x103 CPM vs. 8.9±0.8 x103 CPM).  Thereafter, cell 
proliferation induced by ET-1 was significantly higher than the control even up to 96 h of 
treatment. 
 
7.3.2 VEGF mRNA expression in relation to ANG II and ET-1 
Human ASM cells were treated for 30 min, 1, 2, 4, 8, 16 and 24 h either with ANG II 
(100 nM) or ET-1 (10 nM) in order to examine the VEGF mRNA expression.  Using 
Northern blot hybridisation, we detected two mRNA species of 3.9 and 1.7 kb encoding 
VEGF in human ASM cells treated with ANG II (Figure 7.3, panel A) and ET-1 (Figure 
7.3, panel B).  In order to compare the expression pattern and to verify the integrity of total  
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Figure 7.2: Graphic representation of human ASM cell proliferation in relation to ET-1 
Panel A:  Dose-dependent increases in [3H]thymidine uptake in ASM cells after 48 h stimulation 
with increasing concentrations (0, 1, 10, 100 nM) of ET-1.  Panel B: Time course of [3H]thymidine 
uptake in ASM cells after stimulation with 10 nM of ET-1.  Data represent mean fold increase in 
relation to control from three independent experiments performed in quadruplicate.  Values are 
shown as mean±SEM.  *P≤0.05 versus the control serum deprived cells. 
 
 
Figure 7.3: ANG II and ET-1 induced expression of VEGF in human airway smooth 
muscle cells 
A representative Northern blot showing a major 3.9 and a minor 1.7 kb mRNA band of VEGF.  
Total RNA from control and treated human ASM cells was hybridised with a cDNA insert encoding 
human VEGF.  Growth arrested cells were incubated with ANG-II or ET-1 in serum free growth 
medium for the times indicated on the top.  Filters were rehybridised with GAPDH cDNA probe for 
reference purposes. 
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RNA samples, GAPDH, a housekeeping gene was used to re-hybridise the membranes.  A 
strong dark band at 1.4 kb, hybridising to a cDNA insert encoding GAPDH in each RNA 
preparation is visible (Figure 7.3 lower panels). As shown in the blot and in the graphs 
expressing the relative mRNA levels, stimulation with ANG II induced the expression of 
VEGF mRNA reaching maximal levels at 2 h, whereas ET-1 induced VEGF mRNA 
expression peaked at 4 h and remained elevated as compared to serum free controls.  Serum 
also induced mRNA expression of VEGF in human ASM cells in vitro (data not shown). 
 
Figure 7.4: Time-dependent production of VEGF protein in relation to ANG II or ET-1 
Growth arrested human ASM cells were stimulated with 100 nM ANG II or 10 nM of ET-1 for 
various time points.  Control cells (C) received serum free medium.  Data represent the mean±SEM 
of triplicate values from independent experiments using conditioned medium from ASM cells 
cultured from four patients.  *P ≤ 0.05 as compared to respective controls. 
 
7.3.3 ANG II and ET-1 induced release of VEGF from human airway smooth 
muscle cells 
The effects of ANG II and ET-1 on VEGF release in human ASM cells are shown in Figure 
7.4.  Conditioned media obtained from ANG II (100 nM)- and ET-1(10 nM)-treated human 
ASM cells were assessed for the VEGF release using ELISA method.  In our study, we 
observed a time-dependent release of VEGF from human ASM cells treated with ANG II 
and ET-1. We found a significant increase in VEGF concentration in conditioned medium 
from ANG II treated ASM cells at 4h of incubation (391±28 pg/ml) as compared to the 
control (237±39 pg/ml) (Figure 7.4, panel A). In the conditioned medium from ET-1 treated 
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cells, we found significant increase at 4h (397±60 pg/ml) and 16h (413±40 pg/ml) and then 
the levels of secreted VEGF remained elevated at later time points (Figure 7.4, panel B).  
However, ANG II induced the secretion of VEGF protein in a transient manner where the 
levels declined after 8 h of incubation.  
 
7.3.4 Effects of ASM conditioned medium on DNA biosynthesis and cell 
number in porcine pulmonary artery endothelial cells 
To decipher the angiogenic potential of the conditioned medium obtained from vasoactive 
peptides treated human ASM cells, proliferation assays were conducted on porcine 
pulmonary artery endothelial cells.  Figure 7.5 (Panel A) shows significant increase in 
[3H]thymidine incorporation after 24 h treatment with conditioned medium from 
ET-1-treated ASM cells (2.4±0.5 x103 CPM), 5 ng/ml VEGF (1.07±0.3 x103 CPM) and 
5 ng/ml PlGF (1.07±0.2 x103 CPM) as compared to serum free control cells (0.35±0.06 x103 
CPM).  However, the conditioned medium obtained from ANG II-treated human ASM cells 
did not induce significant proliferation (0.48±0.6 x103 CPM) as compared to the control.  
Similarly, the cell count experiments revealed enhanced cell numbers (2-4 fold) after 
treatment with the conditioned medium from cells treated with ET-1, VEGF and PlGF at 
48 h (Figure 7.5, Panel B). 
 
7.3.5 Inhibition of conditioned medium induced endothelial cell proliferation 
by VEGF receptor blocker 
To verify the potential mitogenic activity of VEGF secreted from ET-1 treated human ASM 
cells, a HUVEC based cell proliferation model was exploited. Serum deprived cultured 
HUVECs were pre-treated with the VEGF receptor tyrosine kinase inhibitor (VRI) prior to 
treatment with the conditioned medium of ET-1 treated human ASM cells and the data is 
shown in Figure 7.6. We observed a significant increase (1.45 ±0.23 fold) in HUVEC 
proliferation when cells were incubated with conditioned medium as compared to respective 
control cells (P<0.05).  However, pre-treating the HUVEC with VRI showed a drastic 
inhibition in HUVEC proliferation as compared to cells without the VRI pre-treatment 
(P<0.001) as well as in comparison to control cells (P<0.05). 
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Figure 7.5: Effects of angiogenic factors and conditioned medium (CM) obtained from 
ANG II or ET-1 treated ASM cells on the biosynthesis of DNA in porcine pulmonary 
artery endothelial cells 
Conditioned medium (CM, 100 μl) obtained from human ASM cells treated with ANG II (100 nM-) 
or ET-1 (10 nM)-were added to serum deprived endothelial cells and [3H]thymidine incorporation 
assay was performed.  Values are mean ± SEM from three experimental determinations.  Note that 
VEGF (5 ng/ml), PlGF (5 ng/ml), and fetal calf serum (FCS) are potent mitogens for the endothelial 
cells (P≤0.05).  CM from ET-1 (10 nM- treated ASM cells is mitogenic for the cells at 24 h and 48 h.  
However, CM from ANG II-treated ASM cells did not elicit the mitogenic effect (P≤0.05) at 24 h. 
 
 
Figure 7.6: Pretreatment 
with VEGF receptor 
inhibitor and HUVEC 
proliferation in response 
to condition medium 
Graphic representation of 
fold change in percentage 
HUVEC proliferation in 
response to DMEM 
(Control), and condition 
medium from human ASM 
cells treated with ET-1 for 8 
h . Proliferation of HUVEC 
with the ET-1 conditioned 
medium increased 
significantly compared to the 
control. This stimulating 
effect was strongly diminished when the HUVECs were pre-treated with 10 µM VEGF receptor 
blocker (VRI) before addition of the ET-1 conditioned medium. Data represents values ± SEM from 
two experimental determinations. * compared to medium alone (P<0.05), # in relation to ET-1 
treated human ASM conditioned medium (P<0.05) at 48h.  
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7.4 Discussion 
In this study, we have shown that ET-1 induced a time dependent DNA biosynthesis in 
cultured human ASM cells. We have previously demonstrated the mitogenic and 
hypertrophic potential of ANG II in human ASM cells (26).  Furthermore, both ANG II and 
ET-1 induced the mRNA expression and secretion of VEGF from human ASM cells. The 
conditioned medium derived from ET-1 treated ASM cells induced cell proliferation in 
porcine pulmonary artery endothelial as well as human umbilical vein endothelial cells and 
VEGF tyrosine kinase receptor inhibitor blocked the conditioned medium induced 
mitogenesis in endothelial cells.  These results suggest that ANG II and ET-1 contribute 
differentially to human airway smooth muscle cell growth and up-regulation of VEGF for 
paracrine action on endothelial cells, which could potentially lead to angiogenesis and 
vascular remodelling during chronic airway diseases.  Besides regulating the bronchial tone 
and contributing to the hyper responsiveness (30), studies have clearly shown the important 
role of airway smooth muscle in the perpetuation of inflammation by its enhanced secretory 
nature and thus contributing to the remodelling process in chronic airway diseases.  
Remodelling is a complex process (31) involving cell migration, proliferation, angiogenesis 
(2) and extra cellular matrix alteration (32) ultimately leading to a modified airway vascular 
structure. 
In our study, we used confluent human ASM cells as a model to study the role of vasoactive 
peptides in expression and secretion of VEGF, thereby mimicking vascular remodelling 
pathways in airways.  Our data on the increased expression of VEGF in human ASM cells 
support the notion that this angiogenic molecule is transcribed and translated in these cells 
for paracrine action on neighbouring endothelial cells. This is in accordance with previous 
studies where its expression is regulated by growth factors and cytokines, including TNF-α, 
TGF-β, and interleukin-1β (18, 33).   Several lines of evidence suggest that VEGF levels are 
up-regulated in asthma (34, 35) and COPD patient (2, 11).  Moreover, increased expression 
of VEGF in asthmatic airways with positive correlation with increase in blood vessel 
number and size suggests that VEGF significantly contribute to angiogenesis (36) and 
vascular remodelling and hence to the airway wall remodelling processes.  Moreover, the 
mitogenic effects of the conditioned medium derived from ET-1 treated ASM cells on the 
pulmonary artery endothelial cells supports the hypothesis that the VEGF synthesised by 
ASM under influence of these molecules is biologically active.  However, the conditioned 
medium derived from ANG II-treated human ASM cells could not result in endothelial cell 
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proliferation and warrants further investigation.  This could also be attributed to the sub-
threshold levels of secreted VEGF from ANG II treated cells as compared to ET-1-treated 
ASM cells.  Both mRNA and protein data on VEGF production in ANG II treated cells 
showed transient and rapid increase which declined within 8 h indicating for degradation as 
compared to stable levels in ET-1 treated cells.  Also itcan not be ruled out that either the 
released VEGF is an inactive variant or that VEGF, a known survival factor, is being 
utilised by the cells rapidly.  Additionally, the fact that only ET-1 induces significant 
proliferation of ASM cells, while ANG II induces cellular hypotrophy but does not increase 
cell numbers, as we reported previously (26), may suggest that predominantly proliferating 
ASM cells secrete VEGF.  Inhibition of the conditioned medium-induced HUVEC cell 
proliferation with the VEGF receptor blocker clearly demonstrates and confirms the 
importance of the angiogenic molecule, VEGF in whole milieu. 
In conclusion, our study demonstrated that potent vasoactive peptides (ANG II and ET-1), 
via increased production of VEGF in proliferating human ASM cells, could indirectly 
contribute to vascular remodelling and angiogenic processes during bronchial 
pathophysiology.  Our previous results (18, 2) and the current data clearly demonstrate that 
ASM cells are an important source of angiogenic mediators in these airways.  The 
mechanism underlying the signalling events leading to the expression of VEGF mRNA in 
response to vasoactive peptides are not entirely clear.  It is now well established that the 
angiogenic factors such as, VEGF produced by ASM cells in the vicinity of the endothelial 
cells appear to be a key paracrine event in the airways that contributes to the pulmonary 
vascular remodelling.  Undoubtedly, more research focus has been recently directed 
towards the molecular events underlying the airway vascular remodelling.  Though the 
precise nature of these events is far from clear, our study sheds a possible mechanism of 
vascular remodelling that could take place in chronic airway diseases. 
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Chapter 8:  Regulation of VEGF Expression by Nitric Oxide in ASM Cells 
 
Summary 
Angiogenesis and microvascular changes are features of chronic inflammatory diseases, 
including asthma where vascular endothelial growth factor (VEGF) and placenta growth 
factor (PlGF) have been implicated.  We investigated the effects of nitric oxide (NO) 
pathway on interleukin-1β (IL-1β)-induced expression and secretion of VEGF and PlGF 
from porcine airway smooth muscle (ASM) cells.  Serum deprived (for 48 h) porcine ASM 
cells were stimulated with IL-1β (5 ng/ml) alone or with nitric oxide donor L-arginine 
(10 mM) and/or NO synthase inhibitor L-NAME (2 mM) for 4 and 24 h.  IL-1β did not 
affect PlGF release, but augmented VEGF release at 24 h from control levels 
(398.6±11 pg/ml) to 968.4±123 pg/ml.  This VEGF release was inhibited by L-NAME 
(531.8±52 pg/ml), restored and further elevated by L-arginine (1529±287 pg/ml).  IL-1β 
induced expression of VEGF mRNA (1.8 fold vs. control) and this response was attenuated 
by L-NAME (1.1 fold vs. control cells) and augmented by L-arginine (3.8 fold vs. control) 
at 4 h.  Restoration of nitric oxide pathway by L-arginine in L-NAME-treated cells 
increased VEGF mRNA expression (2.2 fold). [3H]Thymidine incorporation assay revealed 
enhanced pulmonary artery endothelial cell proliferation in response to IL-1β, VEGF and 
PlGF (5 ng/ml each). Interestingly, the conditioned medium obtained from porcine ASM 
cells treated with IL-1β did not induce endothelial cell proliferation. Moreover, the IL-1β-
induced endothelial cell proliferation was not affected by interference with nitric oxide 
pathway.  Taken together, our findings suggest that nitric oxide pathway modulates the 
synthesis of VEGF during airway inflammation and this may subsequently result in vascular 
remodelling in chronic airway diseases. 
 
8.1 Introduction 
Chronic airway diseases are characterized by reversible/irreversible airway obstruction, 
hyperresponsiveness and wall inflammation (1, 2) and are associated with increased airway 
smooth muscle (ASM) mass (3, 4).  Airflow obstruction has been linked with airway and 
pulmonary vascular remodelling (5, 6), of which the molecular mechanisms are poorly 
understood.  Angiogenesis and microvascular changes are documented features of chronic 
inflammatory diseases, including asthma and other airway diseases (7-10).  Evidence 
suggests that the number and size of bronchial vessels is moderately increased in patients 
with asthma compared with normal individuals (8, 9, 11-15).  Bronchial vascular changes 
and the associated hyperaemia are contributing factors in airway wall remodelling in 
patients with chronic asthma, proposing for the ongoing mechanisms like angiogenesis and 
vascular dilatation (5, 6).   
 
Specific angiogenic and hyperpermeability factors, like vascular endothelial growth factor 
(VEGF) and placental growth factor (PlGF) could directly contribute to the pathological 
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events including wound healing in chronic lung diseases such as asthma (16).  Several 
studies have shown that VEGF and PlGF play an important role in airway and vascular 
remodelling (6, 17, 18).  The potent mitogen VEGF, which is produced by different cell 
types, including endothelial, vascular smooth muscle and tumour cells, induces proliferation 
and growth of these cells (19, 20).  Among various cytokines and growth factors that 
mediate inflammation in chronic airway diseases, interleukin (IL)-1β has been shown to 
augment VEGF (21) and nitric oxide (22, 23) production by smooth muscle cells.   
 
Nitric oxide is known to mediate many physiological and pathological functions, including 
angiogenesis and vascular permeability (24).  VEGF induces nitric oxide synthase (NOS) 
expression and promotes nitric oxide production in vascular endothelial cells in vitro (25).  
Inhibition of in vivo nitric oxide production results in reduced angiogenesis and vascular 
permeability induced by VEGF (24).  Recent evidence shows that nitric oxide induces 
VEGF synthesis in numerous cell types, including vascular smooth muscle cells, 
macrophages, keratinocytes, and tumor cells (23).  Moreover, recently the role of nitric 
oxide as been discussed as ‘actor’ as well as 'director’ of angiogenesis, both functions being 
equally expressed during physiological and pathological processes (26).   
 
In this study, we investigated the role of nitric oxide pathway on IL-1β-induced expression 
and secretion of VEGF and PlGF from porcine ASM cells in culture.  Furthermore, we 
elucidated the of nitric oxide in the mitogenic action of IL-1β on porcine pulmonary artery 
endothelial cells by using the the NOS-inhibitor N(omega)-nitro-L-arginine methyl ester (L-
NAME) and nitric oxide donor L-arginine.    
8.2 Materials and methods 
8.2.1 Materials 
All cell culture reagents were obtained from Invitrogen (Life Technologies BV, Breda, The 
Netherlands) and recombinant (rh) IL-1β was from Sigma-Aldrich BV (Zwijndrecht, The 
Netherlands).  Foetal calf serum (FCS) was obtained from Bio-Whitaker BV (Verviers, 
Belgium).  Antibodies and the enzyme-linked immunosorbent assay (ELISA) kits were 
from R & D Systems Europe Ltd (Abingdon, UK). 
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8.2.2 Porcine ASM cell isolation and culture 
The lungs were obtained from Yorkshire x Landrace female pigs after sacrifice and ASM 
cells were isolated and cultured as described previously (21).  Briefly, after removal of the 
epithelium, parts of smooth muscle was dissected, free of adherent tissue under aseptic 
conditions.  Smooth muscle pieces were incubated in Hank's balanced salt solution (HBSS; 
Invitrogen, Breda, The Netherlands) containing bovine serum albumin (BSA, 10 mg/ml), 
collagenase (type XI, 1 mg/ml) and elastase (3.3 U/ml; Sigma-Aldrich BV, Zwijndrecht, 
The Netherlands) at 37 °C in a humidified incubator containing 5% CO2/95% air for 30 
min.  After enzymatic digestion, the cell suspension was centrifuged and the pellet was 
washed in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Breda, The 
Netherlands) containing 10% (v/v) heat-inactivated foetal bovine serum (FBS; Cambrex, 
Verviers, Belgium) supplemented with sodium pyruvate (1 mM), nonessential amino acid 
mixture (1:100), gentamicin (45 μg/ml), penicillin (100 U/ml), streptomycin (100 μg/ml) 
and amphotericin B (1.5 μg/ml) (Invitrogen, Breda, The Netherlands).  Cells were 
subsequently seeded at 2x105 cells per 35 mm dish and maintained in culture by replacing 
the medium every 48 h.  After 10-14 days in culture, ASM cells grew to confluence and 
were then detached by trypsinization (0.5% trypsin; 0.02% EDTA; Invitrogen, Breda, The 
Netherlands) and subcultured into 25 cm2 and 75 cm2 tissue culture flasks.  Confluent 
serum-deprived primary cultures of porcine ASM cells were characterized by 
immunocytochemistry using monoclonal antibodies to smooth muscle α-actin (Sigma-
Aldrich BV, Zwijndrecht, The Netherlands) demonstrating that the cultures were essentially 
free (<5%) of other contaminating cell types. Cells in 4th -5th passage were used for 
experiments. 
 
8.2.3 Porcine pulmonary artery endothelial cell isolation and culture 
Major porcine pulmonary artery was dissected free of all connective tissue and cleaned with 
HBSS.  After incubation with collagen I for 30 min endothelial cells were isolated by 
scraping gently the inner surface of the artery with a surgical blade and cultured up to fourth 
passage in M-199 medium containing 10% foetal calf serum (FCS; Cambrex, Verviers, 
Belgium) at 37 °C in a 5% CO2-humidified atmosphere.  Cells were maintained in culture 
by replacing the medium every 48 h and when confluent was further passaged using 
trypsin/EDTA solution into 75 cm2 tissue culture flasks.  Porcine pulmonary artery 
endothelial cells had the characteristic cobblestone appearance when cultured in monolayer.  
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Cells were characterized immunocytochemically, using monoclonal antibodies against 
CD31 and visualised under the light microscope.  Porcine pulmonary artery endothelial 
cells in culture revealed cobblestone appearanc.  Immunocytochemical staining of confluent 
serum-deprived primary cell cultures of using monoclonal antibodies against CD31 
demonstrated that the cultures were essentially free (<5%) of other contaminating cell types. 
Cells were maintained in culture by replacing the medium every 48 h and, when confluent, 
were further passaged using trypsin/EDTA solution into 75 cm2 tissue culture flasks up to 4th 
passage. 
 
8.2.4 Measurement of VEGF and PlGF in conditioned media 
To obtain information on the release of VEGF and PlGF and the role of nitric oxide 
pathway from stimulated pulmonary ASM cells in culture, conditioned medium was 
collected at various time points from control (untreated) cells and cells treated with IL-1β 
with or without L-NAME (NOS-inhibitor) and L-arginine (nitric oxide donor).  Human 
specific solid-phase ELISA was performed for measuring the secreted VEGF and PlGF in 
the media.  A standard curve using recombinant VEGF and PlGF protein was first 
established and then 0.5 ml of conditioned medium was used for the assay.  Samples of 
conditioned medium were diluted until the levels of angiogenic proteins were within the 
linearity limits of the standard curve of the assay.  Subsequently, the samples were 
pre-incubated with respective capture antibodies followed by biotinylated detecting antibody.  
After addition of the streptavidine-peroxidase conjugate tetramethylbenzidine (TMB), the 
absorbance of the resulting coloured product was measured using an automated 
spectrophotometer (Biorad Laboratories BV, Veenendaal, The Netherlands).  The detection 
limit of the ELISA method was 20 pg/ml for both VEGF and PlGF. 
 
8.2.5 Isolation of total cellular RNA and RT-PCR 
Porcine ASM cells were washed in phosphate buffer solution (PBS, 140 mM NaCl, 2.6 mM 
KCl, 1.4 mM KH2PO4, 8.1 mM Na2HPO4.2H2O, pH 7.4) and directly lysed in guanidinium 
thiocyanate buffer (4M guanidium thiocyanate, 25mM sodium citrate, 0.5% N-
lauroylsarcosine, 0.1% anti foam A, 1% beta-mercaptoethanol).  Genomic DNA was 
sheared by passing lysates repeatedly through 23-gauge needles.  Total cellular RNA was 
isolated, as described previously (21), treated with RNase-free DNase to eliminate 
contaminating genomic DNA and processed for the synthesis of cDNA and PCR.  Porcine 
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specific forward and reverse primers spanning over a 319 bp fragment encoding VEGF-A 
(27) and a 625 bp fragment of β-actin (28) were employed.  The human primers used were 
checked with the Basic Local Alignment Search Tool (BLAST) from the national centre for 
biotechnology information (NCBI) to be compatible with the porcine sequence.  The PCR 
products were separated on 1.5% agarose gel, digitally photographed and the intensity of 
the bands was quantified in relation to β-actin band using Molecular Analyst (V 1.5) image 
analysis program (Biorad Laboratories, Hercules, USA).  The arbitrary optical 
densitometric (OD) values were expressed as a ratio to the controls. 
 
8.2.6 [3H]Thymidine incorporation assay 
Porcine growth-arrested pulmonary artery endothelial cells were incubated for 24 h with 
IL-1β, with or without L-NAME and L-arginine, in 100 μl FCS-free M199 medium.  
Control incubations consisted of cells that were incubated with FCS-free M199.  Five hours 
prior to the end of the incubation period, 10 μl of [3H]thymidine was added at a final 
concentration of 1 μCi/110 μl per well.  The plates were frozen overnight at -20 °C after 
which the cells were harvested on glass fibre filters using a Filtermate 196-cell harvester 
(Packard, Meridan, USA) and the activity was counted using a Microplate Scintillation 
β-counter (Topcount, Packard, Meridan, USA).  Measured radioactivity was expressed as 
counts per min (CPM) and the mean ± SEM CPM of quadruple wells and subsequently 
three different cell isolations were expressed as fold induction (as ratio to the control cells). 
 
8.2.7 Cell counting 
In a parallel series of experiments, cells were incubated with same compounds as above for 
24 and 48 h.  Thereafter, the cells were harvested in 50 μl of trypsin/EDTA solution for 
10 min and the suspension were added to 10 ml of Casy®1 isotonic solution (6.38 g/l NaCl, 
0.2 g/l Na-tetraborate, 1.0 g/l Boric acid and 0.2 g/l EDTA). An aliquot of 200 ul cell 
suspension was inserted in to Casy®1 coulter cell counter and cell numbers in one ml were 
assessed using system software (Sch¨arfe System GmbH, Reutingen, Germany). 
 
8.2.8 Statistical analysis 
All data in the figures are given as mean±SEM.  Statistical analysis was performed by using 
two-tailed, independent sample "t"-test.  Significance was accepted at p≤0.05. 
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8.3 Results 
8.3.1 Regulation of IL-1β induced VEGF and PlGF secretion by nitric oxide 
pathway 
Figure 8.1 depicts the release of VEGF (upper panel) and PlGF (lower panel) following 
incubation of ASM cells with IL-1β in the absence or presence of L-NAME and L-arginine.  
IL-1β augmented VEGF release at 24 h from 398.6±11 pg/ml (control) to 968.4±123 pg/ml.  
This VEGF release was inhibited by L-NAME (531.8±52 pg/ml) and restored by L-arginine 
(1529±287 pg/ml).  In contrast to VEGF levels, PlGF could not be detected at 4 h of IL-1β 
treatment and then levels rose in all experimental conditions from non detecting level to 28-
50 pg/ml and did not differ significantly.   
 
Figure 8.1: Role of nitric oxide 
in VEGF and PlGF secretion by 
IL-1β treated porcine ASM cells 
Graphic representation of VEGF 
(pg/ml) and PlGF (pg/ml) release at 
4 and 24 h time in culture medium 
of ASM cells stimulated with vehicle 
(control) or IL-1β (5 ng/ml), in the 
absence or presence of L-NAME 
(2 μmol/ml) and/or L-arginine 
(L-Arg, 10 μmol/ml).  Values 
represent mean ± SEM of three 
different cell batches.  * p≤0.05 as 
compared to control (untreated 
ASM cells). 
 
 
 
 
 
 
8.3.2 Effects of NO pathway on IL-1β induced VEGF mRNA expression 
IL-1β induced the expression of VEGF mRNA (1.8 fold vs. control) at 4 h, but apparently 
this effect had dissipated by 24 h as no increase was detected at this latter time point 
(Figure 8.2).  The IL-1β-induced VEGF mRNA expression was attenuated by L-NAME 
(1.1 fold vs. control cells) whereas, L-arginine restored the response to IL-1β by increasing 
the levels by 3.8 folds vs. control (Figure 8.2). 
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Figure 8.2: RT-PCR analysis of VEGF mRNA expression in porcine ASM cells 
Panel A:  Agarose gel electrophoresis of RT-PCR products of VEGF (319 bp) and β-actin (625 bp) 
synthesised from porcine ASM cells treated with vehicle (control) or IL-1β (5 ng/ml), in the absence 
or presence of L-NAME (2 μmol/ml) and/or L-arginine (L-Arg, 10 μmol/ml). 
Panel B:  The intensity of the bands was analysed using digital image analysis software and 
VEGF/β-actin ratio was calculated as described in the text.  Values are mean ± SEM from 
3 independent measurements. 
 
8.3.3 Endothelial cell proliferation 
Endothelial cell proliferation was assessed in response to various mitogens and IL-β treated 
ASM conditioned media.  [3H]thymidine incorporation assay revealed an increased cell 
proliferation in cells treated with IL-1β (5 ng/ml), VEGF (5 ng/ml) or PlGF (5 ng/ml), but 
not in the case of pulmonary artery endothelial cells incubated with conditioned medium 
obtained from IL-1β (5 ng/ml)-treated porcine ASM cells (Figure 8.3).  Similarly, cell count 
experiments revealed increased cell number in pulmonary artery endothelial cells treated 
with IL-1β (5 ng/ml), VEGF (5 ng/ml), PlGF (5 ng/ml) or FCS as compared to control cells.  
However, conditioned medium collected at 24 h from porcine ASM cells treated with IL-1β 
(5 ng/ml) did not increase cell number significantly (Figure 8.4). 
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Figure 8.3: [3H]Thymidine incorporation showing DNA biosynthesis in pulmonary artery 
endothelial cells 
Effects of vehicle (control), IL-1β, VEGF, PlGF and 100 μl of conditioned medium obtained at 24 h 
from IL-1β-treated porcine ASM cells (IL-1β CM) on [3H]thymidine incorporation.  Values are 
mean±SEM from three experimental determinations.  Note that IL-1β, VEGF and PlGF, but not the 
conditioned medium, showed a potent mitogenic activity.  *P≤0.05 vs. control. 
 
 
 
Figure 8.4: Cell count in pulmonary artery endothelial cells 
Effects of vehicle (control), IL-1β, VEGF, PlGF, 100 μl of conditioned medium obtained at 24 h 
from IL-1β-treated porcine ASM cells (IL-1β CM) and FCS (positive control) on pulmonary 
endothelial cell count.  Values are mean±SEM from three experimental determinations.  Note that 
IL-1β, VEGF, PlGF and FCS, but not the conditioned medium, showed a potent mitogenic activity.  
*P≤0.05 vs. control. 
Regulation of VEGF by NO        Chapter 8 
 164 
8.3.4 Role of nitric oxide in IL-1β-induced cell proliferation in pulmonary 
artery endothelial cells 
In order to decipher the role of nitric oxide pathway in the increase in cell number due to 
IL-1β, cells were pretreated with the NOS inhibitor L-NAME and the nitric oxide donor 
L-arginine and their number was counted after 24 and 48 h.  Figure 8.5 shows that 
compared to serum deprived (control) cells, IL-1β (as well as FCS) induced clear cell 
proliferation at 48 h and this effect of IL-1β was not inhibited by the pretreatment of the 
cells with L-NAME.  Moreover, treatment with L-arginine did not significantly affect the 
response to IL-1β. 
 
 
 
Figure 8.5: Role of nitric oxide in IL-1β-induced proliferation of pulmonary artery 
endothelial cells 
Serum deprived pulmonary artery endothelial cells were treated with medium alone (control), IL-1β 
(5 ng/ml) alone or in combination with 2 μmol/ml L-NAME (IL-1β+LN), 10 μmol/ml L-arginine 
(IL-1β+LA) or (IL-1β+LN+LA). FCS was used as positive control.  Values are mean±SEM from 
three experimental determinations.  *P≤0.05 vs. control. 
 
8.4 Discussion 
Our data clearly demonstrate that IL-1β stimulates porcine airway smooth muscle cells by 
upregulating VEGF for paracrine action on endothelial cells.  This clearly supports our 
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previous results that IL-1β induces mRNA expression and the secretion of VEGF from 
human ASM cells (21).  Furthermore, in this study we established that nitric oxide pathway 
modulates the synthesis of VEGF in ASM cells by using inhibitors of NOS and nitric oxide 
augmenter L-arginine.  This suggests that nitric oxide pathway may play a potential role in 
vascular remodelling in chronic airway diseases. 
 
The inhibition of IL-1β-induced VEGF expression and secretion by NOS inhibitor L-
NAME has been reported (22), though in a different cell type and species.  Dulak et al. (22) 
described in rat vascular smooth muscle cells the role of nitric oxide in the synthesis of 
VEGF.  This effect of NO on VEGF is also reported in other cell types, such as tumour cells 
(29) and keratinocytes (30).  Our results are consistent with previous observations that 
IL-1β induces the NO generation via inducible nitric oxide synthase (31, 32) and/or VEGF 
(21, 33) as reported for vascular smooth muscle cells.  However, we show for the first time 
that nitric oxide synthesis augments VEGF expression in porcine ASM cells.  L-NAME 
inhibited VEGF generation in IL-β-stimulated porcine ASM cells suggesting the pivotal role 
played by nitric oxide in the whole milieu of pulmonary angiogenesis and remodelling since 
VEGF is one of the key  angiogenic factor known (34).  We have earlier reported that 
bronchial expression of VEGF is enhanced during COPD and that this molecule plays a role 
in bronchial remodelling associated lung function decline (6).  Inhibition of IL-β-induced 
VEGF by L-NAME was reversed by addition of nitric oxide donor L-arginine reinforcing 
the critical role of nitric oxide.  Recently, Kimura et al. (30) demonstrated that nitric oxide 
donors up-regulated the activity of the human VEGF promoter in human glioblastoma and 
hepatoma cells, independently of a cGMP-mediated pathway and supporting our findings in 
porcine ASM cells. 
 
Angiogenesis is a complex multistep process that involves endothelial cell migration, 
proliferation and differentiation into vascular tubes.  Nitric oxide has been reported to be a 
downstream mediator in the angiogenic response to a variety of growth factors, but the 
mechanisms by which nitric oxide promotes neovessel formation is not clear.  Our study 
has focused on the regulation of VEGF by nitric oxide in ASM cells and it is clear that nitric 
oxide indeed plays a pivotal role.  Babaei et al. (35) demonstrated that nitric oxide directly 
contributes to endothelial cell migration and capillary tube formation.  These data support 
an important paracrine role for endogenously produced nitric oxide in endothelial cell 
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migration and differentiation in vitro, and suggest that the cell-based eNOS gene transfer 
may be a useful approach to increase new blood vessel formation in vivo.  Figure 8.6 
summarizes the possible role of nitric oxide in autocrine/paracrine manner in the regulation 
of VEGF and, in turn, angiogenesis in relation to smooth muscle and endothelial cells. 
 
 
Figure 8.6: Autocrine /paracrine role of nitric oxide in regulation of VEGF in smooth 
muscle and endothelial cell cross talk 
Note that IL-1β induced VEGF production in ASM cells is NOS dependant and that this VEGF may, 
in turn, be involved in angiogenesis via the nitric oxide pathway in endothelial cells.  Adapted from 
reference (36). 
 
Interestingly, the second part of our study to look at the role of nitric oxide in IL-1β-induced 
endothelial cell proliferation revealed that IL-1β was potent mitogen for porcine pulmonary 
artery endothelial cells, similar to the angiogenic molecules VEGF and PlGF.  However, the 
conditioned medium from IL-1β-treated ASM cells did not induce significant endothelial 
cell proliferation though it contained sufficient VEGF as revealed by ELISA.  We believe 
that super oxide radicals formed as a result of IL-1β treatment of the porcine ASM cells 
may be the reason for the unaltered cell proliferation.  Further studies are required to 
explore these possibilities.  Moreover, IL-1β mediated mitogenesis seen in the pulmonary 
artery endothelial cells does not depend on the nitric oxide pathway as we have 
demonstrated by inhibiting NOS using L-NAME. 
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Taken together, our results suggest that nitric oxide pathway may modulate the synthesis of 
VEGF during airway inflammation and subsequently result in vascular remodelling in 
chronic airway diseases.  The induction of VEGF synthesis by nitric oxide may be of great 
importance in the maintenance of vascular homeostasis e.g in the response to endothelial 
injury as well as during vascular remodelling in the airways.  It is clear that two pathways 
synergistically regulate vascular remodelling and function via enhanced reciprocal synthesis 
of nitric oxide and VEGF; this interaction may contribute to the bronchial remodelling 
during chronic airway inflammation. 
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Chapter 9:  Cyclically Stretched Human ASM Cells and Angiogenic 
Molecules 
 
Summary 
Bronchial hyperresponsiveness associated with chronic inflammation is a key feature in 
asthma where airway smooth muscle undergoes cyclical strain that may alter its molecular 
phenotype.  Using a cyclical stretch model, we explored the protein expression profile, 
signalling pathways and the secretion of angiogenic molecules in human cultured airway 
smooth muscle (ASM) cells.  Human ASM cells were isolated from bronchial rings 
obtained from patients who underwent lobectomy/pneumonectomy.  Serum deprived (48 h) 
human ASM cells, seeded in collagen-I coated 6-well BioFlex plates, were subjected to a 
pattern of 0.5 s stretch and 0.5 s relaxation (frequency 1 Hz) for 5, 15, 30 min and 1, 2, 4, 8, 
24 and 48 h in a Flexer strain unit.  Cells were harvested and the conditioned medium as 
well as cell extracts were collected at each time point and analyzed by antibody arrays, 
ELISA and Western blotting. Protein profiling by antibody arrays revealed enhanced 
secretion (2-10 fold) of various direct/indirect angiogenic molecules such as vascular 
endothelial growth factor (VEGF), angiogenin, interleukin (IL)-6 and IL-8 in the 
conditioned medium derived from ASM cells subjected to cyclical stretch. VEGF secretion, 
assessed by ELISA, was significantly higher after 8 h (p≤0.02) and 24 h (p≤0.001) as 
compared to controls.  Western blot analysis showed robust phosphorylation of ERK1/2 
after 15 min and Akt; P-Thr-Akt (p≤0.001) and P-Ser-Akt (p≤0.004) after 30 min of stretch.  
Pre-treatment of cells with respective blockers for Akt, ERK1/2 and RhoA/ROCK pathways 
revealed significant inhibition of VEGF release only in case of ERK1/2 inhibitor, U0261 
after 8 h. Whereas, both ERK1/2 and RhoA/ROCK pathways inhibition resulted in 
diminished secretion of IL-6 (p≤0.05) and IL-8 (p≤0.01) in cyclical stretched ASM cells 
after 8 h. Our results demonstrate that hyper contractile human ASM cells secrete pro-
angiogenic molecules predominantly via ERK1/2 pathway and cytokines via RhoA/ROCK 
pathways and subsequently contributing to vascular and airway remodelling during chronic 
airway diseases 
 
9.1 Introduction 
Asthma is a chronic inflammatory disease characterized by bronchial hyper-responsiveness 
and airway remodelling of which molecular mechanisms are poorly understood.  Airway 
smooth muscle (ASM) cells undergo cycles of stretching and shortening during breathing.  
Bronchial hyper-responsiveness, a common feature of asthma (1), leads to excessive 
narrowing of the airways driven mainly by the increased muscle mass and contractility.  
Mechanical stress experienced by ASM has been implicated in such excessive airway 
narrowing or remodelling (2, 3); molecular mechanisms underlying this behaviour of ASM 
remain unclear.  Many studies have indicated the importance of periodic deep inspirations 
in maintaining bronchodilatation in normal subjects (4, 5).  Furthermore, prolonged 
withholding of deep inspiration induces asthma-like bronchoconstriction in normal subjects 
(6).  These findings suggest that strain/stretch has a complex modulatory effect on airway 
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smooth muscle contractility and it is known that physical forces and changes in the 
mechanical structure of tissues influence cellular physiology (7).  Although it is recognized 
that significant mechanical distension takes place in the lungs and that several airway 
diseases, including asthma, involve changes in airway mechanics, little is known about the 
influence of mechanical stimulation on the function of ASM.  To learn more about the 
effects of these hyper-contractile states, various in vitro stretch models using rat bronchial 
rings, bovine trachea or human ASM cells have been attempted (6, 8, 9).  Different methods 
of in situ or in vitro mechanical stretch have been developed to mimic what the ASM cells 
are exposed in vivo (8). 
 
Some in vitro studies (9, 11) have suggested the role of mitogen-activated protein (MAP) 
kinase and protein kinase C (PKC) signalling pathways in human ASM cells in response to 
mechanical strain.  However, there is little information on how different signalling 
pathways interact with each other and what their role is in mediating the expression of 
various angiogenic molecules.  Kumar et al. (9) suggest that the stretch-induced IL-8 release 
is mediated via increased activation of activator protein-1 (AP-1) and CCAAT/enhancer 
binding protein (C/EBP) transcription factors via Extra cellular regulated kinase-1 and 2 
(Erk1/2) and p38 MAP kinase signalling pathways.  In the same context, the study of Li et 
al. (12) suggests that stretch-induced transcriptional regulation of IL-8 mRNA and IL-8 
production is via activation of AP-1 and NF-κB and dependent on the activation of c-Jun 
NH2-terminal (JNK) and NF-κB-inducing (NIK) kinases, respectively.  Wang et al. (11) 
suggest a role for the PKC signalling pathway and its interaction with the RhoA-ROCK-1 
(Rho kinase-1) signalling, required for the nuclear localization of serum response factor 
(SRF) in cyclically stretched human ASM cells.  Furthermore, evidence points to role of 
RhoA and its downstream effector Rho kinase in the enhancement of smooth muscle 
contractility due to mechanical stress (13). 
 
In view of our previous experience with the stretch model on cardiac myocytes (14) and the 
available evidence (9, 12), we hypothesized that in response to cyclic mechanical strain, the 
molecular phenotype of human ASM cells is altered.  This may result in the expression and 
secretion of a number of known and unknown molecules, such as growth factors and 
cytokines that may be relevant in the airway and vascular remodelling process.  Using an 
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in vitro cyclical stretch model, we investigated the expression profile, signalling pathways 
and the secretion of direct and indirect angiogenic molecules in cultured human ASM cells. 
9.2 Materials and methods 
9.2.1 ASM cell culture 
In accordance with procedures approved by the Erasmus MC Research Ethics Committee, 
human ASM cells were obtained from the lobar or main bronchus of patients undergoing 
lung resection for carcinoma of the bronchus, using cell isolation and culture methods 
described previously (15).  Briefly, after removal of the epithelium, fragments of smooth 
muscle were dissected free of adherent tissue under aseptic conditions and incubated in HBSS 
containing bovine serum albumin (BSA, fraction V, 10 mg/ml), collagenase (type XI, 1 
mg/ml) and elastase (type IV, 3.3 U/ml) at 37 °C in a humidified incubator containing 5% CO2 
in air.  After enzymatic digestion, the cell suspension was centrifuged and the pellet was 
washed in Dulbeco’s Modified Eagle’s Medium (DMEM) containing 10% (v/v) foetal calf 
serum (FCS) supplemented with sodium pyruvate (1 mM), nonessential amino acid mixture 
(1:100), gentamicin (45 μg/ml), penicillin (100 U/ml), streptomycin (100 μg/ml) and 
amphotericin B (1.5 μg/ml).  Cells were subsequently seeded in 35 mm dishes and maintained 
in culture by replacing the medium every 72 h.  At confluency, cells were further passaged 
using trypsin/EDTA solution into 75 cm2 tissue culture flasks.  Experiments were performed 
on near confluent cells between the 4th and 6th passage.  Human ASM cells in culture 
appeared spindle or ribbon-shaped with central oval nuclei containing prominent nucleoli.  Cells 
were characterized immunocytochemically using α-smooth muscle actin and myosin 
monoclonal antibodies visualized by using a FITC-conjugated secondary antibody and viewed 
under a fluorescence microscope. 
 
9.2.2 Cyclical stretch model 
The human ASM cells (200.000 cells per well) were seeded on BioFlex® six well plates 
coated with collagen.  Cells were grown in DMEM with 10% foetal calf serum (FCS) for 
72 h, followed by serum deprivation for 48 h.  Before the start of the experiment, the serum 
free medium (DMEM) was refreshed in each well.  The flexible bottomed (silastic 
membrane) 6-well plates were placed in the base plate (loading post) of the Flexercell 
stretch apparatus (model 2000FX), Flexcell International Corporation, Hillsborough, USA).  
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The loading posts where the 6 well bioflex plates are placed, allow the flexible membrane 
bottom of each culture well to be stretched in a uniform biaxial pattern.  The stretch was 
induced using a computer controlled vacuum regulator to result in a 15% stretch in a 
cyclical pattern of  0.5 s stretch and 0.5 s relaxation (frequency 1 Hz) (9).  Cyclical 
mechanical stretch was applied to the human ASM cells for shorter (0, 5, 15, 30, 60 and 120 
min) or longer time periods (1, 4, 8 and 24 h).  Time-matched control cultures were also 
plated and grown on collagen coated BioFlex plates with no external mechanical strain 
applied.  The experiments were repeated in duplicates using at least three different batches 
of cells. 
 
9.2.3 Human cytokine antibody array 
Conditioned media were collected from human ASM cells subjected to cyclical stretch for 
24 h and the protein expression profiles of multiple cytokines were examined in relation to 
unstretched cells by using the RayBio® Human Cytokine Antibody Array III (Raybiotech, 
Inc., Norcross USA).   Table.9.1 shows the 42 cytokines and proteins that are detectable 
using this array; mapped in the same order on the membrane.  The membranes were blocked 
with a blocking buffer for 1 h and were then incubated with 1 ml of the conditioned medium 
from stretched or unstretched cells for overnight at 4 ºC.  The membranes were then washed 
and incubated with Biotin-Conjugated Anti-Cytokines for 3 h at room temperature.  
Subsequently, they were washed again and incubated with HRP-conjugated streptavidin for 
2 h at room temperature; all incubations and wash steps were performed under gentle 
rotation.  The membranes were visualized using detection reagents and exposed to x-ray 
films.  After developing, the films were scanned and analyzed in the BioRad® GS800 
scanner using the Quantity One-4.2.1® program. 
 
9.2.4 Cell signalling 
To investigate whether mechanical stretch activates the Erk1/2, phosphoinositide 3-kinase 
(PI3k)-Akt and Rho/ROCK signalling pathways, human ASM cells were mechanically 
stretched for 0, 5, 15, 30, 60 and 120 min.  Furthermore, ASM cells were pre-treated with 
the inhibitors of these pathways, followed by 15 min and 1 h stretch.  Based on the 
literature, we chose 30 min pre-incubation time and 20 µM/well inhibitor concentration for 
wortmannin (PI3k; Sigma-Aldrich, Zwijndrecht, Netherlands) (16-18), U0261 (Erk1/2; 
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Promega®, Madison, USA) (9, 19) and Y27632 (Rho-A/ROCK-1, Calbiochem, La Jolla, 
USA) (19, 20).  Conditioned medium was collected after 1 h and 8 h, following the 1 h 
stretch with and without kinase inhibitors to investigate if the activation of these pathways 
was crucial for the production and secretion of VEGF, IL-6 or IL-8.  Cell lysates after each 
time point were analysed using western blot assay for respective signalling pathways.  Basal 
cell activation of the signalling pathways was noted from cells directly harvested at zero 
time point.  Respective time matched controls were taken to compare the effect of the 
inhibitors. 
 
Total protein extraction and measurement 
After the application of mechanical stretch for different time periods, human ASM cells 
were lyzed in Laemmli loading buffer containing 62.5 mM Tris-HCl pH 6.8, 10% glycerol, 
2% sodium dodecyl sulphate (SDS), 5% 2-mercaptoethanol, and 0.0025 % bromophenol 
blue in water for the Western blot analysis.  BioRad RC DC protein assay kit and bovine 
serum albumin as standard were used to measure the amount of protein in the cell lysates. 
 
Western blot analysis 
Cell lysates protein samples (10-20 µg) were separated on a 10% acrylamide gel using 
standard SDS-PAGE procedures and transferred to polyvinylidene difluoride membranes 
using the Bio-Rad® mini ProteanTM II system.  The membranes were afterwards blocked 
with 5% bovine serum albumin (BSA) or 5% milk powder in TTBS buffer (10 mM 
Tris/HCL, pH 7.6, 150 mM NaCl, 0.1% (w/v) Tween) supplemented 0.1% Goat serum, for 
at least 30 min.  After blocking, the membranes were incubated for overnight at 4 °C with 
the rabbit polyclonal antibodies (Cell Signalling®, Danvers, USA) directed against 
total-Erk 1/2, Phospho-Erk 1/2, total-P38, Phospho-P38, total-Akt or Phospho-Akt 
(Thr308), or with the mouse monoclonal antibody directed to Phospho-Akt (Ser473).  After 
incubation with the first antibody, the blots were washed with 150 mM TTBS and incubated 
for at least 3 h with the second antibody, horseradish peroxidase conjugated goat anti-rabbit 
(GARPO) or HRP conjugated goat anti-mouse (GAMPO) antibodies (PIERCE® Rockford, 
USA) in TTBS buffer supplemented with 0.5% milk powder.  Immunoreactivity was 
visualized using enhanced chemiluminescene (ECL) detection reagent (PIERCE® Rockford, 
USA).  After developing, the films (Amersham Hyperfilm ECL) were scanned and analyzed 
in the BioRad® GS800 scanner using the Quantity One-4.2.1® program. 
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9.2.5 Enzyme-Linked Immuno-Sorbent Assay (ELISA) 
Conditioned media were collected from human ASM cells that were unstretched or 
stretched for 1, 4, 8 and 24 h and assessed for VEGF (ELISA, R & D, Abingdon, UK) and 
IL-6 and IL-8 (PeliKine Compact ELISA, Sanquin, Amsterdam, NL).  Furthermore, 
conditioned media were collected after 1 h and 8 h following 1 h stretch, with and without 
the kinase inhibitors, and were assessed using the above human-specific ELISA kits. 
9.2.6 Statistical analysis 
All data in the figures are given as mean±SEM.  Statistical analysis was performed by using 
two-tailed, independent sample "t"-test.  Significance was accepted at p≤0.05. 
9.3 Results 
9.3.1 Protein profiling by antibody array 
Conditioned media from human ASM cells that were unstreched (control) or mechanically 
stretched for 24 h were analyzed to investigate the protein release, using the human 
cytokine antibody array.  Figure 9.1 shows blots from control (upper left panel) and 
stretched (upper right panel) cells.  Out of the possible 42 proteins mapped on the 
membrane, stretching of cells resulted in upregulation of 8 and downregulation of 1 
(Figure 9.1).  The representative quantative data show that mechanical stretch of human 
ASM cells increased the expression of angiogenin (ang), vascular endothelial growth factor 
(VEGF), growth-related oncogene (GRO), regulated on activation, normal T cells expressed 
and secreted (RANTES), interleukin (IL)-6, IL-8, monocyte chemotactic protein (MCP)-1 
and tumour necrosis factor (TNF)-β (Figure 9.1, lower panels A and B; Table 9.1). 
 
9.3.2 Signal transduction pathways: PI3K-Akt, ERK 1/2 and RhoA/ROCK 
To investigate the activity of Erk1/2, P38 and Akt kinases in response to mechanical stretch, 
human ASM cells stretched for shorter time periods were analyzed using Western blots.  
Data in Figure 9.2 (left panels) demonstrate that the application of cyclical mechanical 
stretch to human ASM cells significantly activated Erk1/2 phosphorylation as early as 5 min 
compared with the total Erk 1/2 (stretch 1.19±0.099 vs. control 0.03±0.10 arbitrary 
densitometric unit (ADU), p=0.000025); it peaked at 15 min (stretch 1.16±0.11 vs. control 
0.03±0.099 ADU, p=0.000047) and then significantly decreased after 30 min (stretch  
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Figure 9.1: Representative blots demonstrating the stretch-induced expression of direct 
and indirect angiogenic factors in human ASM cells. 
Protein array of supernatant obtained from human ASM cells mechanically stretched for 24 h shows 
enhanced expression of a number of (A) direct and (B) indirect angiogenic factors compared to 
control (unstretched) cells.  The bar diagram is a quantitative representation of fold change in 
expression of angiogenic molecules and cytokines between the stretched and unstretched cells.  
Data represent mean value± SEM of three experiments. Angio=angiogenin, VEGF=vascular 
endothelial growth factor, GRO=growth-related oncogene, RANTES =Regulated on activation, 
normal T cells expressed and secreted, IL-6= interleukin-6, IL-8=interleukin-8, MCP-1=monocyte 
chemotactic protein-1, TNF-β= tumour necrosis factor-β.  *P≤ 0.05 vs unstretched ASM cells 
(control).  
 
Table 9.1: Cytokines detected (bold letters) out of the possible 42 cytokines using 
RayBio® Human Cytokine Antibody Array III 
A B C D E F G H I J K L 
Pos Pos Neg Neg ENA-78 GCSF GM-CSF GRO GRO-α I-309 IL-1 α IL-1β 
Pos Pos Neg Neg ENA-78 GCSF GM-CSF GRO GRO-α I-309 IL-1 α IL-1β 
IL-2 IL-3 IL-4 IL-5 IL-6 IL-7 IL-8 IL-10 IL-12  IL-13 IL-15 IFN-γ 
IL-2 IL-3 IL-4 IL-5 IL-6 IL-7 IL-8 IL-10 IL-12  IL-13 IL-15 IFN-γ 
MCP-1 MCP-2 MCP-3 MCSF MDC MIG MIP-1  RANTES SCF SDF-1 TARC TGF-β1 
MCP-1 MCP-2 MCP-3 MCSF MDC MIG MIP-1  RANTES SCF SDF-1 TARC TGF-β1 
TNF-α TNF-β EGF IGF-I Ang OSM Tpo VEGF PDGF  Leptin Neg Pos 
TNF-α TNF-β EGF IGF-I Ang OSM Tpo VEGF PDGF  Leptin Neg Pos 
Pos, Positive; Neg, negative; MCSF, macrophage colony-stimulating factor; IGF-I, insulin-like 
growth factor I; MDC, macrophage-derived chemotactic factor; Ang, angiogenin; GCSF, 
granulocyte colony-stimulating factor; MIG, monokine induced by IFN-γ; OSM, oncostatin M; 
GRO, growth-related oncogene; VEGF, vascular endothelial growth factor; SCF, stem cell factor; 
PDGF, platelet-derived growth factor; SDF-1, stromal cell-derived factor-1; TARC, thymus- and 
activation-regulated cytokine; RANTES, Regulated on activation, normal T cells expressed and 
Stretch Control 
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secreted; IL, interleukin; MCP,monocyte chemotactic protein; TNF, tumour necrosis factor;  TGF-
β, Transforming growth factor-β; EGF, Epidermal growth factors; Tpo, Thrombopoietin. 
 
0.53±0.16 vs. control 0.03±0.099 ADU, p=0.023).  Cyclical stretching also caused a 
significant increase in P38 phosphorylation after 5 min (stretch 0.18±0.020 vs. control 
0.047±0.09 ADU, p=0.0043) and 15 min (stretch 0.29±0.032 vs. control 0.047±0.09 ADU, 
p=0.0019) of stretch, with maximum activation being observed after 30 min (stretch 
0.60±0.081 vs. control 0.047±0.09 ADU, p=0.0024) of mechanical stretch (Figure 9.2, right 
panels). 
 
As shown in Figure 9.3 (left panels), Akt phosphorylation (Thr308) significantly increased 
in response to mechanical stretch after 30 min (p=0.0012), peaking at 60 min (p=0.019) and 
then reverting slightly at 120 min (p=0.005).  The other phosphorylated form of Akt 
(Ser473) showed significant increases after 30 (p=0.0004), 60 (p=0.024) and 120 min 
(p=0.003) of mechanical stretch (Figure 9.3, right panels). 
 
The activation of these different signalling mechanisms was also investigated by using 
respective inhibitors.  Data in Figure 9.4 (left panels) demonstrate a significant inhibition of 
Erk1/2 phosphorylation by U0261 after 15 (p=0.041) and 60 min (p=0.036) mechanical 
stretch.  Also the measurement after 480 min (p=0.015) following the 60 min stretch 
protocol shows a significant inhibition of phosphorylated Erk1/2 by U0261. The 
downstream signalling of the RhoA kinase was investigated using the RhoA/Rock inhibitor 
Y27632.  We evaluated stretch-induced P38 phosphorylation in human ASM cells treated 
with Y27632.  As shown in Figure 9.4 (right panels), phosphorylation of P38 was 
significantly inhibited after 60 min (p=0.0000028) stretch, but there was no inhibition after 
15 min stretch or at the 480 min time point. 
 
The role of Akt phosphorylation was investigated using Wortmannin.  Figure 9.5 (left 
panels) shows the time dependent inhibition of Thr308 form, which significantly increased 
after 15 (p=0.0029) and 60 min (p=0.00043) stretch in controls.  This inhibition was also 
present even at the 480 min (p=0.0039) time point.  The Ser473 form was not affected 
significantly (Figure 9.5, rightt panels). 
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Figure 9.2: Effect of cyclical stretch on Erk1/2 and p38 activation 
Human ASM cells were mechanically stretched for 5, 15, 30 and 60 min, and the activation of 
(A) Erk1/2 and (B) p38 was determined by the western blot method (upper panels).  Unstretched 
cells were included as control.  The bar diagrams depict quantification of phosphorylated Erk1/2 
activation as the ratio between the phosphorylated forms of Erk 1/2 or P38 relative to their 
respective total forms.  Values are shown as mean±SEM of three experiments.  * P ≤ 0.05 
 
 
 
 
Figure 9.3: Effect of mechanical stretching on the phosphorylation of Akt 
Human ASM cells were mechanically stretched for 5, 15, 30 60 and 120 min, and the activation of 
Akt was determined by the western blot method with antibodies against phophorylated (Ser473 and 
Thr308) and non-phosphorylated forms of Akt.  Unstretched cells were included as control.  The bar 
diagrams depict the quantification of the respective Akt activation at different time points as fold 
change from the baseline value.  Values are shown as mean±SEM of three experiments.  * P≤0.05, 
C=control (con) FCS=serum (positive control). 
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Figure 9.4: Inhibition of Erk1/2 and P38  phosphorylation 
Human ASM cells were pretreated for 30 min with 20 μM U0261 (Erk1/2 inhibitor; left panels) or 
20 μM Y27632 (P38 inhibitor; right panels) followed by mechanical stretch for 15 and 60 min.  
Cells were lyzed and analyzed using Western blot method with respective phospho antibodies after 
these time points and after 480 min, following the 60 min protocol.  The bar diagrams depict the 
percentage inhibition of Erk1/2 or p38 phosphorylation in relation to the controls without 
inhibitors.  Values are shown as mean±SEM.  *p≤0.0.5, C=control; U=U0261, Y= Y27632. 
 
 
Figure 9.5: Inhibition of Akt phosphorylation 
Human ASM cells were pretreated for 30 min with 20 μM wortmannin (Akt inhibitor) followed by 
mechanical stretch for 15 and 60 min.  Cells were lyzed and analyzed using Western blot method 
with respective phospho antibodies after these time points and after 480 min, following the 60 min 
protocol.  The bar diagrams depict the percentage inhibition of Akt phosphorylation in relation to 
the controls without the inhibitors.  Values are shown as mean±SEM.  *p≤0.05, C=control; 
W=Wortmannin. 
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9.3.3 Measurement of IL-8 and IL-6 
By application of the novel human cytokine antibody arrays we obtained a clear-cut 
evidence for the release of IL-8 as well as IL-6 in human ASM cells subjected to 
mechanical stretch compared to the unstretched cells (see Figure 9.1).  To get real 
quantitative measurements of these cytokines, we analyzed the same conditioned medium 
using ELISA.  Figure 9.6 demonstrates a significant increase of IL-8 (6782±464 vs. 
4029±389 pg/ml, p=0.01) and near significant increase of IL-6 (1436 ±191 vs. 1054 ±40.9 
pg/ml, p=0.06) as compared with control, unstretched cells. 
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Figure 9.6: Effect of mechanical stretch on the release of IL-8 and IL-6 
Conditioned medium from human ASM cells was collected after 24 h mechanical stretch and 
controls (unstreched) for the measurement of cytokine release using ELISA.  The bar diagrams 
depict IL-8 and IL-6 release in pg/ml.  Values are shown as mean±SEM.  * p≤ 0.05. 
 
To investigate whether IL-8 and IL-6 production is linked with the activation of Erk1/2, 
RhoA or Akt signalling pathways, we treated the ASM cells with inhibitors of these 
pathways and measured the release of these cytokines at 8 h after 1 h of stretch.  The results 
were almost the same for both cytokines and are summarized in Figure 9.7.  There was a 
significant decrease of IL-6 release in the presence of Erk1/2 (U0261, p=0.022) or 
RhoA/Rock (Y27632, p=0.0023), compared with stretched cells without the inhibitors 
(Figure 9.7A).  The IL-8 release was also attenuated by U0261 (p=0.0017) and Y27632 
(p=0.0077; (Figure 9.7B).  However, the Akt inhibitor Wortmannin did not block the 
release of IL-6 and IL-8; they rather increased it at 8 h (Figure 9.7). 
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Figure 9.7: Effect of inhibition of Erk1/2, RhoA/Rock and Akt pathway on the release of 
IL-6 and IL-8 
Human ASM cells were pretreated for 30 min with Wortmannin (PI3k inhibitor), U0261 (ERK1/2 
inhibitor) or Y27632 (ROCK inhibitor), followed by 1 h mechanical stretch.  The production of IL-6 
(A) and IL-8 (B) in condition medium was measured after 8 h following 1 h stretch, using ELISA.  
The bar diagrams depict cytokine release in fold change between the cells treated with the inhibitor 
and cells not treated.  Values are shown as mean±SEM.  *p≤0.05. 
 
 
 
Figure 9.8: Effect of mechanical stretch  and  inhibition of Erk1/2, RhoA/Rock and Akt 
pathway on the release of VEGF from human ASM cells 
(A) Human ASM cells were mechanically stretched for 1, 4, 8 and 24 h, and VEGF release was 
measured in conditioned medium using ELISA.  (B) Human ASM cells were pre-treated for 30 min 
with wortmannin (PI3k inhibitor), U0261 (ERK1/2 inhibitor) or Y27632 (ROCK inhibitor), followed 
by 1 h mechanical stretch.  The production of VEGF in conditioned medium was measured after 8 h 
following the 1 hr stretch, using ELISA.  The bar diagram depicts VEGF release in fold change 
between cells with and without inhibitor treatment.  Values are shown as mean±SEM.   *p≤0.05. 
 
9.3.4 Measurement of VEGF 
The human cytokine antibody array showed an increased production of VEGF in stretched 
human ASM cells compared with unstretched cells (see Figure 9.1).  Figure 9.8A 
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demonstrates the time dependent release of VEGF, which is significantly increased after 8 h 
(149.27 vs. 93.02 pg/ml, p=0.019) stretch compared with unstretched cells.  To investigate 
whether VEGF production is linked with the activation of Erk1/2, RhoA or Akt signalling 
pathway, we measured the VEGF release in conditioned medium treated from cells treated 
with inhibitors for these pathways.  Figure 9.8B show a significant (p=0.0030) decrease of 
VEGF release in the presence of the Erk1/2 inhibitor U0261, compared with stretched cells 
without inhibitor.  However, VEGF release was not blocked in the presence of the 
RhoA/Rock inhibitor, Y27632 or the Akt inhibitor, Wortmannin. 
9.4 Discussion 
Our study explored the effects of uniform biaxial cyclic mechanical stretch on the 
expression and production of direct and indirect angiogenic factors by human ASM cells 
and identifies the signalling mechanism that leads to the release of these mediators.  Protein 
array of supernatant obtained from human ASM cells shows upregulation of angiogenic 
molecules such as VEGF, angiogenin and GRO in addition to cytokines such as IL-6, IL-8, 
RANTES, MCP-1 and TNF-β.  Most of these molecules have been implicated in the airway  
 
and vascular remodelling process in chronic airway diseases, such as asthma and COPD 
(21, 22).  Enhanced release of VEGF, IL-6 and IL-8 protein in stretched ASM cells as 
compared to the unstretched was confirmed by quantitative ELISA assays.  In addition, our 
study provides an insight into the significant role of Erk 1/2 signalling pathway in the 
production of VEGF, Erk 1/2 and Rho/ROCK signalling pathways in the production of IL-6 
and IL-8 by human ASM cells subjected to cyclical stretch. 
 
Given the highly dynamic environment of the airway wall, there have been surprisingly few 
reports examining the responses of airway cells to mechanical stimuli.  Supporting the 
available evidence (15, 22-24), our data confirms the “synthetic” nature of human ASM 
cells, particularly in the state of hypercontraction.  These results when viewed in the context 
of airflow obstruction further affirm the plausible role of ASM cell-derived mediators in 
airway and vascular remodelling.  Recently, the potential of ASM cells to produce various 
cytokines and chemokines in the conditioned medium in response to a variety of mediators 
has been discussed and demonstrated by employing antibody array technique (21).  There is 
a clear distinct pattern of enhanced expression of molecules in these mechanically stretched 
cells favouring tissue remodelling.  Angiogenin and VEGF, in particular, are documented as 
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the most potent angiogenic molecules (25, 26).  Moreover, the cytokines and chemokines, 
such as IL-6, IL-8, and MCP-1, are reported to be inducers of angiogenesis (27, 28), though 
not directly but via induction of VEGF (28-30).  Evidence supports the hypothesis that 
airway pressure and secondary mechanical stretch are the primary stimuli of tracheal 
occlusion-induced lung growth (31). 
 
With the use of tracheal rings isolated from rats, Fukunga et al. (8) investigated the 
isometric contractile responses. In another study the smooth muscle strips from bovine 
tracheas were stretched in vitro to investigate the effect of a single rapid stretch on post 
stretch force and myosin phosphorylation (6) or to investigate that sinusoidal length 
oscillation and receptor activation interactively regulate the abundance of mRNA encoding 
smooth muscle actin and myosin isoforms (10).  Previous work by Kumar et al. (9) revealed 
that prolonged uniaxial cyclic mechanical stretch of human ASM cells induced the 
expression and production of IL-8.  The induced production of IL-8 was also found in a 
study by Li et al. (12).  Our data that biaxial cyclical mechanical stretch induced not only 
the production of IL-8 but also of IL-6, MCP-1, TNF-β and RANTES and, the angiogenic 
molecules VEGF, angiogenin and GRO confirms and adds onto the reports.  Our study 
based on the stretch model clearly demonstrates a role for the Erk 1/2 pathway in VEGF 
release in these cells.   Additionally, the production of the indirect angiogenic factors, IL-6 
and IL-8 is dependant on the RhoA/ROCK pathway and Erk 1/2 pathway as evident from 
the blockage of release of these proteins with the pre-treatment of the cells with the 
respective inhibitors.  This supports the finding of Kumar et al. (9) wherein the inhibition of 
ERK1/2 and p38 MAP kinase inhibited the expression and production of IL-8 in these cells.  
Akt signalling pathway has been implicated in survival response (32, 33) and this pathway 
is activated under cyclical stretch of cells in vitro.  Though this pathway is activated in our 
model, we do not see a role of it in the release of VEGF; a known survival factor.  
Moreover, inhibition of this pathway with Wortmanin did not block the release of VEGF, 
IL-6 or IL-8 from stretched cells suggesting that an alternative signal transduction 
mechanism may be at work.  Furthermore, Wang et al. show the importance of 
RhoA-ROCK signalling for serum response factor (SRF)-dependent transcription of smooth 
muscle-specific genes, the pathway which plays also a well-defined role in controlling 
F-actin polymerization and stress fibres formation in cultured cells (11).  That study 
suggests inhibition of activation of RhoA in cultured cells upon stretch in contrast to the 
reported data indicating that RhoA activation in ASM cells under mechanical strain (13).  
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Though, we could observe the activation of p38 upon cyclical mechanical stretch our 
findings show that Y27632 inhibited contraction-induced p38 phosphorylation, suggesting 
that RhoA/Rho kinase activation was upstream of p38 and induced its activation similar to 
what has been shown earlier in stretching of rabbit facial vein (34). 
 
Cytoskeletal changes and functional consequences of mechanical strain on human ASM 
cells have been investigated by a number of groups, we are among the few who have 
reported on the synthetic phenotype of human ASM cells in culture in relation to different 
mediators of asthma and now we report under the condition of cyclical strain.  Further 
studies are needed to demarcate the complexity in signalling events and their independent 
role in ASM phenotype in the conditions such as in asthma.  Moreover, the limitations of an 
in vitro model need to be taken into account when extrapolating the results to an in vivo 
diseased condition.  Already difference in the data emerging between uniaxial and biaxial 
stretch (11, 13) have to be properly reconciled.  Recently a study (35) has attributed the 
difference in response to stretch in vitro to the fundamental differences in the ASM 
environment in asthma and in culture.  Even the most sophisticated technology cannot 
mimic the complicated interactions among cells, tissues and organs that occur in humans 
and animals. 
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Chapter 10:  General Discussion 
 
Airflow obstruction in chronic airway disease has been shown to be associated with airway 
and pulmonary vascular remodelling. Repetitive injury/repair of airway epithelium and 
associated remodelling processes are common features in asthma and chronic obstructive 
pulmonary disease (COPD).  Regulated repair is a crucial event for restoration of barrier 
function and reduction of inflammation.  A number of growth factors have been implicated 
in regulating this epithelial repair processes.  The data presented in the first half of the thesis 
focussed on unravelling molecular mechanisms involved in epithelial injury and repair 
where our results suggests a role for the IGF-I/IGFR-I and FGF/FGFR-1 system in 
modulating bronchial epithelial repair and hence airway remodelling.  Increase in size and 
number of blood vessels both within and outside the smooth muscle layer as well as 
hyperaemia of bronchial vasculature are contributing factors in airway wall remodelling in 
patients with chronic respiratory disease.  Results included in this thesis clearly support the 
notion of ongoing complex mechanisms leading to angiogenesis/vascularisation and 
vascular dilatation. Emerging evidences indicate that vascular changes directly add to the 
airway narrowing and hyperresponsiveness by exudation and transudation of pro-
inflammatory mediators, cytokines and growth factors (1, 2).  This facilitates trafficking of 
inflammatory cells. We have further shown that specific angiogenic and hyperpermeability 
factor like VEGF, could directly contribute to pathological events resulting in vascular 
remodelling in the airways.  Moreover, various pro-inflammatory cytokines (IL-1β and 
TNF-α) and mediators (ANG II and ET-1) synthesized during the disease process enhance 
expression and secretion of the angiogenic molecule (VEGF) that directly participates in 
vascular remodelling.  In addition, nitric oxide seems to perpetuate the expression and 
secretion of VEGF in ASM cells for paracrine action.  Finally, simulating the in vivo state 
of hypercontractility seen in chronic airway diseases, we established an in vitro model of 
cyclical stretch and observed an enhanced expression of direct and indirect angiogenic 
molecules in ASM cells clearly advocating for an important role of these cells in ongoing 
angiogenic processes during airway diseases. 
10.1 Epithelial injury/repair and bronchial remodelling 
It is now well established that particles from cigarette smoke cause damage to the airways, 
particularly the lining epithelium (3, 4).  Both non-symptomatic smokers and patients with 
General Discussion  Chapter 10 
 189
COPD show signs of damage and repair to the epithelial surface in the form of a denuded 
epithelium and squamous metaplasia (2).  Epithelial injury is normally followed by a 
complex repair process that comprises subsequent epithelial migration, proliferation, and 
differentiation and cell death (5).  The primary aim is to rapidly restore the denuded 
epithelium and this process has been reported to be mediated via growth factors, such as 
Transforming Growth Factors-β (TGF-β), Keratinocyte Growth Factor (KGF), Epidermal 
Growth Factor (EGF) and their receptors (6-8).  The processes of normal and abnormal 
wound healing as a response to injury have been studied extensively (9-13).  The 
environment of cytokines and growth factors, (myo)fibroblast-derived extracellular matrix 
and adequate capillaries facilitate epithelial cell proliferation and migration, leading to 
wound closure (13).  Within the airways, the bronchial epithelium, subepithelial 
myofibroblasts and ASM cells are the major cell types involved in tissue repair processes. 
 
Our results add up to the available evidence that indeed IGFs and FGFs have the potential to 
stimulate epithelial repair similar to EGFs (14, 15) and defensins (5), which are innate 
immune factors present in airway surface liquid and make up part of the lung's natural 
defence.  The increased bronchial IGF-I expression in COPD patients and its receptor 
localization in epithelium in addition to the wound repair potential of IGF-I advocate for its 
crucial role in tissue repair mechanisms during smoke-induced lung injury.  Considering our 
data in this context, we conclude that ASM cell-derived IGF-I acts in a paracrine fashion on 
the IGFR-I positive epithelial cells resulting in their proliferation and thus contributing to 
the airway remodelling during COPD.  Various studies suggest a differential localization 
and expression pattern of IGF-I and IGF-II in foetus, infants and adults (16-19) and with 
advancing gestational age the presence of IGF-I decreases in the mesenchyme and cuboidal 
epithelium (19) but IGF-I is markedly increased in neonates with bronchopulmonary 
dysplasia and respiratory distress syndrome (19).  This indicates that there may be an re-
emergence of foetal pattern of IGF-I expression during intense repair after lung injury, as 
also reported in hyperoxic rat lung injury (20).  Additional support for the involvement of 
IGF-1 comes from our observation that levels of IGF-I were inversely correlated with the 
disease severity (as reflected by lung function), suggesting for the repair mechanisms in 
analogy to those during foetal development.  Similarly, in our previous study (21) we found 
up-regulated FGF-1, FGF-2 and FGFR-1 expression in bronchial epithelium indicating that 
such compensatory mechanisms are also active in COPD. 
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Figure 10.1: Autocrine and paracrine mechanisms of FGFs and IGFs mediated 
epithelial wound closure 
Note that the injured or activated epithelium signals the other resident and infiltrating cells to 
release FGF-1,2 and IGF-I,II, which could act in autocrine or paracrine fashion on the injured 
epithelium and enhance the repair process. 
 
 
Our current results support the notion that increased bronchial expression of FGF-1, FGF-2 
and FGFR-1 in patients with COPD could participate in regulating the process of airway 
remodelling.  The correlation of clinical data (lung function) with the epithelial Ki-67 
staining suggests an initiation of the repair process, which in turn may be successful 
depending upon the availability of the necessary factors and host conditions. Apart from 
stopping smoking, modulation of these pathways should be considered in the development 
of therapeutic interventions aimed at restoring the epithelial integrity and hence prevent or 
even reverse chronic airflow limitation in COPD.  Figure 10.1 is a schematic representation 
of the possible mechanisms involved in bronchial epithelial repair mediated through growth 
factors. 
 
10.2 Vascular remodelling and role of airway smooth muscle derived 
mediators 
The current thesis supports the hypothesis that ASM cells are active sources of mediators 
relevant to the pathogenesis of airway disease.  Pro-inflammatory cytokines such as IL-1β 
and TNF-α that are associated with chronic inflammation of the airways drive production of 
VEGF by ASM cells (Chapter 4).  Similarly, vasoactive peptides, ANG II and ET-1 
(Chapter 7), or cyclic mechanical stretch (Chapter 9) enhance VEGF release which via 
paracrine mechanisms in the vicinity of bronchial endothelial cells may perpetuate the 
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bronchial vascular remodelling that has been documented in asthma and COPD.  The 
relative importance of each cell type for VEGF release under pathophysiological conditions 
is unknown.  However, we and others have demonstrated that human ASM cells express 
VEGF both in vitro and in vivo (Chapter 5 and 6) in the intact myobundles of patients with 
COPD (22-24).  These latter findings suggest that VEGF release by human ASM cells in 
culture is not an artefact.  Rather, ASM represents a possible pathophysiologically 
important pool of VEGF available during airway inflammation that may be amenable to 
therapeutic intervention. 
 
Increasing experimental evidence suggests that inhibition of VEGF activity via blockade of 
its receptors has a potential therapeutic value by decreasing angiogenesis and vascular 
remodelling (25).  This approach reverses pathophysiological symptoms including airway 
hyperresponsiveness and inflammation in a mouse model of asthma (26).  One likely 
mechanism for the effectiveness of this approach could be prevention of VEGF-induced 
vascular permeability, thereby suppressing inflammation by reducing vascular leakage and 
migration of cells and mediators into the airways.  However, the inhibition of VEGF could 
be beneficial or detrimental depending on the type of chronic airway disease.  For example, 
some reports suggest that increased levels of VEGF are associated with airflow limitation in 
bronchitis and decreased levels with airflow limitation and alveolar destruction in patients 
with emphysema (27, 28).  Likewise, long-term glucocorticoids treatment in patients with 
asthma significantly affects airway remodelling by reducing basement membrane thickness, 
and reducing indices of submucosal vascularity, including blood vessel number and total 
vascular area (29, 30).  Our findings that dexamethasone completely inhibits the expression 
and release of the angiogenic factor VEGF from cultured ASM cells would support this 
notion.  The effect of glucocorticoids on airway remodelling, however, remains 
controversial.  Inhibition of VEGF production by ASM cells may be one mechanism by 
which glucocorticoids might affect tissue remodelling. 
 
Current in vivo and in vitro data indicate that interactions between various airway cells like 
smooth muscle cells, endothelium, myofibroblasts and inflammatory cells via growth 
factors and cytokines and other mediators contribute in vascular remodelling during 
different pathophysiological conditions (31-34) as its clearly depicted in a schematic 
diagram (Figure 10.2). Undoubtedly, more research focus has been recently directed 
towards unravelling molecular events underlying the bronchial vascular remodelling that 
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may directly or indirectly participate in the pathogenesis of chronic lung diseases.  Though, 
the precise nature of these events is far from clear, our study sheds light on potential 
mechanisms of vascular remodelling that could take place in chronic airway diseases. 
 
 
Figure 10.2: Central dogma of airway smooth muscle cells in bronchial and vascular 
remodelling 
Schematic illustration that depicts various cellular interactions and underlying molecular events, 
where human ASM cells are the central mediators of the airway remodelling in chronic airway 
diseases.  Note the flow of events from stimuli to ECM alteration, epithelial repair, vascular 
remodelling and bronchial hyperresponsiveness. 
 
Moreover, our results (Chapter 8) suggest that the nitric oxide pathway may modulate the 
synthesis of VEGF during airway inflammation and subsequently vascular remodelling in 
chronic airway diseases. The induction of VEGF synthesis by nitric oxide may be of great 
importance in the maintenance of vascular homeostasis and in the response to endothelial 
injury and during vascular remodelling in the airways.  Because nitric oxide and VEGF 
reciprocally enhance their synthesis, this interaction may play a significant role.  A variety 
of signalling pathways have been implicated in the upregulated production of VEGF in 
ASM cells.  Prostaglandin (PGE)2-stimulated VEGF production has been proposed to be 
mediated via cAMP activation (35).  Knox et al. reported that bradykinin activates PKC, 
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which then induces COX-2.  The major cyclo-oxygenase (COX) product, PGE2 then 
activates VEGF via cAMP that in its turn activates e.g. PKA and subsequently activate 
MEK1/2, ERK1/2, CREB pathways in human ASM cells (35).  Our study (Chapter 9) based 
on the stretch model clearly demonstrates a role for the Erk 1/2 pathway in VEGF release in 
these cells.  Additionally, the production of the indirect angiogenic factors IL-6 and IL-8 is 
dependant on both RhoA/ROCK and Erk 1/2 pathways.  Furthermore, we observed Akt 
phosphorylation in our cyclic stretch model, but we did not see the role of Akt signalling 
pathway in the expression and release of VEGF in human ASM cells. Therefore, it is quite 
possible that Akt signalling pathway being implicated in survival responses (36, 37) is also 
involved in stress/survival responses under cyclical stretch conditions in our in vitro model.  
 
10.3 Limitations of in vitro models 
Cells in culture-based in vitro models are cost effective and they are important tools to 
understand the underlying molecular events in a variable-controlled environment. However, 
there are limitations to these cultured cell based models due to several inherent conditions.  
Monolayers of cells, such as H292 and primary human ASM cells in culture may loose their 
phenotype due to culture conditions, coated matrix and due to lack of tissue 
microenvironment. The number of passages would also affect cells in culture.  Although 
intrinsic characteristics of the individual cell type in relation to disease may be retained (38, 
39) if obtained from asthmatics or other airway diseases, many of them may loose this 
property over a long period of time  in culture. 
 
Caution should be exercised when extrapolating the results from a study based on cell lines 
or even primary cell in relation to the in vivo situation.  The cell line NCI-H292, derived 
from a human lung mucoepidermoid carcinoma cells, has growth characteristics in culture 
that could influence the response to growth factors.  However, NCI-H292 cells have been 
successfully used in many studies (5, 40) and we do not believe that using other cell 
line/cells would change the results significantly; at least the repair experiments have been 
conducted in different epithelial cells and the results were not significantly different from 
each other (40).  In vitro wound repair model that we have developed and used in this thesis 
was primarily based on NCI-H292 cells and it was used only to demonstrate the potential of 
IGFs/FGFs in repair in relation to controls using the same cell line. Additionally, primary 
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bronchial epithelial cells could be used in future studies to confirm our data obtained with 
this cell line.  
 
We studied the angiogenic potential of the stimulated ASM conditioned medium using a 
cell-based system of pulmonary artery endothelial cells or HUVEC.  This is a monolayer 
cell system, which could be used to assess the proliferation of endothelial cells.  However, 
angiogenesis involves cell migration, proliferation and then tube formation.  Future studies 
using a sophisticated model reflecting in vitro or in vivo angiogenesis needs to be employed 
to investigate further the role of these ASM-secreted mediators.  Recently, a 3D in vitro 
model of angiogenesis has been developed in this area of research (41). 
 
Our in vitro cyclic mechanical stretch model based on human ASM cells is a novel 
approach to extend the hypercontractile responses observed in vivo conditions in patients 
with chronic airway diseases and in this regard few other studies have also been attempted 
before  (42-45).  However, being realistic is to understand that this model is an isolated 
system of cell culture wherein the rate and force of contraction is regulated via a computer 
controlled apparatus.  This system cannot guarantee a true representation of in vivo 
conditions existing in disease states, such as asthma.  However, the interesting part of this 
model is its dynamic environment in which there is an alternate phase of contraction and 
relaxation of the cells under study.  This helps us to at least have an idea of the possible 
underlying mechanisms in these conditions.  Recently, the difference in response to stretch 
in vitro has been attributed to the fundamental differences in the ASM environment in 
asthma and in culture (46).  Even the most sophisticated technology cannot mimic the 
complicated interactions among cells, tissues and organs that occur in humans and animals.  
Scientists must understand these interactions before confirming a new hypothesis or 
treatment.  The final test, however, has to be done in a whole, living system. 
  
10.4 Clinical relevance and implications for future research 
There has been a constant search for effective treatment strategies to prevent the progression 
of airflow obstruction or to treat debilitating and distressing symptoms of chronic 
respiratory conditions.  Novel, possibly broad-acting, anti-inflammatory compounds include 
specific inhibitors of phosphodiesterase 4 (PDE 4), 5-lipoxygenase (leukotriene synthesis 
blockers), COX (prostaglandin synthesis blockers) and leukotriene receptors (47, 48).  
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However, more specific therapies directed against inflammation and remodelling without 
adverse effects are needed.  Current therapies offer symptom control only but not an 
effective cure.  A significantly growing area of unmet medical research where there is a 
constant need to develop strategies in disease modifying and curative treatments. 
 
Different levels of intervention could be explored.  The currently examined interventions 
include:  
1. Scavenging and neutralisation of proteins by binding to soluble receptors or 
neutralising antibodies,   
2. Inhibition of protein binding to its receptor by small compounds or incomplete and 
non-activating cytokines,  
3. Inhibition of protein activation (processing of preprotein into mature protein), and 
4. Inhibition of signal transduction and transcription via inhibition of receptor-
dependent tyrosine kinases, MAPK, or nuclear factor κB (NFκB) and its inhibitors 
IKK and IκB and via antisense mRNA or small interference (si) RNA molecules for 
growth factors or cytokines.   
 
A number of potential drugs are still in preclinical development or in clinical trial. 
 
Table 10.1: Examples of VEGF, VEGFR and FGFR1 antagonists in clinical trial 
potentially useful for the treatment of chronic airway disease* 
 
Name  Type of compound  Function 
Bevacizumab (Avastin®) Humanized mouse IgG1 anti 
VEGF antibody 
inhibits binding VEGF to 
VEGFR 
VEGF Trap VEGFR1 and VEGFR2 
binding domains linked to 
IgG1 constant region 
Neutralisation VEGF 
CEP-7055 indenopyrrolocarbazole 
derivate 
inhibits pan-VEGFR kinase  
 
SU 6668 IgG2a  fusion protein inhibits VEGFR2, FGFR1, 
PDGFRb tyrosine kinase 
PTK 787    
Based on reference (49) 
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In this context, this thesis and our published articles shed light towards the development of a 
novel therapeutic target in chronic respiratory conditions.  Several studies, including ours 
(22, 50), have pointed out to the involvement of VEGF/VEGFR in pulmonary and vascular 
remodelling and inflammation.  VEGF transgenic mice showed alveolar vascular and 
airspace remodelling as well as increased numbers of alveolar macrophages, or a Th2-type 
airway inflammation in a murine asthma model (51).  An in vitro study demonstrated that 
VEGF induces monocyte migration via VEGFR1 expressed by monocytes (52).  Therefore, 
such inhibitors may be of potential use for the treatment of vascularisation as seen in asthma 
or specific subtypes of COPD, like chronic bronchitis but not in emphysema as pointed out 
in early chapters (chapter 4).  Several drugs have been developed to reduce tumour growth 
and metastasis by impairing the neovascularisation.  Antagonists include those which have 
entered in clinical trials and in preclinical investigations (Table 10.1).  Among those in 
clinical trial are bevacizumab (Avastin®), CEP-7055, VEGF Trap and PTK787 (53).  Many 
other small molecules as VEGFR inhibitors are being developed for clinical therapy (54, 
55).  SU6668 is a IgG2a fusion protein inhibiting tyrosine kinase activity of FGFR1, 
VEGFR2 and platelet growth factor receptor-B.  SU6668 was demonstrated to inhibit 
tumour growth, lung cancer metastasis and tumour vascularisation (56).  Its broader 
spectrum of inhibitory effects may be more effective in treating airway remodelling in 
COPD.   Despite these data, not much has been published on such treatments in asthma or 
COPD.  Also the redundancy of the VEGF-VEGFR system may temper applicability and 
efficacy of VEGF/VEGFR inhibitors (57).  In addition, for example, in patients with 
emphysema, inhibitors of apoptosis are needed where, in contrast to chronic bronchitis, 
expression of hypoxia inducible factor VEGF and VEGFR2 may be stimulated to overcome 
endothelial and epithelial cell death and improve vascular restoration (58-60). Hence, 
treatment with VEGF/VEGFR inhibitors should be further investigated and may be 
restricted to specific subtypes of chronic lung diseases. Furthermore, keeping in view of the 
role of IGFs and FGFs in bronchial epithelial repair as demonstrated in this thesis, it would 
be tempting to explore the possibilities to extend the therapeutic potential of these growth 
factors in chronic airway diseases, such as in COPD. 
 
10.5 Concluding remarks 
Airway remodelling in chronic respiratory diseases has been extensively documented while 
the focus lately has been also towards examining vascular remodelling in chronic airway 
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diseases.  This thesis is among the first few to explore the underlying mechanisms in this 
aspect.  New data in this area are very exciting and will continue to provide input into the 
development of new medications, anti-inflammatory drugs and drugs directed at the 
pathophysiology of these chronic respiratory conditions.  Alternative therapeutic approaches 
are needed at this time where we have reached a ceiling in the improvement of symptoms 
with the current therapies.  Physiologic outcomes such as FEV1 are long established and 
widely accepted standard but currently debated.  Appropriate endpoints to assess the clinical 
efficacy needs to be developed while novel and complex endpoints will need to be assessed.  
Newer outcomes that include a broader range of parameters will be more suitable in case of 
COPD.   For example, the BODE index that also includes physical strength in the 6 minutes 
walking test would take into account that COPD is a systemic disease.  Such measures will 
be better to test the effectiveness of a drug that improves all aspects of the disease.  
Otherwise, the new drug should affect a specific and essential part of the disease, and in 
combination with one or more other drugs, address all aspects of the disease. 
  
Cigarette smoking and exposure to air pollution is associated with extensive injury and 
reparative changes alongside the inflammatory response.  The capacity of repair declines 
with age.  We need to probe whether enhancement of the reparative mechanism is a suitable 
therapeutic goal.  The first part of the thesis harps on the possible role of the growth factors 
such as IGFs and FGFs in bronchial epithelial repair after injury.  Future studies in the 
direction of wound repair would determine novel therapeutic approaches in this area. 
 
Over the years, the role of ASM cells in airway remodelling has been established. In this 
thesis, we extend the ASM biology to include it in the perpetuation of angiogenesis and 
vascular remodelling via enhancing mediators, such as VEGF involved primarily in these 
processes.  We show that ASM cells play a central role by responding to mediators of 
asthma and COPD and expressing angiogenic molecules.  Recent investigations also point 
to the potential molecules involved in these processes, including growth factors and cyto- or 
chemokines.  Specific antagonists capable of reducing growth factor and cytokine 
expression or signalling pathways are already available or being developed.  Some of these 
drugs seem to be effective in different inflammatory diseases or in reducing tumour growth. 
However, these antagonists have not yet been tested extensively with regard to reducing the 
remodelling processes in chronic inflammatory lung diseases.  Experimental models and 
expression studies suggest that anti-VEGFR strategies could be of importance to use in 
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patients with emphysema.  Feedback on the respiratory impact from current therapies using 
anti-VEGF measures in other diseases would be crucial.  This suggests the need of 
stratification of antagonist therapy.  However, a complete block of cytokine-driven or 
growth factor-dependent repair mechanisms may be disadvantageous as defence reactions to 
infection being very crucial may be impaired.  Furthermore, other drugs like retinoids and 
even growth factors may provide restoration of lung tissue structure.  Such approaches, 
however, will have to wait for the initial results based on growth factor or cytokine 
antagonist therapy available for chronic lung diseases. 
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Summary   
 
Summary in English 
 
The work embodied in this thesis mainly focuses on the molecular mechanisms underlying 
bronchial angiogenesis and tissue remodelling that eventually contribute to the airway 
remodelling, a hallmark in the pathogenesis of chronic lung diseases. The thesis constitutes of 
two main parts; the first two major chapters deals with bronchial epithelial injury and repair 
mechanisms during airway remodelling and the second part spanning over six chapters covers 
the aspects of bronchial vascular remodelling studied using both human lung tissue in situ 
(immunohistochemistry) as well as in vitro (ASM cells). The data presented in this thesis 
illustrate the role of a number of cytokines and growth factors in airway remodelling and can 
be summarised as below: 
 
Chapter 1, being the general introduction covers the review of current literature and 
introduces the two main sections: 1. Bronchial remodelling and 2. Vascular remodelling.  It 
provides an overview of the clinical characteristics, pathogenesis of chronic airway 
diseases, COPD and asthma in relation to airway remodelling. The structural abnormalities 
as observed in epithelial repair, bronchial remodelling and vascular changes are described.  
Documented evidence regarding microvascular changes and altered bronchial vessels are 
presented.  The role of cytokines and growth factors in airway as well as vascular 
remodelling and pulmonary angiogenesis in airways are introduced.  The role of ASM 
beyond its established profile in the process of airway vascular remodelling and cellular 
interaction is discussed.  In vitro models used in this project to decipher the bronchial and 
vascular remodelling are explained.  The role of growth factors such as insulin like and 
fibroblast growth factors in bronchial repair and the role of mediators of chronic airway 
disease such as TNF-α, IL-1β, ANG II, ET-1 or stretch in vascular remodelling is 
hypothesized. An extensive review of literature has been included on the topic of 
angiogenesis and vascular remodelling in relation to mainly VEGF and its receptors but 
other cytokines are also included in detail. Finally, in view of the current literature, a 
hypothesis was proposed to examine the expression pattern and the role of various key 
growth factors and cytokines in tissue repair and remodelling processes in the airways. 
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In Chapter 2, we focussed on the role of the IGF-I/IGFR-I system in bronchial epithelial 
repair and hence airway remodelling in COPD patients.  We investigated the bronchial 
expression pattern of IGF-I and IGFR-I in COPD patients and correlated the expression 
levels with corresponding lung function data.  Using an in vitro epithelial wound repair 
model in NCI-H292 cells, we further assessed the mitogenic effects of IGFs.  Enhanced 
expression of IGF-I was localized in airway smooth muscle and vascular smooth muscle 
cells in patients with COPD as compared to those without COPD.  IGFR-I was localized in 
epithelial cells and alveolar macrophages and its expression levels did not differ between 
the two groups.  Expression of IGF-I in ASM and VSM cells inversely correlated with the 
respective lung function data (FEV1/FVC) in two groups.  In vitro experiments revealed that 
both IGF-I and IGF-II induced cell proliferation (2-5 folds) and growth (2-4 folds) of ASM 
as well as NCI-H292 cells.  Our wound repair experiments demonstrated accelerated and 
significant closure of a mechanically injured confluent monolayer of NCI-H292 cells at 
72 h of IGF treatment.  Taken together, our results suggest that the IGF-I/IGFR-I system play 
a pivotal role in epithelial repair processes and hence contribute to the airway remodelling in 
COPD. 
 
In Chapter 3, we explored the proliferative activity of bronchial epithelial cells in COPD 
(by Ki-67 staining in airway epithelium) in relation to lung function (FEV1 values) and 
examined the mitogenic role of FGF-1 and FGF-2 and their wound closure potential in an in 
vitro wound repair model, using the bronchial epithelial cell line (NCl-H292).  Ki-67 
Labelling Index values showed significant doubling in COPD patients as compared to non-
COPD and inverse correlation with FEV1 values (r = -0.43; p<0.03).  Both FGF-1 and FGF-
2 increased cell proliferation (3-7 folds) after 24 h and cell counts (2 folds) after 48 h.  Both 
FGF-1 and FGF-2 also increased proliferation (3-7 folds) as assessed by [3H]thymidine 
incorporation and cell counts (up to 2 fold, after 48 h of incubation).  Analysis of images of 
the wounds taken at different time points (24, 48, 72 h) revealed that injured epithelial 
monolayers showed enhanced wound closure with FGF-1 (67%) or FGF-2 (61%) as 
compared to controls (38%) after 72 h.  Specific inhibitors of ERK1/2 (U0126) and FGFR-1 
(SU5402) completely blocked FGF-1- and FGF-2-induced ERK1/2 activation after 15 min.  
FGF-1 stimulates wound closure by 1.8 times, which was inhibited over 90% by U0126 or 
over 60% by SU5402. FGF-2 stimulates wound closure by 1.6 times which was inhibited 
over 75% by U0216 or 50% by SU5402.  Similarly, the phosphatidylinositol-3-kinase 
inhibitor, LY294002 blocked epithelial repair in FGF-1 (28%) and FGF-2 (22%) treated 
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cells.  The increased bronchial epithelial expression of fibroblast growth factors and their 
receptor, FGFR1, in COPD and the higher number of proliferating bronchial epithelial cells 
in COPD suggest a potential role for the FGF/FGFR-1 system in bronchial airway 
remodelling and repair in patients with COPD; this is further supported by the mitogenic 
response of NCI-H292 cells to FGFs and the wound repair potential of FGF-1 in vitro. 
 
We further explored in Chapter 4 the vascular remodelling component in chronic 
bronchitis and emphysema. Based on the available evidence, we hypothesize that in chronic 
bronchitis, expression of VEGF and VEGFR-2 expression leads vascular remodelling, 
which is inefficiently compensated by the low expression of VEGFR-1.  In subjects with 
emphysema, however, VEGFR2 expression was lower.  Preferential activation of VEGFR-1 
resulted in higher MMP activity, alveolar destruction and endothelial apoptosis.  Hence, the 
balance between VEGF, VEGFR-1 and VEGFR-2 are critical in the pathogenesis of COPD 
subtypes. 
 
In Chapter 5, we described the expression of VEGF and its receptors VEGFR-1 (flt-1) and 
VEGFR-2 (KDR/flk-1) in central as well as peripheral lung tissues obtained from (ex-) 
smokers with or without COPD. VEGF, Flt-1 and KDR/Flk-1 immunostaining was 
localized in vascular and airway smooth muscle (VSM and ASM) cells, bronchial, 
bronchiolar and alveolar epithelium and macrophages.  Additionally, endothelial cells 
throughout the lungs abundantly expressed Flt-1 and KDR/flk-1. VEGF expression was 
enhanced in VSM cells of microvessels in the bronchial mucosa and submucosa as well as 
in ASM cells in COPD patients as compared to non-COPD. VEGF expression was more 
intense in COPD in the intimal and medial VSM of the peripheral pulmonary arteries 
associated with the bronchiolar airways. KDR/Flk-1 expression was enhanced in endothelial 
cells, intimal and medial VSM of the peripheral pulmonary arteries, whereas Flt-1 
expression was higher in endothelial cells only. Furthermore, VEGF staining was 
significantly increased in bronchiolar, alveolar epithelium and bronchiolar macrophages as 
well as the Flt-1 receptor in the bronchiolar epithelium.  VEGF expression in bronchial 
microvessels in the mucosa, bronchial ASM cells and bronchiolar epithelium inversely 
correlated with FEV1 values.  Our results implicate VEGF and its receptors, Flt-1 and 
KDR/Flk-1, in peripheral vascular and airway remodelling processes in COPD. 
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Chapter 6 assesses the role of proinflammatory mediators such as IL-1β and TNF-α 
towards airway vascular remodelling. We investigated IL-1β and TNF-α-induced secretion 
and expression of VEGF by human ASM cells in culture.  IL-1β (0.5 ng/ml) and TNF-α (10 
ng/ml) each increased VEGF mRNA expression in human ASM cells, reaching maximal 
levels between 16-24 h and 4-8 h, respectively. Both cytokines also induced a time 
dependent release of VEGF, which was not associated with increased ASM cell 
proliferation.  Preincubation of cells with 1 μM dexamethasone abolished the enhanced 
release of VEGF by TNF-α. These data suggest that human ASM cells express and secrete 
VEGF in response to pro-inflammatory cytokines and that VEGF may participate in 
paracrine inflammatory mechanisms of vascular remodelling in chronic airways disease. 
 
To further explore the role of ASM in bronchial angiogenesis and remodelling, we 
examined in Chapter 7 the effects of conditioned media from ASM cells on the 
proliferation and growth of pulmonary artery endothelial cells.  Angiotensin II (ANG II) and 
endothelin-1 (ET-1) are potent vasoconstricting circulatory hormones implicated in asthma.  
ET-1, but not ANG II, induced ASM cell proliferation and DNA biosynthesis as indicated 
by increased [ H]thymidine incorporation.  Northern blot hybridization showed that both 
ET-1 and ANG II induced the expression of two mRNA species of 3.9 and 1.7 kb encoding 
VEGF in cultured ASM cells reaching maximal levels between 4-8 h of incubation.  
Induced expression and release of VEGF declined after 8 h of ANG II incubation and the 
levels remained elevated in the case of ET-1.  Furthermore, conditioned medium from ASM 
cells treated for 8 h with ET-1 resulted in pulmonary artery endothelial cell proliferation as 
assessed by the [ H]thymidine incorporation assay, and cell counts after 24 h.  Our results 
suggest that proliferating ASM cells produce angiogenic factors, like VEGF that could 
induce pulmonary artery endothelial cell growth resulting in bronchial angiogenesis and 
remodelling. 
 
In Chapter 8, we investigated the effects of nitric oxide pathway on the pro-inflammatory 
cytokine IL-1β-induced expression and secretion of VEGF and PlGF from cultured porcine 
ASM cells.  IL-1β did not affect PlGF release, but augmented VEGF release at 24 h from 
399±11 pg/ml (control) to 968±123 pg/ml.  This VEGF release was inhibited by L-NAME 
(532±52 pg/ml) and restored by L-arginine (1529±287 pg/ml).  IL-1β induced expression 
(1.8 fold vs. control) of VEGF mRNA at 4 h, but no increase was detected at 24 h.  IL-1β 
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induced expression of VEGF mRNA was attenuated by L-NAME and augmented by L-
arginine at 4 h.  Restoring the nitric oxide pathway by L-arginine in L-NAME-treated cells 
elevated expression of VEGF.  However, the IL-1β-induced endothelial cell proliferation 
was not affected by interference with nitric oxide pathway.  Our findings suggest that the 
nitric oxide pathway modulates the synthesis of VEGF and this may subsequently result in 
vascular remodelling in chronic airway diseases. 
 
Chapter 9 employs a cyclical stretch model to investigate the expression profile of proteins, 
signalling pathways and the secretion of angiogenic molecules in human ASM cells in 
culture.  This in vitro model revealed that hypercontractile human ASM cells release VEGF, 
angiogenin and cytokines, such as interleukin (IL)-6, IL-8, monocyte chemotactic protein 
MCP-1, RANTES, TNF-β and growth-related oncogene.  VEGF secretion, as assessed by 
ELISA, was significantly higher after 8 h and 24 h, as compared to controls.  Western blot 
analysis showed robust phosphorylation of ERK 1/2 after 15 min and P-Thr-Akt and P-Ser-
Akt after 30 min of stretch.  Respective blockers of Akt (wortmannin), ERK 1/2 (U0261) 
and Rho/ROCK (Y27632) pathways revealed significant inhibition of VEGF release only 
with U0261 after 8 h.  Furthermore, cyclical stretch induced significant release of IL-6 and 
IL-8 after 24 h that was inhibited by blockers of ERK 1/2 and RhoA/ROCK pathways.  Our 
results demonstrate that the hypercontractile human ASM cells secrete angiogenic 
molecules via activation of the ERK1/2 pathway, which, in turn, could contribute to 
vascular and airway remodelling. 
 
Finally in chapter 10, a comprehensive discussion has been put forward in the light of our 
findings and the current literature on molecular interactions that possibly underlie the 
pathogenesis of bronchial and vascular remodelling during chronic airway diseases.  
 
In conclusion, we have demonstrated that; 1) IGF-I/IGFR-I and FGF/FGFR-1 systems play 
a pivotal role in epithelial repair and airway remodelling during chronic airway diseases,  2) 
the enhanced expression of VEGF and its receptors (Flt-1 and KDR/Flk-1) contribute to 
bronchial angiogenesis in COPD, 3) ASM cells express and release biologically active 
VEGF in response to pro-inflammatory cytokines as well as vasoactive peptides, 4) Nitric 
oxide donors augment interleukin-1β induced VEGF expression in human cultured ASM 
cells and 5) mechanically stretched airway smooth muscle cells produce pro angiogenic 
molecules via ERK1/2 signalling pathway. It is anticipated that our findings may be useful 
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in selectively developing therapeutic strategies to achieve regulated bronchial angiogenesis 
and diminished tissue remodelling in patients with chronic airway diseases, like COPD and 
asthma. 
 
Samenvatting (Summary in Dutch) 
 
De studies beschreven in dit proefschrift richten zich met name op de moleculaire 
mechanismen van bronchiale angiogenese en veranderingen in het luchtwegweefsel. Deze 
processen liggen mogelijk ten grondslag aan de luchtwegveranderingen die een kenmerk 
zijn van de pathogenese van chronische luchtwegziekten. Het proefschrift bestaat uit twee 
delen. Het eerste deel bestaat uit twee hoofdstukken waarin schade en herstelmechanismen 
in bronchiaal epitheel zijn bestudeerd die kunnen optreden tijdens luchtwegveranderingen. 
Het tweede deel beslaat de volgende zes hoofdstukken waarin aspecten van bronchiale 
vasculaire veranderingen zijn bestudeerd in zowel menselijk longweefsel door middel van 
immunohistochemie, en in gekweekte luchtweg gladde spiercellen (in vitro ASM cellen). 
De in dit proefschrift gepresenteerde gegevens illustreren de rol van een aantal cytokinen en 
groeifactoren bij luchtwegveranderingen. In de volgende paragrafen worden de resultaten 
beschreven. 
 
Hoofdstuk 1 is onderverdeeld in twee secties namelijk 1) bronchiale herstructurering en 2) 
vasculaire herstructurering. Het geeft een overzicht van de klinische kenmerken, 
pathogenese van de chronische luchtwegaandoeningen COPD en astma in relatie tot 
luchtwegherstructurering. De structurele veranderingen die plaatsvinden door epitheliale 
herstelprocessen, bronchiale herstructurering en vasculaire veranderingen worden 
beschreven. De recente literatuur aangaande micro-vasculaire veranderingen en  
vaatveranderingen in de bronchiale wand wordt besproken. Verder wordt de rol van 
cytokines en groeifactoren in luchtweg- en vasculaire herstructurering, en pulmonaire 
bloedvatvorming in de luchtwegen geïntroduceerd. Nieuwe inzichten op het gebied van  
luchtweg gladde spier (ASM) biologie in het proces van luchtweg- en vasculaire 
herstructurering worden uitgelegd. De  in vitro modellen die centraal staan in dit project 
worden ingeleid. Het doel van dit proefschrift wordt aan het eind van dit hoofdstuk 
gegeven. De rol van groeifactoren zoals “insulin-like” en “fibroblast growth factors” die 
betrokken zijn bij bronchiale herstelprocessen alsmede de rol van mediatoren zoals TNF-α, 
IL-1β, ANG II en ET-1 met betrekking tot chronische luchtwegziekten worden belicht in de 
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hypothese. Tenslotte wordt mechanische rek van de bloedvatwand als hypothese onderzocht 
voor vasculaire herstructurering.  
 
In hoofdstuk 2 ligt de nadruk op de rol van het IGF-I/IGFR-I systeem in bronchiale, 
epitheliale herstelprocessen in luchtwegherstructurering in COPD patiënten. Hier 
onderzochten we de bronchiale expressie van IGF-I en IGFR-I in patiënten met en zonder 
COPD en correleerden deze expressie niveaus met de corresponderende longfunctie data 
van de patiënten. De mitogene effecten van IGFs werden met behulp van een epitheliaal 
wondherstelmodel in vitro in  NCI-H292 cellen verder onderzocht. Verhoogde expressie 
van IGF-I was aanwezig in  ASM en “vasculaire  gladde spier, vascular smooth muscle 
(VSM)” cellen in patiënten met COPD vergeleken met controle patiënten. IGFR-I was 
aanwezig in het bronchiale epitheel en alveolaire macrofagen, maar de expressie was niet 
verschillend tussen de twee experimentele groepen. De expressie van IGF-I in ASM en VSM 
cellen was omgekeerd evenredig met longfunctie data (FEV1/FVC) in de twee groepen. Verder 
toonde we in in vitro experimenten aan dat zowel IGF-I als IGF-II de groei van ASM en 
NCI-H292 cellen bevorderden. Ons model liet ook zien dat IGF stimulatie leidt tot 
significant versnelde heling van een mechanische verwonde NCI-H292 cellaag na 72h. 
Samengevat wijzen onze resultaten erop dat het IGF-I/IGFR-I systeem een belangrijke rol 
speelt bij epitheliale herstelprocessen en dus mogelijk bijdraagt aan de pathogenese van 
COPD. 
 
In hoofdstuk 3 bekeken we de proliferatieve activiteit van bronchiale epitheelcellen in 
COPD (d.m.v. Ki-67 kleuring in het luchtwegepitheel) in relatie tot longfunctie (FEV1 
waarden).  Tevens worden de mitogene rol van FGF-1 en FGF-2 en hun capaciteit op 
wondheling in  hetzelfde in vitro model met de bronchiale epitheelcellijn (NCl-H292) 
onderzocht. Ki-67 tellingen lieten een significante verdubbeling van het aantal delende 
cellen in COPD patiënten zien vergeleken met non-COPD patiënten, die tevens  omgekeerd 
evenredig was met  de FEV1 waarden (r = -0.43; p<0.03). FGF-1 en FGF-2 verhoogden de 
proliferatie gemeten door celtellingen na 24 uur en 48 uur. Zowel FGF-1 en FGF-2 
verhoogden ook de proliferatie zoals gemeten door incorporatie van radioactief 3H-
thymidine. Verder laat de analyse van foto’s van beschadigd epitheel zien dat FGF-1 (67%, 
P <0.01) of FGF-2 (61%, P<0.01) op verschillende tijden (24, 48, en 72 uur) gunstig waren 
voor wondheling, tegenover 38% in afwezigheid van deze groeifactoren. Specifieke 
antagonisten van ERK1/2 (U0126) en FGFR-1 (SU5402) leidden tot complete blokkade van 
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ERK1/2 activatie door FGF-1 of FGF-2 na 15 minuten.  De stoffen U0126 en SU5402 
blokkeerden ook de door FGF-1 gestimuleerde wondheling met 90% c.q. 66%, en de door 
FGF-2 gestimuleerde wondheling met  85% c.q. 50%. Tevens blokkeerde LY294002, een 
fosfatidylinositol-3-kinase antagonist, de epitheliale wondheling door FGF-1 (28%) en 
FGF-2 (22%) behandelde cellen. Samengevat, de verhoogde bronchiale expressie van FGFs 
en hun receptor, FGFR-1 en verhoogde proliferatie in COPD suggereren een rol voor het 
FGF/FGFR-1 systeem in bronchiale luchtwegherstructurering in COPD, verder ondersteund 
door onze in vitro data. 
 
We beschreven in hoofdstuk 4 de rol die vasculaire herstructurering speelt in chronische 
bronchitis en emfyseem door literatuur studie aangevuld door data die op ons eigen lab 
gegenereerd zijn. De huidige kennis aangaande luchtweg- en vasculaire herstructurering in 
COPD is verre van volledig. Vermeerderde infiltratie van ontstekingscellen in de adventitia, 
voornamelijk CD8+ T-lymfocyten, in de spieren rondom pulmonaire en  bronchiolaire 
arterieën is beschreven.  Vele groeifactoren, waaronder VEGF en FGF, spelen een essentiële 
rol in het handhaven van cellulaire homeostase en in weefselherstel.  Gebaseerd op het 
beschikbare bewijs postuleren wij dat de expressie van VEGF en VEGFR-2 leidt tot 
vasculaire herstructurering in chronische bronchitis, dat in geringe mate gecompenseerd 
wordt door de lage expressie van VEGFR-1.  In patiënten met emfyseem, echter, is 
VEGFR-2 expressie  veel lager. De activatie van VEGFR-1 leidt, op zijn beurt, tot hogere 
activiteit van enzymen die alveolaire schade en apoptose in het endotheel veroorzaken. 
Samenvattend, de  balans tussen VEGF, VEGFR-1 en VEGFR-2 is van groot belang voor 
de pathogenese van COPD subtypes. 
 
In hoofdstuk 5 werd de pulmonale expressie beschreven van VEGF en zijn twee receptoren 
VEGFR-1 (flt-1) en VEGFR-2 (KDR/flk-1) in de longen van COPD patiënten.  Het proteïne 
expressie patroon van VEGF, VEGFR-1 en VEGFR-2 werd gekwantificeerd in perifeer 
longweefsel en in de centrale bronchi  van (ex-)rokers met en zonder COPD. VEGF, 
VEGFR-1 en VEGFR-2 kwamen tot expressie in bloedvat en luchtweg gladde spiercellen, 
bronchiale, bronchiolaire en alveolaire epitheelcellen en macrofagen. Bovendien, brachten 
endotheelcellen door de gehele longen VEGFR-1 and VEGFR-2 in sterke mate tot 
expressie. In de bronchiale luchtwegen was VEGF expressie verhoogd in bloedvat gladde 
spiercellen van microbloedvaten in de bronchiale mucosa en submucosa lagen in de 
luchtweg gladde spier cellen vergeleken met patiënten zonder COPD. De expressie van 
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beide receptoren VEGFR-2 and VEGFR-1 was onveranderd tussen beide groepen in de 
bronchiale luchtwegen. Ter hoogte van het longparenchym was VEGF expressie 
toegenomen voor COPD patiënten in de intimale en mediale bloedvatgladde spiercellen van 
pulmonaire arteriën die geassocieerd zijn aan de bronchiolaire luchtwegen alsmede in de 
kleinere parenchymale bloedvatvertakkingen. Bovendien was in COPD de expressie van 
VEGFR-2 verhoogd in endotheelcellen, intimale en mediale bloedvatgladde spiercellen van 
pulmonaire arteriën alsmede in de kleinere alveolaire bloedvatvertakkingen. VEGFR-1 
expressie was voor COPD toegenomen in endotheelcellen van beide bovenstaande 
bloedvatcategorieën. VEGF kleuring was significant toegenomen in bronchiolaire en 
alveolaire epitheelcellen alsmede in bronchiolaire macrofagen, terwijl de VEGFR-1 
receptor alleen in het bronchiolaire epitheel was verhoogd. Tenslotte, werd een negatieve 
correlatie gevonden van de FEV1 met de expressie van VEGF in zowel de bronchiale 
microbloedvaten in de mucosa, alsmede in de bronchiale luchtweg gladde spiercellen en het 
bronchiolaire epitheel, wanneer de totale patiëntengroep onderzocht werd. Samengevat, 
wijzen deze resultaten uit dat VEGF en de twee receptoren, VEGFR-1 en VEGFR-2, 
betrokken zijn bij bloedvat- en luchtwegherstructurering in zowel de perifere long als in de 
centrale bronchustakken van COPD patiënten. 
 
Hoofdstuk 6 beschrijft de rol van pro-inflammatoire mediatoren zoals IL-1β en TNF-α in 
relatie tot luchtweg- of vasculaire herstructurering. We hebben de secretie en expressie van 
VEGF na IL-1β en TNF-α  stimulatie in humane ASM cellen in kweek onderzocht.  Zowel 
IL-1β (0.5 ng/ml) als TNF-α (10 ng/ml) verhoogde de VEGF mRNA expressie in humane 
ASM cellen met een maximum tussen respectievelijk 16-24 uur en 4-8 uur. Beide cytokines 
leidden ook tot een tijdsafhankelijke secretie van VEGF dat niet toegewezen kon worden 
aan toename van de hoeveelheid ASM cellen. Voorbehandeling met 1 μM van het 
glucocorticosteroïde dexamethason onderdrukte deze VEGF toename na TNF-α  volledig. 
Deze data tonen het belang van bovenstaande cytokines voor ASM cellen aan en versterken 
zo hun bijdrage aan inflammatoire mechanismen in chronische longaandoeningen.  
 
In hoofdstuk 7 beschreven we de effecten van geconditioneerd medium van ASM cellen op 
de proliferatie en groei van pulmonaire arteriële, endotheelcellen om een link te vinden 
tussen factoren uit ASM naar VSM in bronchiale angiogenese. Angiotensin II (ANG II) en 
Endothelin-1 (ET-1) staan bekend om hun potente vaatvernauwende werking en zijn mogelijk 
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betrokken bij astma. ET-1, maar niet ANG II, leidt tot proliferatie van ASM cellen (zoals 
gemeten middels [ H]-thymidine incorporatie). Northern blot hybridisatie toonde twee 
mRNAs voor 3.9 en 1.7 kb VEGF aan in ASM cellen in kweek. ANG II en ET-1 
induceerden VEGF mRNA expressie (2-3 keer) en secretie (1.8-2.8 keer) na 4-8 uur 
stimulatie en deze inductie daalde weer na 8 uur voor ANG II, maar niet na ET-1. Verder 
kon geconditioneerd medium van ASM cellen die gedurende 8 uur geïncubeerd waren met 
ET-1 proliferatie van endotheelcellen veroorzaken (gemeten via H-thymidine incorporatie 
en celtellingen) na 24 uur. Deze data suggereren dat ASM cellen factoren kunnen maken, 
mogelijk VEGF, die betrokken zijn bij bronchiale angiogenese en vasculaire 
herstructurering. 
 
In Hoofdstuk 8 onderzochten we de effecten van de stikstofmonoxide (NO) 
signaaltransductie route op de expressie van VEGF en PlGF en de secretie door gekweekte 
ASM cellen door  middel van stimulatie met het pro-inflammatoire cytokine, interleukine-
1β (IL-1β). IL-1β had geen effect op PlGF secretie maar verhoogde wel de secretie van 
VEGF na 24 uur (van 398.6±11 pg/ml in de controle naar 968.4±123 pg/ml na IL-1β 
behandeling). Deze VEGF secretie was onderdrukt door L-NAME (531.8±52 pg/ml) en 
hersteld na behandeling met L-arginine (1529±287 pg/ml). Verder, induceerde IL-1β een 
VEGF mRNA expressie (1.8 keer t.o.v. de controle) na 4 uur maar niet na 24 uur. De 
expressie van VEGF mRNA na IL-1β stimulatie was verlaagd door L-NAME en juist 
verhoogd door L-arginine na 4 uur. Suppletie van de NO signaaltransductie route met L-
arginine in L-NAME behandelde cellen leidt tevens tot een verhoogde expressie van VEGF. 
Celproliferatie was niet beïnvloed door NO na IL-1β stimulatie. Samengevat, onze 
resultaten geven aan dat NO signaaltransductie belangrijk is voor de VEGF synthese wat 
grote gevolgen kan hebben voor het begrip van chronische luchtwegaandoeningen. 
 
In patiënten met astma treedt regelmatig een overmatige contractie van de luchtwegspieren 
op. In hoofdstuk 9 gebruikten wij een repetitief “rek en strek” model om de expressie van 
contractiele eiwitten en signaaltransductie routes, en de secretie van bloedvatvormende 
moleculen te onderzoeken in gekweekte humane ASM cellen. Dit in vitro model toonde aan 
dat hypercontractiele humane ASM cellen vele factoren zoals VEGF, angiogenin en 
cytokines inclusief IL-6, IL-8, MCP-1, RANTES, TNF-β (lymphotactin), en GRO 
uitscheidden. VEGF secretie, gemeten met ELISA, was significant hoger na 8 uur (p<0.02) 
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en 24 uur (p<0.001) vergeleken met controle cellen. Met Western blot analyse toonden we 
na 15 minuten ASM ”strekken” fosforylering van ERK1/2, en na 30 minuten P-Thr-Akt 
(p<0.001) en P-Ser-Akt (p<0.004) aan. Antagonisten van Akt en Rho hadden verder geen 
effect op VEGF uitscheiding maar een antagonist van ERK1/2 (U0261) na 8 uur wel. 
Verder, leidt repetitief strekken van ASM cellen tot een significante secretie van IL-6 
(p<0.05) en IL-8 (p<0.01) na 24 uur wat weer geblokkeerd werd door antagonisten van 
ERK 1/2 en RhoA/ROCK route. Onze resultaten laten zien dat de hypercontractiele, 
humane ASM cellen factoren uitscheiden die betrokken kunnen zijn (via ERK1/2 
signaaltransductie) bij  vasculaire- en luchtweg herstructurering. 
 
Conclusie: onze resultaten tonen aan dat 1) IGF-I/IGFR-I en FGF/FGFR-1 systemen een 
belangrijke rol spelen bij epitheliaal herstel en luchtwegveranderingen in chronische 
longziekten, 2) de verhoogde expressie van VEGF en zijn receptoren (Flt-1 en KDR/Flk-1) 
bijdragen aan bronchiale angiogenese in COPD, 3) ASM cellen biologisch actief VEGF tot 
expressie brengen en uitscheiden als reactie op blootstelling aan pro-inflammatoire 
cytokinen en vasoactieve peptiden, 4) stikstofoxidedonoren de door interleukine 1β 
geïnduceerde VEGF expressie verhogen in gekweekte menselijke ASM cellen, en 5) 
mechanisch gestrekte luchtweg gladde spiercellen pro-angiogene moleculen maken via de  
ERK1/2 signaaltransductie route. Deze resultaten kunnen bijdragen aan de ontwikkeling 
van specifieke therapeutische strategieën om bronchiale angiogenese te reguleren en een 
vermindering van weefselveranderingen teweeg te brengen bij patiënten met chronische 
luchtwegziekten als astma en COPD. 
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